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‘cause sometimes there’s nothing else besides our FAITH, 
 
This is for You! 
You know I Love You… Forever! 
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Resumo 
i 
Resumo 
 
 
A relação entre a infecção pelo Vírus do Papiloma Humano (HPV) e o desenvolvimento do 
cancro do colo do útero foi estabelecida no final do século XX. Em Portugal, preconiza-se o rastreio 
do cancro do colo do útero na mulher adulta por constituir uma das neoplasias mais frequentes. 
Foram recentemente implementados programas de rastreio numa base regional; contudo, o respectivo 
impacto na redução do número de casos de cancro do colo do útero levará algum tempo. Por outro 
lado, o recurso a potenciais indicadores de prognóstico, permitirá auxiliar a identificação precoce de 
mulheres em risco de desenvolver cancro do colo do útero, contribuindo para o estabelecimento de 
estratégias de prevenção mais efectivas e eficazes. 
A vacina profiláctica contra a infecção por HPV foi recentemente disponibilizada para 
administração à população feminina jovem, tendo sido incluída no plano nacional de vacinação. 
Neste contexto, torna-se importante conhecer os genótipos circulantes na população Portuguesa, de 
forma a prever o impacto da vacinação (apenas inclui dois ou quatro genótipos de HPV) na infecção 
por HPV e nas lesões a esta associada. 
 
O presente trabalho de doutoramento teve os seguintes objectivos: 1) determinação da 
proporção da infecção pelos diferentes genótipos de HPV numa amostra da população feminina 
Portuguesa (obtida por rastreio oportunista), e respectiva associação com o diagnóstico citológico; 2) 
avaliação dos testes de detecção e genotipagem do HPV relativamente à clínica associada; 3) 
avaliação de diferentes indicadores de prognóstico, de acordo com o diagnóstico clínico; e, 4) 
desenvolvimento de um modelo matemático aplicável ao estudo da infecção genital por HPV. 
 
A determinação da frequência dos diferentes genótipos de HPV foi efectuada numa 
população com sinais clínicos sugestivos de infecção por HPV, tendo sido possível estabelecer 
associações significativas entre as alterações clínicas e a infecção persistente por genótipos de alto 
risco. Adicionalmente, foi possível identificar os genótipos mais frequentes, nomeadamente os HPV 
16, 18, 31, 51, 53 e 66, e verificar que a infecção por HPV é mais frequente nas mulheres até aos 29 
anos, sobretudo devido à multiplicidade de contactos e de parceiros sexuais (maioritariamente 
infecções transitórias). Já nas mulheres com idade superior a 30 anos, a infecção por HPV foi menos 
frequente mas apresentou maior risco de persistência e, dada a elevada proporção de genótipos de 
alto risco (mesmo em mulheres com citologia normal – assintomáticas), constituiu, por si só, um 
importante factor de risco para o desenvolvimento de cancro do colo do útero. 
 
 
  
 
 
 
Resumo 
iii 
 
Foi efectuada uma caracterização epidemiológica da infecção por HPV, assim como dos 
programas de rastreio do cancro do colo do útero em Portugal, tendo sido salientadas as 
especificidades do rastreio em cada região. 
O desempenho de diferentes testes comerciais de detecção e genotipagem do HPV foi 
avaliado de acordo com a clínica (sensibilidade, especificidade, valor preditivo positivo e negativo). 
A compreensão dos princípios e fundamentos de cada metodologia facilita uma correcta apreciação 
do respectivo desempenho laboratorial em fases distintas da infecção por HPV, assim como da sua 
aplicabilidade a programas de rastreio. Os testes de detecção do DNA viral, com elevada 
sensibilidade, revelaram constituir uma boa alternativa à recorrente citologia, enquanto teste de 
rastreio primário. De facto, a abordagem conjunta de teste HPV com triagem citológica, 
especialmente nas mulheres com mais de 30 anos, permitirá alargar o tempo de intervalo entre os 
exames de rastreio, devido ao elevado valor preditivo negativo do teste HPV. Mais, os testes de 
detecção do DNA viral, que incluem a genotipagem dos HPV 16 e 18 (oncogénicos e frequentemente 
associados ao desenvolvimento de lesões precursoras de cancro do colo do útero), possibilitam 
estratificar mais eficazmente as mulheres em maior risco de persistência da infecção viral e 
respectivas consequências clínicas. 
Relativamente à detecção de RNAm do HPV, foi avaliada uma metodologia comercial de 
detecção e genotipagem de transcritos de RNAm para alguns genótipos de HPV de alto risco 
(NASBA). Esta metodologia permite a identificação precoce de infecções clinicamente relevantes por 
compreenderem um risco acrescido de desenvolvimento de lesões precursoras do cancro do colo do 
útero. Verificou-se que a utilização desta metodologia como teste de segunda linha pode aumentar a 
especificidade do teste de detecção de DNA do HPV nas mulheres infectadas, reduzindo a indicação 
clínica para colposcopia (que inflige elevada morbilidade e ansiedade na mulher) como método de 
rastreio das lesões associadas à infecção por HPV, e evitando o tratamento excessivo, ao possibilitar 
excluir lesões com maior probabilidade de regressão. 
A utilização de diferentes indicadores de prognóstico da infecção por HPV facilitará a 
identificação precoce de mulheres em risco de desenvolvimento de lesões precursoras de cancro do 
colo do útero. Neste contexto, foram avaliadas a carga viral e o estado físico do DNA viral dos HPVs 
16 e 18, tendo sido possível determinar uma associação entre o aumento da carga viral do HPV 16 e a 
gravidade da lesão do colo do útero, pelo que foi considerado como um importante marcador de 
prognóstico em mulheres infectadas por um dos mais frequentes genótipos de alto risco na população 
Portuguesa. Para o HPV 18, frequentemente associado ao desenvolvimento de adenocarcinomas (tipo 
de cancro cervical de difícil identificação citológica), verificou-se que a carga viral é potencialmente 
preditiva da persistência da infecção. 
 
  
 
Resumo 
v 
 
A determinação do estado físico do DNA viral, como metodologia alternativa a 
procedimentos médicos invasivos (colposcopia e biopsia), foi avaliada em associação com o 
diagnóstico citopatológico. Durante o processo de carcinogénese viral ocorre integração do genoma 
viral no genoma da célula hospedeira, por disrupção do gene viral E2 e subsequente sobre-expressão 
dos oncogenes virais E6 e E7. Foi possível identificar, especialmente para o HPV 18, uma associação 
entre a presença de formas lineares (maior risco), as lesões precursoras e os casos de 
adenocarcinoma, o que sugere a utilidade clínica deste indicador de prognóstico para as mulheres 
infectadas por HPV 18. No caso do HPV 16, a associação entre a determinação do estado físico do 
DNA viral e o diagnóstico citopatológico não foi tão evidente, pelo que outros mecanismos virais 
poderão estar associados à transformação maligna que antecede o desenvolvimento de cancro do colo 
do útero. 
Por último, o desenvolvimento de um modelo matemático aplicado à infecção genital por 
HPV incluiu transições entre os diferentes estadios clínicos que correspondem ao processo de 
carcinogénese viral. Os cenários previstos foram extrapolados a partir da população de estudo (de 
rastreio oportunista) e posteriormente comparados com uma população Portuguesa de referência (de 
rastreio organizado), por forma a estimar a evolução e flutuações relacionadas com a infecção por 
genótipos de HPV de alto risco e respectivas lesões associadas. A utilização eficaz da vacina a nível 
mundial poderá levar a uma diminuição de casos de cancro do colo do útero na ordem dos 70% (valor 
estimado de cancros associados à infecção por HPV 16 e 18), decorrente da prevenção vacinal para 
os referidos HPVs. No entanto, a existência de uma proporção considerável de outros genótipos de 
alto risco não incluídos nas vacinas disponíveis poderá alterar esta estimativa, pelo que a 
monitorização constante dos genótipos circulantes de HPV será importante. De facto, estima-se que 
sejam necessárias algumas décadas até eliminar os casos de infecção associados aos HPV 16 e 18, já 
que a grande maioria das mulheres já foi exposta à infecção por HPV. 
 
 
 
 
 
 
 
Palavras-chave: Portugal, Vírus do Papiloma Humano, cancro do colo do útero, rastreio, estratégias 
de prevenção. 
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Abstract 
 
 
Cervical cancer development has been aetiologically linked to human papillomavirus (HPV) 
infection. In Portugal, routine screening for cervical cancer has been regionally implemented and was 
recommended for adult women because it constitutes one of the most frequent malignancies for 
women aged 15 to 44 years. HPV prophylactic vaccination (which only includes two or four 
oncogenic genotypes) was made available in the last decade for young girls, but the knowledge of 
HPV circulating genotypes is crucial for predicting its clinical impact. 
This PhD thesis comprised the following objectives: 1) assessment of the proportion of HPV 
genotypes among Portuguese women (opportunistic screening) according to cytological diagnosis; 2) 
clinical evaluation of several HPV tests; 3) evaluation of some prognostic markers according to the 
clinical diagnosis; 4) development of a mathematical model applied to genital HPV infection.  
Portuguese HPV epidemiology and screening programs were characterized, highlighting the 
specificities of screening in each region. The most frequent genotypes were HPV 16, 18, 31, 51, 53 
and 66, and HPV infection was more common in women aged less than 29 years.  In women over 30 
years, HPV infection was less frequent but tend to persist and to involve high-risk genotypes. 
HPV DNA tests demonstrated high sensitivity, constituting an alternative to cytology in 
primary screening, while combined with cytology (especially for women over 30 years) would extend 
the re-screening testing interval, considering the high negative predictive value of HPV testing. 
Moreover, HPV DNA tests with concurrent identification of HPV 16 and 18 (most associated 
genotypes to cervical cancer development) will provide a better risk stratification of women for 
precancerous cervical lesion development. 
The detection of HPV mRNA is highly specific in identifying clinical cervical disease, so 
that its recommendation to reflex testing of HPV DNA-positive women has shown to reduce 
colposcopy referral, avoiding over-treatment by excluding cervical lesions that would most likely 
regress (with associated morbidity and anxiety to HPV-infected women). 
The viral load and physical status of high-risk HPV 16 and 18 were evaluated as prognostic 
markers in women at risk of developing cervical precancerous lesions. An association between 
increased HPV 16 viral load and severity of cervical lesion was observed suggesting its prognostic 
value, whereas for HPV 18, viral load was only predictive of HPV persistency. The presence of linear 
forms (higher risk) in HPV 18-associated precancerous lesions and adenocarcinomas evidenced the 
potential clinical utility of viral DNA physical status as a prognostic marker for women infected with 
HPV 18. The association was not evident for HPV 16, suggesting that other viral mechanisms should 
be responsible for malignant host cell transformation. 
 
 
  
 
 
Abstract 
ix 
 
Finally, the mathematical model applied to genital HPV infection included transition 
probabilities between disease states corresponding to different steps of cervical carcinogenesis, and 
provided scenarios for a Study Population (opportunistic screening), for a Reference Population 
(routine screening) and for a Hypothetical Population, which were further compared to predict HPV 
vaccination impact. Estimates of trends and fluctuations associated with high-risk HPV genotype 
infections and its associated cervical lesions were performed. HPV vaccines may lead to a global 
decrease of cervical cancer cases of about 70%, considering that most cervical cancers are associated 
with HPV 16 and 18 infections. However, the existence of a considerable proportion of other high-
risk genotypes not included in the currently available HPV vaccines may change this estimate. Thus, 
the constant monitoring of circulating HPV genotypes remains of particular importance. Furthermore, 
the vast majority of women have been exposed to HPV infection, alerting to the importance of a 
continuous follow-up and establishment of public health measures through routine screening, while 
improving women’s welfare. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Keywords: Portugal, human papillomavirus, cervical cancer, screening, prevention strategies.  
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Notes of the Author 
 
 
This PhD thesis comprehends the detailed description of an extended work mainly focused on 
how to improve the existent screening strategies applied to the Portuguese female population, on how 
to better manage HPV-infected women, while reducing the associated anxiety and morbidity. 
The presentation order does not follow a chronological sequence according to publication but 
it is rather intended to present a comprehensive approach in view of the objectives. First is presented 
data that correspond to baseline information to the following presented work, from the general to the 
particular point of view. 
Since all published papers are presented here in a PDF format (original layout) , following the 
guidelines from each international journal where they were published, references are not uniformized 
throughout the PhD thesis. Regarding non-published chapters, references follow the guidelines from 
the international journal Clinical Microbiology and Infection (Vancouver style). 
All chapters are presented in an article structure, so abbreviations may be defined more than 
once, and every chapter includes a specific reference section. When Paper IV was submitted the full-
case analysis was not completed, therefore updated results are now presented in Chapter 8. 
 
The author chose not to follow the new spelling agreement for Portuguese language in the 
Resumo section. The author follows USA English spelling throughout this PhD thesis. The fellowship 
institution, Instituto Nacional de Saúde Doutor Ricardo Jorge, I.P., will be further addressed in the 
text as National Institute of Health (INSA). 
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INTRODUCTION 
 
 
 
Aetiological Role of Human Papillomavirus in Cervical Cancer 
 
zur Hausen [1,2] turned all eyes and interest into human papillomavirus (HPV) research after 
repeated and unsuccessful attempts to provide a decisive evidence for an aetiological role of herpes 
simplex virus type 2 (HSV 2) in cervical cancer carcinogenesis, and he formulated the hypothesis that 
HPV would be related to cervical cancer. During the 80’s, the identification of some genotypes of 
papillomavirus in the anogenital tract [3] led to an intensive research in the field, which culminated in 
the development of clinical tests for cervical cancer based on HPV DNA detection, and in the 
conception of vaccines that preclude HPV infections in the present. 
Years of research provided the conclusion that virtually all cervical cancers are related to 
HPV infection [4,5], so that cervical cancer is the first cancer that is acknowledged by the World 
Health Organization (WHO) to be virally induced in essentially all cancer cases. 
Cervical cancer is, after breast cancer, the second most common malignancy among women 
worldwide. The estimated total number of women diagnosed with cervical cancer in 2002 was 
493,000 and 274,000 women died from the disease that same year. The majority of cases (83.0%) 
occur in developing countries, where cervical cancer accounts for 15.0% of the newly diagnosed 
cancers in women. In developed countries comprehending good screening options, invasive cervical 
carcinoma (ICC) is a relatively rare condition and accounts for only 3.6% of the new cancers [6]. The 
2008 worldwide estimates
1
 revealed that the incidence of cervical cancer was 15.2 per 100,000 
women (530,232 new cases) and the mortality rate was 7.8 per 100,000 (275,008 deaths) [7]. 
In Portugal, cervical cancer is the fourth most frequent cancer in women of all ages, and the 
second most frequent in women between 15 and 44 years of age. In 2008, 949 new cases of cervical 
cancer were diagnosed, with an age-standardized incidence rate of 12.2 new cases per 100,000 
women, and a total of 346 women died as a consequence of cervical cancer, with an age-standardized 
mortality rate of 3.6 women per 100,000 [7]. 
 
 
                                                 
1 GLOBOCAN is a project that estimates worldwide Incidence, Mortality, Prevalence and Disability -adjusted Life Years 
(DALY’s) from major type cancers at national level; it is developed by the International Agency for Research on Cancer 
(IARC). 
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Classification and Structural Organization 
 
Papillomaviruses are non-enveloped double-stranded circular deoxyribonucleic acid 
(dsDNA) viruses that comprise about 8000 base pairs (bp) in length. The capsid presents an 
icosahedral structure composed by 72 capsomers, and a diameter of 52-55 nm [8]. The genomes of all 
HPV genotypes contain approximately eight open reading frames (ORF), divided into three 
functional parts: the early (E) region that encodes proteins (E1-E7) necessary for viral replication; the 
late (L) region that encodes the structural proteins of the capsid (L1-L2) required for virion assembly 
of new particles; and a non-coding region that is referred to as long control region (LCR), which 
contains cis elements that are necessary for the replication and transcription of viral DNA (Fig.1) 
[9,10]. Early proteins E5, E6, and E7 are involved in promoting host cell proliferation and survival, 
and E6 and E7 play a key role in HPV-associated carcinogenesis. Three other early proteins (E1, E2, 
and E4) are involved in the control of viral gene transcription and viral DNA replication [5,8].  
 
 
Fig. 1: Human papillomavirus (HPV) genome organization [10]. 
 
Papillomaviruses had originally been grouped together with polyomaviruses in one family, 
the Papovaviridae. It was later recognized that the two groups of viruses shared less features than 
expected, being now officially recognized by the International Committee on the Taxonomy of 
Viruses (ICTV) as two separate families – Papillomaviridae and Polyomaviridae [11]. 
Papillomaviruses are designated using the name of their host species, like bovine papillomavirus 
(BPV) or human papillomavirus (HPV). Further taxonomic organization encompasses attributing a 
number to each papillomavirus identified in the same host, e.g. HPV 1 and HPV 2, being designated 
as papillomavirus genotypes [10]. The identification of a novel genotype used to be determined 
through restriction enzyme electrophoresis profile. More recently, only the complete sequencing of 
the full genome may determine a new papillomavirus genotype, mainly based on the comparison of 
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the L1 gene sequences, while grouping them in genera, species and types (Fig.2). Since the L1 ORF 
is the most conserved region within the genome, a new papillomavirus isolate is recognized if the 
DNA sequence of the L1 ORF differs by more than 10.0% from the closest known genotype. 
Differences in homology between 2.0% and 10.0% define a subtype and those of less than 2.0% 
define a variant [11]. The taxonomic classification also relates to both tropism and viral properties. 
The phylogenetic trees for papillomaviruses evidence an evolutionary diversification in which an 
unknown molecular mechanism seems to restrict papillomaviruses to their host species, since it has 
been proposed that viral replication is linked to epithelial host cell replication, resulting in similar 
rates of nucleotide exchanges [10]. 
 
 
Fig. 2: Phylogenetic tree inferred from the L1 nucleotide sequences of 170 papillomaviruses [12]. 
 
More than 120 HPV genotypes have been identified so far and approximately 40 different 
genotypes can infect the anogenital tract. According to the oncogenic potential, HPV can be 
classified into low-risk genotypes (LR-HPV), mainly seen in genital warts and non-progressing low-
grade lesions [13,14]. According to the International Agency for Research on Cancer (IARC) 
Monograph Working Group, at least 13 HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 
58, 59, 66) are considered as high-risk (HR-HPV) [15,16]. 
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Viral Life-Cycle and Oncogenesis 
 
Throughout the years, HPVs have co-evolved with their host, with most of them being able to 
be maintained in the population without causing any apparent disease [17,18]. This co-evolution 
raises the hypothesis of a balance between viral replication and immune tolerance [19]. In fact, the 
different epithelial diseases caused by HPV genotypes appear to be linked to their strategies of 
transmission and propagation within the epithelium, as well as different interactions with the immune 
system. HPVs can be divided into cutaneous and mucosal genotypes, presenting a specific tropism to 
infect epithelial cells and have adapted their life-cycle in accordance to host cell differentiation 
[20,21]. 
The low-risk HPV genotypes present a life-cycle organization which is not able to cause 
neoplasia [22]. The main differences are found in the promoter positioning and its regulation, as well 
as in messenger ribonucleic acid (mRNA) splicing, mainly affecting E6 and E7 protein expression 
[20,23]. Since these proteins are involved in the carcinogenesis process, in low-risk genotypes, such 
as HPV 6, the E6 gene seems to not play a key role in inducing host genome instability, affecting the 
disease phenotype following infection [24,25]. For high-risk HPV genotypes, they seem to be 
preserved through their ability to persist and cause productive infections, promoting cell proliferation 
in the basal cell layer of the epithelium (primary site of infection and reservoir during persistence) 
[26,27]. High-grade lesions correspond to abortive infections, whereas an elevated expression of the 
E6 and E7 proteins is observed which is closely related to an increasing severity of neoplasia 
[22,28,29]. 
High-risk HPV infection is thought to require the presence of a microwound that allows the 
infectious virions to access the basal cell layer of the epithelium, where the viral genome will be 
maintained in a low copy number [30,31]. However, multiple entry pathways have been proposed, 
depending on the genotype of virus or the route of infection. Cell entry has been proposed to occur 
through an interaction implicating heparin sulphate proteoglycans [32-34] and Alpha 6 Integrin [35-
40]. 
HPV infections do not present viraemic phase, and genome amplification often occurs in the 
initial stages of infection followed by maintenance of the viral episome at a low copy number 
[30,41,42]. In this initial amplification phase, the viral proteins E1 and E2 are crucial in regulating 
viral transcription through various binding sites in LCR [23,43-46]. The oncogenic potential of a 
papillomavirus is linked to its ability to overcome growth arrest and maintain a replication-competent 
cell [47]. Expression of the viral E6 and E7 proteins during the next phase of infection delays host 
cell cycle arrests and differentiation (normally observed as epithelial cells move up from the 
basement membrane to become mature keratinocytes). The E7 protein, which has the ability to 
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associate to proteins of the retinoblastoma (pRB) family, enables the virus to manage the control of 
the cell cycle in the upper epithelial layer [27,48]. Of the interactions attributed to high-risk E6 
protein, the capacity to upregulate telomerase activity [49-51] and to maintain telomerase integrity 
during repeated cell divisions, together with their ability to mediate the degradation of p53 within the 
cell, seems to be the most important. This expression of E6 and E7 proteins in the upper epithelial 
layer allows the infected cell to re-enter S-phase, elevating the viral copy number, and usually 
thickening the skin, which is characteristic of some papillomavirus infections. [20,52]. In addition to 
E1 and E2 expression, E4 and E5 proteins are also involved in the viral genome amplification 
through the modification of the cellular environment, where E5 protein is particularly involved in 
koilocyte formation [53].  
When the differentiation of replicating epithelial cells to non-replicating mature keratinocytes 
eventually occurs (in the most superficial layer of epithelial cells), the final step of the viral life-cycle 
mainly involves the expression of the minor coat protein L2, leading to the exit from the host cell, 
and the expression of the major coat protein L1 that culminates in the final genome packaging 
[54,55]. This event contributes to the production of very stable infectious virions [56,57]. In this 
stage, E4 protein enables virion release and infectivity in the upper epithelial layer [21]. Viral 
genome encapsidation requires the assembly of the icosahedral capsid in the host nucleous, prior to 
L1 expression [58,59]. Viral particles are then released from the host cell in the upper layers of the 
epithelium through a nonlytic process (Fig.3). New virus particles may infect new cells of the same 
host or be transmitted to new hosts through sexual contact [20]. 
 
 
Fig. 3: HPV infectious cycle scheme: Virus entry in a cell through a microabrasion and infection beginning with 
binding of HPV particles to the basal cells of the epithelium, where the viral genome will be amplified to several 
copies. In the suprabasal layers of the epithelium, HPV early proteins are expressed and viral replication will take 
place. E4 and the late L1 and L2 proteins will be expressed only in the most superficial layers of the epithelium, 
where HPV DNA will be encapsidated, and the virions released from the epithelial surface [60]. 
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In women with cervical HPV infection the virus particle production becomes disrupted by the 
increase in the expression levels of E6 and E7 from cervical intraepithelial neoplasia grade 1 to 3 
(CIN1 to CIN3), which directly alters the neoplastic phenotype. The overexpression of E6 and E7 
oncoproteins detected in HR-HPV infections that lead to CIN 2 or worse (CIN2+) development, 
which is linked to the accumulation of genetic changes in the host cell, are important to cancer 
progression [61-63]. However, most of the HPV infections are cleared and do not persist long enough 
to occur viral deregulation, and consequently induce genetic errors in the infected host cell. HPV 16 
is associated with a longer persistence of infection than other HR genotypes which can contribute to 
its higher cancer risk [64,65]. 
The HPV transmission rate reported as the transmission probability per partnership (v.g. the 
probability that an infected partner transmits HPV to a susceptible partner irrespective of the duration 
of that partnership) has been evaluated through longitudinal studies [66,67]. It has been consistently 
reported a higher rate of female-to-male versus male-to-female transmission (0.19-0.81 vs 0.05-0.28, 
respectively), being higher in short-term interval study visits [68]. Bogaards et al. [69] estimated 
transmission probabilities ranging 0.43-0.94, whereas the highest were for HPV 16 and 18. One study 
revealed that the highest transmission rate occurs when one of the partners have persistent HPV 
infection, suggesting that transmission is linked with extended exposure and high viral load [67]. 
However, due to recent sexual intercourse (prior to study visit), some false HPV positivity may over-
estimate transmission rates [70]. 
 
 
Natural Immune Response 
 
The exclusively intraepithelial nature of the HPV infection without viraemia or virus-induced 
cell death stages is not associated with inflammation and thus, may suggest that presentation of 
antigen to lymph nodes is limited [71,72], resulting in a failure to induce an effective immune 
response, due to inefficient activation of innate immunity and ineffective priming of the adaptive 
immune response. This defective immune response may facilitate viral persistence, a key feature for 
evasion of HR-HPV infections [73]. However, a vast majority of the cervical HPV infections are 
transient, clearing within 1 to 2 years [74]. This suggests that the host immune system somehow 
plays a role in preventing or eliminating HPV infection, through both humoral and cell-mediated 
responses [75]. It has been recently proposed that protection against infection (preventing the virus 
entry in the basal epithelial host cells) would be accomplished through neutralizing antibodies, while 
clearance is thought to be mediated predominantly by cellular immunity [76]. When one HPV 
infection is successively detected in the same woman it is hard to determine if it is due to re-infection 
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after an effective clearance, or if it is due to a reactivation of the same latent infection. Moscicki et al. 
[27
th
 International Papillomavirus Conference and Clinical Workshops, abstract O-08.06] showed 
that after two years, only 3.0 to 5.0% of the women evidenced re-infection with HPV 16, following 
clearance of the first infection (defined as two consecutive negative HPV DNA results), and that after 
five years past, the re-infection rate increased to the range of 10.0 to 17.0%. The results of this study 
are supported by the findings of Trottier et al. [77], which also evidenced differential sexual 
behaviors highly associated with repeated detection of the same HPV genotype infections, suggesting 
that each new infection is probably due to re-exposure. There are some evidences supporting that 
transient infections could be cleared by innate immune responses [78], which do not provide memory 
immune response, leaving women vulnerable to re-infection, but rarely leading to cervical lesion 
development [79]. Re-infection rates should not be based on serologic evidence, because serology 
lacks HPV-genotype specificity, leading to putative contradictory data on whether antibodies are 
protective regarding re-infection or not [27
th
 International Papillomavirus Conference and Clinical 
Workshops, abstract O-08.06;77,80,81]. 
To date, most of the seroepidemiological data on HPV infection have been obtained from the 
populational groups included in the ongoing HPV vaccine trials, in addition to some natural history 
studies held in some cohorts [82-84]. Despite the number of seroepidemiological reports, the detailed 
kinetics of the various components of the humoral immune response following incident HPV 
infection in naïve women remains unclear and somewhat controversial. In fact, although serum IgG 
antibodies to HPV 16 are found in 56.0 to 60.0% of subjects with incident HPV infections within 8 to 
18 months, antibody titers remain low [83,85], but can persist for decades, or rapidly disappear in 
women without HPV-associated lesions [85]. In contrast to the naturally occurring humoral response, 
vaccination with HPV L1 virus-like particles (VLP) has shown to induce high titers of virus-specific 
serum IgG antibodies and protection against virus-induced (pre)malignant lesions [86,87]. 
Immune cells infiltrate the HPV-associated lesion but, during persistent infection, they fail to 
access the infected epithelium. On the other hand, when CD8+ T-cells reach the neoplastic lesion is 
more likely to regress [88]. Circulating T-cells with the ability to access the infected epithelium are 
mediated by chemokines and adhesion molecules [89]. Finally, high-grade lesions and cancer cells 
can lose the expression of human leukocyte antigen (HLA) molecules and immune cells will be 
inefficient as target cells will no longer exhibit cell surface HLA-HPV peptide complexes 
recognizable to the T-cell receptor (TCR). Considering this, therapeutic vaccines that would induce 
or boost HPV T-cell adaptive immunity could be of value [73]. However, therapeutic vaccines have 
been tested in HPV 16-associated diseases without significant clinical impact, probably because they 
fail to induce the necessary effective HPV-specific CD4+ and CD8+ T cell responses [90]. 
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Epidemiology of HPV-related Diseases 
Benign Diseases 
 
Recurrent respiratory papillomatosis (RRP) and genital warts, which are unequivocally linked 
to HPV 6 and 11 infections that are responsible for 96.0 to 100% of all genital warts cases, constitute 
highly recurrent benign HPV-associated diseases [91-94]. 
In developed countries, genital warts present epidemiological trends similar to other common 
sexually transmitted infections (STIs) with a peak of incidence among individuals younger than 25 
years [95]. An eight-fold increase in the incidence of genital warts was observed in the last decades 
[96-98], probably associated with changes in sexual behavior, namely the lower age at sexual debut 
reported by many developed countries [99]. Several recent publications indicate an annual incidence 
of 0.1 to 0.2% with a peak occurring among teenagers and young adults [100-103]. Also, the 
incidence of genital warts seems to be higher in human immunodeficiency virus (HIV)-positive 
women [104]. There is now accumulating evidence that population-based vaccination can result in a 
high decrease in genital warts incidence, with reduction of HPV 6/11 burden [103]. Nonetheless, the 
available treatment options often face recurrence of these benign lesions and imply significant public 
health and emotional costs [93]. 
RRP is caused primarily by HPV 6 and 11, with a small fraction (less than 5.0%) caused by 
HPV 16 or other genotypes [105]. The disease is characterized by the growth of multiple papillomas, 
usually arising from the larynx, and affects mainly in early childhood (juvenile onset). Nonetheless, 
RRP is a rare disorder, with a prevalence of 3 to 7 per 100,000 for both pediatric and adults 
[106,107]. The most important risk factor for the juvenile onset RRP is a maternal history of genital 
warts during pregnancy, for whom it has been estimated 200 times greater risk of associated RRP in 
the infant when compared to women without genital warts upon natural birth [108]. Adult onset RRP 
has been associated with high lifetime number of sexual partners and oral sex [109], as established 
for oropharyngeal cancers. Recurrence rates are highly variable, being more associated with young 
age [110], and the vast majority is benign. However, malignant conversion may occur when 
pulmonary involvement is observed and usually caused by HPV 11 infection [111]. 
 
Head and Neck Cancers 
 
Head and neck cancers are commonly referred to squamous cell carcinomas (SCCs) that are 
diagnosed in the upper digestive and respiratory tracts, affecting the oral cavity, tonsils, base of the 
tongue, oropharynx, and larynx. In 2002, approximately 405,000 new cases were reported causing 
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221,000 deaths worldwide [112], mainly among older men and women (over 60 years) [113]. 
Tobacco use and alcohol consumption constitute potential risk factors for the development of head 
and neck cancers [103]. However, 15.0% to 20.0% of the cases of head and neck cancer have no 
association with these risk factors [113]. 
In SCC, the prevalence of HPV DNA depends on the type of study and geography, but an 
overall prevalence of HPV DNA of 25.9% (23.5% for oral cavity tumors; 24.0% for larynx tumors; 
and 35.6% for oropharynx tumors) has been proposed [114]. The detection of oral HPV infection 
varies among studies, depending greatly on sampling technique. A meta-analysis of 4581 cancer-free 
individuals from 18 different studies established an HPV prevalence of 4.5% [115], but for a 
population-based survey held in the United States of America (USA), the HPV prevalence was 
estimated in 6.9%, (higher HPV positivity in men than in women), and was associated with changes 
in sexual behavior (v.g. oral sex) [93,116,117]. HPV 16 is the most commonly detected HPV 
genotype in head and neck lesions followed by HPV 18 [114,116,118]. The IARC Monograph [15] 
established the average prevalence of HPV infection in the oral cavity in approximately 25.0%, with 
HPV 16 being detected in about 70.0% of the HPV-positive cases. The average prevalence was 
higher for oropharyngeal cancers (35.0%) with HPV 16 being detected in 80.0% of the HPV-positive 
cases, suggesting an aetiological association of this genotype with this type of cancer [110]. Sexually 
transmitted oral HPV infection was proposed as the major cause of the HPV-associated head and 
neck cancers; however, transmission can also occur through open-mouth kissing or hand to mouth 
inoculation [117,119]. Sexual behaviors most consistently associated with head and neck cancers risk 
include high lifetime number of sexual partners (independently of oral or genital intercourse). Less 
frequently, it has been also suggested the influence of younger age at sexual debut, lack of condom 
use, same-gender sexual contacts and oral-genital or oral-anal sexual practices [110]. 
 
Penile Cancer 
 
In men, HPV DNA is frequently detected among penile cancer cases (40.0-45.0%) [93,120]. 
HPV is more frequently detected in the shaft, glans, and scrotum, whereas less in the urethra. Male 
genital HPV prevalence is usually related to female prevalence in the same population [121]. The 
HPV positivity rates in men vary less by age group than the observed for women. However, the 
detection of genital HPV infection in men is influenced by cell sampling techniques [122]. In the 
Human Papillomavirus Infection in Men (HIM) study, in which samples from the coronal 
sulcus/glans, penile shaft and scrotum were combined, the prevalence of any HPV genotype was 
65.2%, whereas 20.7% were LR-HPV genotypes and only 17.8% were HR-HPV genotypes, and no 
association with age could be established [123]. In other study, HPV prevalence was higher among 
men having sex with men (MSM) than in men having sex with women (MSW) (23.0% vs. 8.0%, 
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respectively) [124]. The prevalence of HPV in penile intraepithelial neoplasia (PIN) is higher than the 
reported for invasive cancer of the penis [122]. Several cross-sectional studies have provided 
evidence of risk factors for the acquisition of HPV infection in male genitalia including “not being 
circumcised” [125], “lack of condom use” [126], “history of tobacco smoking habits” [127], and a 
“high number of lifetime partners” [123,128]. 
 
Anal Cancer 
 
Anal cancers are rare malignancies that affect the transitional zone of the epithelium in the 
anal canal. Worldwide, approximately 99,000 new cases of anal cancer were reported in 2002, among 
which 40.0% in men and 60.0% in women. An increasing trend in the incidence rate of this cancer 
(about 2.0% per year) has been reported, affecting both men and women, but affecting particularly 
MSM and HIV-infected men and women [112,129-131]. Several studies reported that over 90.0% of 
the HIV-infected MSM have anal HPV infection, often with multiple genotypes (at least 7.0% 
evidenced one HR-HPV genotype), while a substantially lower proportion of HIV-uninfected MSW 
have anal HPV infection (12.0%) [132]. Studies conducted in women with and without HIV infection 
reported that anal HPV infection is more common than cervical HPV infection [133,134]. The 
majority of invasive anal carcinomas (65.0%) are SCC that develops from precancerous anal 
intraepithelial neoplasia (AIN) lesions. For both sexes, around 88.0 to 94.0% of the cases of anal 
cancer are associated with HPV infection, but the highest prevalence is observed in MSM (73.5%) 
[103,131,135]. The most common HPV genotype detected amongst anal cancer cases is HPV 16 (up 
to 87.0%), followed by HPV 18 (9.0%) [15]. HPV DNA is also detected in AIN lesions and the 
prevalence of the HPV infection increases with the severity of the lesion (75.0% in AIN1, 86.0% in 
AIN2, and 94.0% in AIN3) [136]. The increasing incidence rate of anal cancer may reflect changes in 
sexual behavior during the second half of the twentieth century that might have increased the risk for 
exposure of the anal canal to the HPV infection, considering that anal intercourse became a more 
frequent sexual practice and this is a more efficient mode of HPV acquisition [137]. However, it has 
been considered that anal intercourse is not essential for anal HPV infection, as it might spread from 
cervical HPV infection [133,138]. 
 
Vulvar and Vaginal Cancer 
 
HPV infection has been associated to various cancerous lesions in the female anogenital tract. 
HPV DNA has been detected in vaginal cancer (64.0-91.0%), and its precursor vaginal intraepithelial 
neoplasia grade 3 (VaIN3) lesions (82.0-100%). Similarly, an estimated 40.0 to 50.0% of the vulvar 
Chapter 1 - Introduction 
 
11 
cancer has also been associated to HPV [93,139]. In worldwide estimates from 2008, the age-
standardized incidence rate of vulvar and vaginal cancer did not exceed 2 per 100,000, despite the 
limitations for estimating a trend in the incidence of these types of cancer due to underreporting in 
developing regions [103]. Moreover, the incidence of invasive vulvar and vaginal cancer was 
reported as stable over time signalling the limited impact of cervical cancer screening efforts on other 
genital cancers [93]. This might be linked to the fact that vulvar and vaginal cancers usually affect 
women older than 65 years, age at which women normally exit a cervical cancer screening program.  
Vulvar cancer is thought to be a rather uncommon malignancy, affecting 26,800 women 
worldwide in 2002, which accounted for approximately only 3.0% of all gynaecological cancers 
[140]. SCCs constitute the most common (90.0%) histologic type of primary vulvar cancer, and about 
60.0% of the cases were reported in developed countries [140,141], where they were more common 
among older women, with approximately 66.0% of the cases being diagnosed in women aged 70 
years or older. Regarding genotype-specific HPV prevalence in vulvar lesions, 67.0% relate to LR-
HPV-positivity in vulvar intraepithelial neoplasia grade 1 (VIN1) lesions, whereas only 6.0% of the 
HPV DNA-positive specimens were HPV 16. In contrast, 100% of VIN3 lesions were HR-HPV-
positive and the vast majority (91.0%) were HPV 16-positive [142]. According to IARC Monograph 
[15], HPV DNA-positivity ranges from 72.0 to 100% for VIN3 lesions and from 27.3 to 100% in 
vulvar cancer, with HPV 16 being the most commonly detected genotype (65.0-93.0% in VIN and 
72.0% for vulvar cancer) followed by HPV 18. 
Cancer of the vagina has been a rare condition. In 2002, approximately 13,200 women 
worldwide were diagnosed with vaginal cancer, accounting for less than 2.0% of all gynaecological 
cancers [140]. SCCs are the most common histological type (~90.0%), with the vast majority (68.0%) 
being reported in developed countries [141]. Incidence rates in the range of 0.4 to 0.7 per 100,000 
were reported in the USA, the United Kingdom (UK) and other European countries [143]. An 
increasing trend in the incidence of VaIN has been observed for the last decades, while the incidence 
rate of invasive vaginal cancer was reported to remain stable [144] or even evidencing some decline 
[145]. This type of cancer is usually diagnosed in older women (median age of 69 years; incidence 
peak at 55-70 years), being rare in women under 45 years [146-148]. 
 
Cervical Cancer2 
 
The aetiological role of HPV in cervical cancer has been firmly established biologically and 
epidemiologically, as 99.7% of all cervical cancers actually containing oncogenic forms of the virus 
                                                 
2 The Portuguese prevalence estimates will be described in Chapter 2, due to the importance of epidemiologic data for the 
objectives aimed in this PhD thesis. 
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[4,149,150]. Two HR-HPV genotypes, HPV 16 and 18 have been consistently associated to at least 
70.0% of the cervical cancer cases worldwide, with limited geographical variability [5,151]. 
Estimates from GLOBOCAN 2008 [152,153] evidenced that of the 12.7 million of new 
cancers occurring worldwide, 700,000 occurred at an HPV-associated cancer anatomic site (cervix 
uteri, anus, penis, vulva, vagina, and oropharynx) and it was estimated that 610,000 of those were 
attributable to HPV. This represents 4.8% of the total cancer burden worldwide, which is lower than 
the 5.2% previously estimated in 2002 [112]. However, there was an increase of the estimated new 
cases from 561,000 to 610,000. As expected, 490,000 cases attributable to HPV (80.6% of the total) 
occurred in less developed regions (6.9%), whereas 2.1% were described in more developed regions 
[154], which could be predicted by the differential access to cervical cancer screening.  
Cervical cancer represents the final step of a persistent unresolved HPV infection. The later 
are highly common, especially in young women among who the probability of ever be infected by 
HPV is around 80.0 to 90.0%, considering the 40.0 to 80.0% prevalence observed in many developed 
countries. As the majority of these infections will clear spontaneously without the manifestation of 
any clinical signs, it is estimated that only a fraction of 4.0 to 10.0% will be considered persistent 
HPV infections [137,155]. In cohorts of female university students in the USA and Canada, followed 
through repeated cervical sampling, the cumulative incidence of HPV infection was established in 
40.0 to 60.0% among women that were negative at baseline during three years of follow-up [156-
158]. In a cohort of initially HPV-negative women aged 15 to 19 years in England, the cumulative 
risk for HPV infection was 44.0% after three years and 60.0% after five years [159]. 
The overall global burden of HPV infection has been assessed by using pooled data from 
studies of HPV detection in women with normal cytology. The most recent meta-analysis, including 
data from 194 studies worldwide, estimates the global HPV prevalence in 11.0 to 12.0% [160]. There 
is a considerable regional variation, comprehending higher HPV prevalence rates in less developed 
countries. Regarding age, the HPV prevalence is globally higher in young women, increasing each 
year from 14 to 24 years and then declining rapidly with increasing age [161-164]. The highest 
prevalence is observed in women aged 20 to 24 years (44.8%) (24.5% for women aged 14-19 years 
and 27.4% among women aged 25-29 years) [161,162,165-168]. However, in Asian and African 
populations, HPV prevalence although decreasing after 25 years, increases again among middle-aged 
women [164]. If we look further into HPV genotype-specific data in the meta-analysis, the five most 
prevalent genotypes worldwide are HPV 16 (3.2%), HPV 18 (1.4%), HPV 52 (0.9%), HPV 31 
(0.8%), and HPV 58 (0.7%) [160]. Prevalence rates of the remaining genotypes are 0.6% or less, 
including for HPV 6 (0.5%) and HPV 11 (0.2%) (the two most prevalent genotypes associated with 
genital warts). 
A different meta-analysis, including 260,000 women with normal cytology and 103,000 
women with cervical abnormalities (including 36,000 with invasive cancer), reported an HPV 
prevalence rate of 12.0% among women with negative cytology [169]. This study also showed that 
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the prevalence of the HPV infection increases with the severity of cervical lesions, until about 90.0% 
HPV DNA-positivity among women with CIN3. As expected, apart from being the most prevalent 
HPV genotype worldwide, HPV 16 prevalence greatly increases with the severity of cytological and 
histological findings. The three most commonly found HPV genotypes in women with ICC (HPV 16, 
18 and 45), were detected in a distinct proportion in women with normal cytology, with 20.0%, 8.0% 
and 5.0%, respectively, when compared to 63.0%, 16.0% and 5.0% in women with ICC, respectively 
(Fig.4) [169]. 
 
Fig. 4: Global cervical cancer incidence rate and HPV prevalence in asymptomatic women [www.nature.com]. 
 
It is somewhat difficult to compare the HPV genotype-specific distribution levels associated 
to cervical cancer development between different studies because of different inclusion criteria of 
study subjects and also due to different detection methods [170]. Considering the lifetime risk of 
women for acquiring HPV (80.0%), the most prevalent genotypes found in cervical cancer are HPV 
16 (61.0%), followed by HPV 18 (10.0%), HPV 45 (9.0%), HPV 31 (6.0%), and HPV 33 (3.0%) 
[13,151,171]. Infections with multiple genotypes are fairly common as several population-based 
studies have reported that more than 30.0% of HPV-positive women are infected with more than one 
HPV genotype [161,167,172]. 
A higher HPV prevalence amongst young women might be due to different sexual behavior. 
The prevalence peak in women under 24 years coincides with sexual debut, with increasing risk for 
an early age at sexual initiation. Several studies have found that increasing numbers of lifetime sexual 
partners and numbers of sexual contacts (and consequently the number of sexual partners and 
contacts of the male partner) during the last year is associated with HPV 16 infection 
[157,167,173,174]. Considering that genital and perineal skin constitute reservoirs for HPV infection, 
condoms, if used incorrectly, only offer partial protection [175]. No association between condom use 
and protection from HPV infection was found in population-based cross-sectional studies performed 
by IARC [176]; however, a prospective study reported a 70.0% reduction on HPV incidence among 
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women whose partners “used condoms all the time”, compared to women whose partners “used 
condoms less than 5.0% of the time” [177]. HPV prevalence is higher in immunocompromised hosts 
such as renal transplant recipients and HIV-positive subjects [178]. Other factors that have been 
reported to increase the risk for HPV infection are smoking and oral contraceptives [157,179]. 
However, these factors tend to covariate with sexual risk-taking behavior and some studies have 
failed to find an association [177,180]. 
The potential cofactors involved in the progression from HPV infection to high-grade 
neoplasia, and subsequently invasion to cervical cancer, could be classified as virological, 
environmental and host factors. Virological cofactors includes HPV genotype, HPV variants, 
multiple HPV genotypes, viral load at the time of infection, and viral integration, while 
environmental factors includes use of hormonal contraceptives for a long time [180,181], high parity, 
tobacco smoking, and co-infection with other STIs, namely HSV2, Chlamydia trachomatis [180], and 
HIV [182]. 
 
 
Natural History of Cervical Cancer 
 
Several prospective studies have provided a reasonably complete scenario of the natural 
history of the HPV cervical infection that leads to CIN3, but there is a poorer insight regarding the 
final steps of carcinogenesis (Fig.5) [137,183]. The moment of acquisition of the HPV infection 
seems to be the most difficult event to assess, so the majority of prospective studies based on cross-
sectional populations may mixture short and long-term infections. To this point, a definition of 
persistence has not been established since different studies use distinct, arbitrary cut points. It is 
thought that HPV 16 has the ability to persist longer than other HPV genotypes [184-187] even with 
no development of CIN3 or worse (CIN3+). Moreover, it seems clear that the viral genotype 
constitutes the major risk predictor for CIN3+ development [64]. 
Of the estimated 291 million women infected by HR-HPV, the vast majority will become 
transient or develop persistently infected without any visible clinical symptoms (80.0%). The 
remaining will develop CIN, which may or may not progress to cancer [5,152]. Amongst the different 
cervical abnormalities that may be developed during an HPV infection, mostly will regress 
spontaneously, with subsequent clearance of HPV infection. Although the observed decrease of 
regression rate with increasing severity of CIN, cervical cancer represents a rare complication as it 
only affects nearly 2.0% of the HPV-infected women worldwide, and it occurs throughout a series of 
key events that take more than 10 to 15 years to unfold [188]. 
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Fig. 5: Evolution of HPV infection and cervical cancer development [189]. 
 
The natural history of cervical cancer develops through premalignant lesions. These lesions 
are classified as CIN and are detectable by cervical cytology and/or histopathology. In most of the 
European countries, squamous lesions are classified as CIN1, 2 or 3 representing increased severity 
of lesion [190]. In the USA, lesions are classified according to the Bethesda system where low-grade 
squamous intraepithelial lesion (LSIL) is equivalent to CIN1 and high-grade squamous intraepithelial 
lesions (HSIL) includes both CIN2 and 3 [191]. The histological classification of premalignant 
cervical glandular lesions is less clear but the WHO classifies lesions as glandular dysplasia and 
adenocarcinoma in situ [192]. 
Despite standardized criteria, it has been shown that there is substantial inter-observer 
variability in interpretation of CIN especially regarding CIN1 lesions [193] and CIN2 lesions. Recent 
data evidenced that regression rates of CIN2 among women under 25 years are quite high, reaching 
up to 70.0% in women aged under 24 years (with HPV 16-associated CIN2 regression close to 
50.0%) [194]. In older women the regression rates are lower – around 30.0 to 50.0% through a two-
year period [195,196]. 
The progression from CIN to cervical cancer is generally estimated in 5 to 10 years [5,197]. 
However, not all premalignant lesions will progress into cervical cancer. Estimates of progression 
and regression rates of different histological stages are highly uncertain, primarily due to 
misclassification of lesions and treatment of CIN lesions. Studies examining CIN progression rates 
have found that the risk is related to the severity of dysplasia (Fig.6) [198,199]. 
Women with cervical cancer were 15 times more likely to have had a previous Papanicolau 
(Pap) smear positive for HPV DNA, and a perfect concordance was observed between the HPV 
genotype detected in the Pap smear and the genotype detected in the subsequent cervical cancer. 
Several prospective cohort studies have found that particular HPV genotypes confer an increased risk 
for future premalignant lesions, with HPV 16 consistently inferring a very high-risk, suggesting that 
the most important viral characteristics linked to progression to cervical cancer, are the viral genotype 
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and its associated persistence rates rather than progression through distinct stages of cervical lesions 
[155,162,185,200-203]. 
 
 
Fig. 6: Model of cervical carcinogenesis, where major steps are represented: HPV infection (balanced by viral 
clearance), progression to CIN (partly offset by regression of low-grade lesions), and invasion. The persistence, and 
ultimately the integration, of oncogenic HPV genotypes are necessary for lesion progression and tissue invasion 
[198,204]. 
 
 
Cervical Cancer Prevention 
 
HPV primary prevention aims to avoid the infection and it relies on prophylactic vaccination. 
Secondary prevention attempts to reduce morbidity in pre-symptomatic subjects who already have 
established HPV infection and it is based on early detection and treatment, like screening programs to 
detect CIN and cervical cancer [205,206]. Tertiary cervical cancer prevention is to be applied in 
patients that already have clinical signs of the disease in view of cure, palliation, rehabilitation, or 
prevention of recurrence complications [205]. Preventive measures can be evaluated in terms of 
efficacy, defined as the extent to which an intervention produces a beneficial result in laboratory 
studies, or in terms of effectiveness, defined as the extent to how well that specific intervention does 
what it is intended for the population in clinical practice, when used under routine settings [207]. The 
natural history of cervical cancer makes it somewhat difficult to evaluate the efficacy of primary and 
secondary prevention, which is best assessed in randomized controlled trials while ensuring high 
internal validation [208,209]. 
 
Primary Prevention through HPV Vaccination 
 
Two HPV vaccines are currently available, identified as Gardasil
®
 (Merck & Co., Inc., 
Whitehouse Station, NJ, USA), often referred to as the quadrivalent vaccine and Cervarix
®
 
CIN1 CIN2 CIN3
Regression 57% 43% 32%
Persistence 32% 35% 56%
Progression 11% 22%
>12%
Invasion 1% 5%
HPV Infection
Persistence
CIN1
Regression
CIN2/3 ICC
Progression / Invasion
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(GlaxoSmithKline Biologicals, Rixensart, Belgium), also referred to as bivalent vaccine. Gardasil
®
 
targets the oncogenic HPV 16 and 18 genotypes and two non-oncogenic HPV genotypes (6 and 11) 
that are responsible for genital warts and RRP. Cervarix
®
 only targets for the same two oncogenic 
HPV genotypes (16 and 18) and is formulated with a novel adjuvant, ASO4, intended to boost the 
immune response. At present, one or even both vaccines are licensed in approximately 120 countries 
worldwide, mainly included in routine vaccination programs targeting pre-adolescent and adolescent 
girls plus “catch-up” immunization in older cohorts with variable upper age limits [210,211]. 
To date, these two vaccines evidenced very high levels of efficacy against the CIN2+ disease 
endpoint defined for the oncogenic HPV 16 and 18 genotypes. So far, vaccination trials have shown 
adequate safety and tolerability, high immunogenicity, long-term duration of protection (ongoing 
follow-up of phase II studies have shown vaccine efficacy up to 8.4 years), and strong ability to 
induce immune memory [76]. It has been shown that these two vaccines confer some degree of cross-
protection against CIN2+ lesions associated to other HR-HPV genotypes phylogenetically related but 
not included in the vaccines (HPV 31 for both vaccines and HPV 33 and 45 for Cervarix
®
). 
Therefore, the global estimates for the protection against cervical cancer can be increased up to 
80.0% of cases, accounting for the HPV genotype cross-protection. However, the duration of cross-
protection has not yet been determined and may well be less than for the HPV genotypes included in 
the vaccine. Protection for premalignant lesions of the vulva, vagina and anus has also been 
documented with the same vaccines [212,213]. Similarly, Gardasil
®
 promoted almost complete 
protection (> 95.0%) against genital warts in both men and women [214,215]. Finally, HPV vaccines 
are putatively valid worldwide as HPV genotype-specific cervical cancer estimates show little 
geographical variation. 
HPV vaccines lack therapeutic effects and thus require continuous screening programs, 
including among vaccinated women. Although the high cost of the vaccine has delayed its 
implementation, at present, public tenders reduced the cost, making vaccination and screening 
programs more affordable for developed countries [210,216]. HPV vaccination programs should 
induce substantial modifications over screening algorithms in a near future. First, vaccinated women 
will reduce the incidence of HPV 16 and 18-related precancerous lesions, decreasing the validity of 
screening test results, especially on cytology-based programs [217]. Furthermore, if second-
generation broad spectrum vaccines become available, protection against cervical cancer might 
achieve 90.0 to 95.0%, dramatically reducing the incidence of the disease worldwide, so that 
screening might no longer be cost-effective in immunized cohorts [218]. The results of a nanovalent 
HPV vaccine trial will be soon available and might again change future perspectives for cervical 
cancer prevention [211,219]. 
Recent vaccine trials in men have shown their ability to prevent external genital warts, anal 
and penile HPV infections, as well as its associated lesions in MSM [213,215]. There are several 
major arguments favoring male vaccination for reducing cervical cancer: i) the expected impact on 
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herd immunity, whenever the vaccination coverage in women is lower than 70.0%; ii) the high 
impact on genital warts in men, considering the quadrivalent vaccine; iii) the reduction of HPV-
related cancers in men genitalia; and iv) reduction of social concerns about safety of HPV 
vaccination, raised by promotion of single gender vaccination only. Alternatively, the major 
objections for male vaccination are: i) the late age-related burden of HPV-associated cancers in men 
(as opposed to early focus on cervical cancer in women); ii) the still limited data on potential impact 
of HPV vaccines over men’s health; and iii) the high cost of vaccines that could imp ly that male 
vaccination is not cost-effective. Nonetheless, while women vaccination has been widely 
recommended signalling the public health priority for cervical cancer prevention, licensing of HPV 
vaccines for men has just been released in a few developed countries, so that some high-risk groups 
(MSM) are currently being vaccinated [220]. 
 
Cervical Cancer Screening3 
 
Since the development of cytology-based cervical cancer screening, Pap smears and the new 
cytology-based technologies such as liquid-based cytology (LBC) have been implemented for 
prevention of cervical cancer. The advent of molecular techniques in HPV DNA detection evidenced 
cytological and histological diagnosis as not enough sensitive to predict HPV infection; in fact, no 
cytological or histological correlation of HPV infection can be detected in the majority of women 
who are positive for HPV DNA [168,221,222]. 
Cytological reading of cervical smears has been the primary screening technology, but due to 
test limitations, very frequent re-screening events were required to reach a cervical cancer reduction 
in the range of the 50.0% to 70.0% in the best settings (meta-analysis average) [223]. Indeed, 
cytology is a subjective labour intensive test and in the absence of quality control programs, it is 
virtually impossible to achieve and maintain the clinical necessary standards, due to low 
reproducibility and sensitivity of the Pap smear [224,225]. LBC has logistical and operational 
advantages, but is more expensive without any sensitivity or specificity increase comparing to 
conventional cytology for detection of histologically confirmed CIN2+ lesions [168]. 
HPV DNA testing, as an adjunct to cytology, may be of value in triage
4
 of atypical squamous 
cells of undetermined significance (ASC-US) and LSIL, considering that only 10.0% of the women 
with abnormal smears have a premalignant lesion and colposcopy referral is not necessary for the 
majority of the HPV-infected women [226]. Triage with HPV DNA testing can help to identify 
women at higher risk and consequently improve their management [227-231]. In addition, HPV DNA 
                                                 
3
 The Portuguese cervical cancer screening programs will be described in Chapter 2, due to the importance of epidemiologic 
data for the objectives aimed in this PhD thesis. 
4 Term applied to selection of women with abnormal cytology using HPV DNA test for better risk evaluation in a screening 
program. 
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testing can be useful to predict cure or failure of clinical treatment (by local ablative or excisional 
therapy) in the follow-up of high-grade CIN lesions. The use of combined screening through cytology 
and HPV DNA testing should guide to a better selection of women at risk for residual/recurrent CIN, 
as suggested by some studies [231-234]. This combined procedure might avoid unnecessary 
procedures in patients without this risk factor, with important reduction of health costs and associated 
anxiety among women. 
The persistence of detectable HPV DNA in CIN lesions prompted the evaluation of DNA 
assays as a screening tool for the early detection of CIN2+. All the findings evidenced an increase in 
sensitivity in the range of 35.0 to 40.0%, related with the use of HPV DNA tests when compared with 
conventional cytology or LBC. The corresponding decrease of specificity was in the range of 8.0 to 
12.0% when compared to conventional Pap smears [223,235]. One HPV DNA test that could be used 
for screening in women with ASC-US is Hybrid Capture® 2 High-Risk HPV DNA Test (HC2) 
(Qiagen, Gaithersburg, MD, USA) [236], which has been widely implemented. Data obtained from 
meta-analysis reveals a better performance of HC2 to triage women with ASC-US, higher sensitivity 
and similar specificity, compared to repeated cytology-based re-screening testing [237]. Moreover, 
HC2 is considered significantly more sensitive for detecting CIN2+, favoring its recommendation to 
triage women who need referral to colposcopy [231]. 
New guidelines propose that an HPV DNA test should achieve clinical validation, and a 
clinical sensitivity of at least 90.0% for detecting CIN2+, in order to consider its recommendation for 
triage of abnormal smears [238]. However, this high clinical sensitivity usually means a lower 
specificity, around 40.0 to 60.0% (and the respective positive predictive value (PPV) of 20.0-30.0%), 
which is below optimal, requiring the need for using other specific markers such as HPV RNA 
testing. The management of women infected with HPV, and positive for secondary markers, is 
indicative of higher risk for cervical premalignant lesions and implicates more intensive follow-up 
than being negative for such markers. A recent meta-analysis has revealed that HPV RNA testing 
provides higher specificity but less sensitivity, when compared to HPV DNA testing, suggesting that 
these assays should be considered as reflex tests [231,239]. 
When considering triage of women with LSIL, HC2 test is not recommended, because is not 
more sensitive (and substantially less specific) than repeated cytological screening [235,240,241]. 
Management of women with LSIL requires knowledge on local prevalence of HPV infection and 
cost-effectiveness analyses, considering the high proportion of HR-HPV DNA in women with low-
grade lesions. Women usually undergo colposcopy and if the biopsy reveals to be negative or CIN1, 
it is recommended an HPV test after 12 months or repeated cytology at 6-month interval. However, 
one can wait for viral clearance, especially in younger women, given the high HPV prevalence and 
the high regression rate that would reduce the need for colposcopy [134,240,242]. Restrict HPV DNA 
triage testing only to older women could be an alternative management option, but more accurate 
age-specific data is needed before defining exact age cut-off. 
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HPV DNA testing could be suitable for primary screening, but there is no sufficient data to 
corroborate that the actual cervical cancer incidence might decrease in accordance, more than what it 
would when cytology-based screening was used, mainly because some high-grade lesions might also 
regress. For this reason, HPV DNA-based cervical cancer screening programs have not yet been 
recommended in Europe [243]. Thus, HPV DNA detection is mainly advantageous for women older 
than 30 years, in the absence of more specific tests. If HPV DNA-based screening programs are 
implemented at a later age (since the majority of transient infections affect younger women), together 
with stretching the re-screening intervals (due to the higher sensitivity of these tests), and the 
eventual use of self-collected samples protocols ( in low-resource countries), the efficiency of 
screening may increase [225,244]. 
The high negative predictive value (NPV) of HPV DNA tests, both for screening and for 
post-treatment of high-grade lesions (‘test of cure’), have lead to new clinical procedures changing 
algorithms towards less frequent re-screening visits [233,245]. Low-cost HPV tests have started to be 
implemented in developing countries and should have a significant impact on mortality reduction in 
some settings [246-248]. Considering that they can be applied on self-collected samples, HPV DNA-
based screening could reach socio-cultural environments where conventional cytology is not well 
accepted [244,249]. 
Some data [103,153] seem to show that the incidence of cervical cancer could be decreasing 
at a similar rate worldwide, as a result of the introduction of effective population-based screening 
procedures combined with the generalized easier access to health care and improvements in education 
[250]. 
 
New Screening Technologies 
In this section is described the most promising of the novel screening markers for cervical 
cancer risk. 
 
HPV DNA Tests 
A single positive HPV DNA test predicts a higher risk for the development of a premalignant 
lesion, despite the expected clearance of the majority of infections [251]. HPV genotyping assays 
may differentiate sequential infection caused by different genotypes from a persistent infection with 
the same genotype, which would increase specificity of a routine screening program (Fig.7) 
[183,240,252,253]. Genotype-specific DNA positivity, especially for HPV 16 and 18 is highly linked 
to an elevated risk for development of cervical cancer, now extended to the risk of adenocarcinoma, 
which often escapes cytological screening [254]. The potential benefit in discriminating HPV 16 and 
18 from other high-risk genotypes is the potential increase of the PPV, since these genotypes are 
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responsible for the majority of cervical cancer cases worldwide, which could provide better 
management of the women at risk [255]. In a cytology-based screening program, genotyping of HPV 
16 and 18 from other HR-HPV genotypes may be important to stratify the risk for CIN3+ 
development, with an estimated cumulative risk of 17.0% for HPV 16, 14.0% for HPV 18, and 3.0% 
for other HR-HPV genotype [201,256-259]. 
Several international practice guidelines have recommended the use of HPV DNA testing in 
routine screening. So far, two commercial HR-HPV DNA-based tests have the approval to be used in 
screening from the Food and Drug Administration (FDA): the HC2 test (since April 2003) and the 
Cervista™ HPV HR assay (Hologic, Inc, Marlborough, MA, USA) (since April 2009) [255]. Both 
methodologies detect concurrently 13 HR-HPV genotypes (HPV 16, 18, 31, 33, 45, 51, 52, 56, 58, 
59, and 68); Cervista™ HPV HR assay further includes HPV 66. Other commercial tests consist in a 
pooled detection of HR-HPV genotypes: the Amplicor HPV test (Roche Molecular Systems, Inc, 
Pleasanton, CA, USA), based in PCR amplification, and the Care HPV test (Qiagen, Gaithersburg, 
MD, USA), based on hybrid capture technology (suitable for low-resources settings) [255]. 
 
Fig. 7: Scheme of targeted spectrum of HPV infection/cervical disease cases in a screening population. 
 
The clinical importance attributed to HPV 16 and 18 infections raised the emergence of HPV 
screening tests that include the specific identification of these genotypes, which are referred to as 
HR-HPV DNA detection assays with concurrent or reflex HPV 16 and HPV 18 genotyping [255]. 
There are four commercial assays that include concurrent or reflex HPV 16 and HPV 18 genotyping, 
two of them under FDA approval: the Cobas® 4800 HPV (Roche Molecular Systems, Inc, 
Pleasanton, CA, USA) (April 2011) and the Cervista HPV-16/18 test (Hologic, Inc, Marlborough, 
MA, USA) (April 2009). The other two are the Abbott RealTime High-Risk (HR) HPV test (Abbott 
Molecular, Des Plaines, IL, USA) and the HR HPV 16/18/45 Probe Set test (Qiagen, Gaithersburg, 
MD; USA) [255]. Cobas® 4800 HPV and Abbott RealTime HR HPV tests are fully automated 
systems based in multiplex real-time PCR methodology that identifies HPV 16 and 18 with 
concurrent detection of twelve other HPV genotypes (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, 
and 68). Cervista HPV-16/18 test uses a patented Invader
®
 chemistry to identify HPV 16 and 18 and 
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can be performed either manually or fully automated. HR HPV 16/18/45 Probe Set test consists in 
signal amplification based on hybrid capture technology using a specific probe designed for HPV 
16/18/45 detection [255]. 
HPV genotyping tests are commonly used in studies regarding HPV genotype-specific 
prevalence, HPV vaccines evaluation and monitorization. The specific identification of HPV 16 and 
18 is intended for screening programs. Nevertheless, each commercial assay should take part in 
international proficiency studies in order to assess their performance and potential clinical use in 
detecting precancerous lesions [260-262]. Several studies were published comparing HPV 
genotyping tests with HR-HPV DNA screening tests with reflex HPV 16 and HPV 18 genotyping 
and there seems to be some variability concerning their analytical sensitivity [263-265]. 
Concerning HPV genotyping systems, there are several commercial assays available, 
partially automated, that are either based on reverse-line blot hybridization: the INNO-LiPA HPV 
Genotyping Extra (Innogenetics, Gent, Belgium) (28 HPV genotypes) and the Linear Array HPV 
Genotyping Test (Roche Molecular Systems, Inc, Pleasanton, CA, USA) (37 HPV genotypes); or 
based on PCR-based microarray for genotyping: the PapilloCheck® Test Kit (Greiner Bio-One 
GmbH, Frickenhausen, Germany) (24 HPV genotypes); the CLART® Papillomavirus Humano 2 
(Genomica, Madrid, Spain) (35 HPV genotypes); and the Infiniti HPV Genotyping Assay 
(AutoGenomics Inc, CA, USA) (26 HPV genotypes) [16,255]. 
Other commercial systems could serve as triage for HPV DNA-positive women, but there is 
still insufficient data. For instance, to use RNA testing in HR-HPV DNA-positive women, with 
cytology-negative and/or HPV 16/18-negative could increase specificity in detecting high-grade 
lesions with minimal loss of sensitivity [266]. 
It is anticipated that, since the implementation of HPV vaccines, the use of HPV genotyping 
in post-vaccination screening and/or surveillance studies is required. Population-based genotyping 
characterization pre- and post-vaccination should be important to determine overall vaccine 
effectiveness and potential unmasking of niche replacements by non-vaccine HPV genotypes. 
 
HPV Viral Load 
High viral load for most HR-HPV genotypes is associated with prevalent cervical cancer 
precursors [267]. HPV 16 viral loads have been associated with CIN2+ in cross-sectional studies and 
with progression to CIN2+ or ICC in prospective studies [268,269]. In fact, the association of high 
viral load with CIN2+ lesions seems to be true for most oncogenic genotypes; however, the 
prospective increased risk for CIN2+ associated with high viral loads is independent upon the 
genotype detected, and may be restricted to HPV 16 [270]. Translation of these observational viral 
load and disease associations into the clinical management of CIN is limited, due to the complexity of 
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the necessary evaluation of the assays, specimen sampling variability, and the common presence of 
more than one carcinogenic genotype. 
At present, the few commercial methodologies available do not provide exact viral load 
quantitation data, but the HC2 test is a semi-quantitative methodology for detection of HPV DNA. 
Other methods for viral load quantitation include both conventional and real-time polymerase chain 
reaction (PCR). The obvious limitation of the real-time PCR method is the requirement for multiple 
genotype-specific assays. Yet, quantitative assays of HPV genotype-specific viral load lack 
prognostic value, and require cost-efficacy studies on genotype-specific quantitation testing 
compared to other screening approaches. 
 
HPV Integration 
HPV 16 integration is commonly detected in CIN2+. Multiple methods for detection of 
integrated HPV DNA have been described [271-273]; however, most of them evidenced limitations 
similar to those described for HPV viral load quantitation. Because cervical epithelial cells from 
women with CIN1 or CIN2+ may simultaneously contain episomal and integrated HPV DNA, the 
use of integrate-specific DNA PCR methods could be misleading and induce misclassification of 
cases [274]. Differentiation of transcriptionally active integrants could, in theory, constitute a more 
specific marker of disease risk; however, at present, the assays are too complex to be used for routine 
purposes. In addition, recent data suggest that integration frequency among pre- and malignant 
lesions varies with the HPV genotype involved, further reducing the desired gains in specificity 
[275]. A comparative study between integrated forms of HPV 16 and 18 DNA in CIN development 
showed a trend in the prognostic value of this biomarker for HPV 18 infection cases, related with a 
more aggressive biological behavior of this genotype [276]. 
It is unlikely that a single screening test will provide the necessary clinical sensitivity, thus, 
some false negatives are to be expected. An increment in the clinical specificity or the PPV is the 
goal of future screening tests. The identification of potential biomarkers with predictive value for 
cervical neoplastic progression remains an important priority, following future adaptation in 
screening programs. 
 
HPV mRNA 
The oncoproteins E6 and E7 play a leading role in the carcinogenesis process, as these 
proteins are overexpressed throughout epithelial cells in high-grade lesions and cancer. This means 
that overexpression of E6 and E7 would distinguish transient infections from productive, inductive of 
malignant changes, infections. Thus, detection and quantitation of mRNA from E6 and E7 genes of 
HR-HPV could be a more specific marker of the presence of CIN2+ and ICC. 
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Commercial tests targeting HPV mRNA are now available: APTIMA® HPV (Hologic Gen-
Probe Incorporated, San Diego, CA, USA) and NucliSENS® EasyQ® HPV (bioMérieux SA, Marcy 
l’Etoile, France). These assays present different approaches, meaning that they should be used at 
different stages of the screening algorithm. The APTIMA® HPV assay does not distinguish the HR-
HPV genotype; in fact, it can qualitatively detect the presence of mRNA of at least one of 14 HR-
HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), and is already 
approved by the FDA. The approach used in this assay, while increasing the specificity and the PPV, 
will also achieve sensitivities and NPVs similar to HPV DNA tests, recommending its possible use in 
routine screening as co-testing with cytology [223,277,278]. But working with mRNA represents 
higher technical complexity related with the low RNA stability, which resolution would increase 
costs, and more importantly, the compatibility with the different sample collection buffers is  
unknown. NucliSENS® EasyQ® HPV only semi-quantifies the overexpression of E6 and E7 genes 
for five HR-HPV genotypes (HPV 16, 18, 31, 33, and 45), the most associated with cervical cancer 
cases. The higher specificity of this mRNA assay would reduce false positives, as they would exclude 
transient infections, so they could be used as a triage test for HPV DNA-positive women, reducing 
the colposcopy referral in cytological abnormalities and therefore improving patient management 
[233,279]. 
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OBJECTIVES 
 
 
 
Worldwide, cervical cancer is a major public health problem, and there is irrefutable evidence 
that cervical infection by oncogenic (high-risk) HPV genotypes is the primary risk factor for the 
development of this neoplasia. 
Despite the introduction of HPV vaccines in several developed countries, the expected 
reduction on HPV infection rate among women, and the reduction in cervical cancer incidence rates 
are yet to be observed, mostly because, when the vaccine was introduced, a vast majority of women 
was already infected by HPV. Also, considering the discrepancy between HPV vaccination age and 
cervical cancer screening age, several decades will be needed before considering any slowdown on 
cervical cancer screening programs. 
Nowadays, cervical cancer prevention through organized screening programs is essential for 
the management of HPV-infected women. Conventional cytology, highly specific, has long been 
considered as the standard cervical cancer screening method; however, it lacks sensitivity  for 
detecting the early stages of the disease. More recently, molecular biology research boosted the 
sensitivity of HPV molecular diagnostic tests, but the later recognizably lack specificity and, more 
importantly, they lack clinical validation to predict disease, which is essential for its recommendation 
for cervical cancer screening (even when used together with cytology). So, which is the best strategy 
for cervical cancer screening in a near future? The answer relies on country economical conditions 
and population characteristics (age distribution, sexual habits), and on local HPV epidemiological 
data (prevalence, HPV genotype-specific distribution) which, together, would determine the optimal 
management of HPV-infected women. 
From the exposed and considering the impact of cervical cancer in Portugal (one of the 
highest rates in Europe), the general goal of the present PhD thesis was to better understand HPV 
biology and carcinogenesis by evaluating different biomarkers for cervical disease. Particularly, 
several HPV DNA tests (in what concerns sensitivity and specificity, PPV and NPV, and adequacy 
for screening in each disease stage) were evaluated as well as some recognized molecular markers 
(HPV genotype, viral load, viral integration), either during opportunistic and selected screening 
(involving women with and without cervical lesions). Cervical cancer screening in Portugal was 
analyzed and alternative strategies and future scenarios were proposed, the later according to the 
mathematical models developed during the present study. 
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In detail, the following objectives were pursued, constituting the subject of each chapter of 
the present PhD thesis: 
 
To further the understanding of HPV infection in women, in order to develop cancer 
prevention strategies applied to local settings (Main goal 1): 
 To assess the overall prevalence of HPV in cytological normal smears, ASCUS, LSIL, HSIL, CIN, ICC 
and other glandular lesions (including adenocarcinoma) in the general female population of selected areas in 
Portugal; 
 To determine HPV infection age-specific d istribution; 
 To determine oncogenic HPV genotype-specific d istribution; 
 To determine HPV-specific patterns concerning single and mult iple infect ions; 
 To perform clinical validation of HPV DNA assays. 
 
As a way to fulfil this main goal, 2149 samples were selected from women attending to 
Human Papillomavirus Reference Laboratory at National Institute of Health (INSA) for HPV testing 
(opportunistic screening), and further associated with the respective clinical diagnosis and age 
anonymously. This global evaluation constituted a prospective epidemiological study, where it was 
evaluated risk factors for HPV infection and cervical cancer. In Chapter 3, the selection criteria were 
exposed in detail, as well as the laboratory procedures performed to assess the overall HPV 
prevalence and HPV genotype-specific distribution. A new selection of 731 samples of women with 
and without cervical disease (within the primary 2149 samples) constituted the study group to 
evaluate the clinical performance of different HPV tests for further use in clinical practice (Chapter 
5). A control group was constituted by samples from women who had not developed disease at the 
time of HPV diagnosis. An extensively detailed evaluation and clinical validation of one commercial 
system HPV DNA test was the subject of Paper II (Chapter 4). 
 
 
To evaluate the importance of molecular markers for early diagnosis of women at risk for 
HPV persistence and lesion progression (Main goal 2): 
 To establish the clinical utility of a commercial system of E6/E7 mRNA assay in routine 
screening/triage of normal, ASCUS and low-risk lesions by predicting which  HPV-positive women will 
develop pre-malignant or malignant lesions; 
 To assess viral load as a predictive molecu lar marker of persistent high-risk in fection; 
 To assess physical status of HPV DNA as a molecular marker for disease progression. 
 
The detailed evaluation of the clinical performance of one mRNA commercial system was 
the subject of Paper III (Chapter 6). The evaluation of potential molecular markers (viral load and 
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physical status assessment) was performed on a subset of 499 samples that were previously 
genotyped as HPV 16 and 18 within the primary 2149 samples. This evaluation relied on real-time 
PCR methodology, and each molecular marker was assessed in the same specimen (Chapters 7 and 
8). In order to apply these methodologies to cytological cervical samples, while reducing the need for 
colposcopy referral, the same nucleic acids extraction was used to each individual molecular marker 
under evaluation. Further analysis on which methodology was more adequate to prevent HPV 16 and 
18 high-grade cervical lesions development was discussed on Chapter 10. 
 
To provide baseline information to evaluate future screening and vaccination strategies 
suitable for the population of the selected areas (Main goal 3): 
 To apply mathemat ical models in the evaluation of the impact of HPV vaccination and to estimate the 
risk factors for HPV infection. 
 
All data collected throughout the following chapters was used to formulate different 
scenarios applying a mathematical modelling approach which was discussed in detail in Chapter 9. A 
proposed screening strategy was presented in Chapter 10 that includes general discussion and future 
perspectives. 
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ABSTRACT 
Portugal has one of the highest incidence and mortality rates for cervical cancer in Europe, 
evidenced by the 949 new cases and 346 deaths registered in 2008. The CLEOPATRE Portugal 
Study has provided baseline epidemiological data, where primary prevention through human 
papillomavirus (HPV) vaccination appears to be a promising tool for preventing cervical cancer. 
Furthermore, that study showed that an appropriate screening strategy could reduce the current 
cervical cancer incidence in almost 50.0%. 
Cervical cancer screening programs have been implemented regionally in Portugal, and the 
different algorithms may influence the expected reduction in cervical cancer incidence rates. The 
imbalanced geographical distribution of these programs can worsen the access to HPV opportunistic 
screening of low-resource populations that rely completely on the free of charge programs provided 
by the national healthcare system. HPV vaccination has been introduced in the national immunization 
program for girls aged 13 years, with an estimated coverage rate of 80.0%. 
Worldwide, cervical cancer is an important public health problem, and the intention to reduce 
its incidence includes taking public health decisions and the design of strategies for prevention, 
screening and treatment. Preventive measures include health education to decrease risk behaviors, 
and, more recently, HPV vaccination. Screening aims to early detect and diagnose cytological 
abnormalities and precancerous lesions, in time to apply successful treatment options and ultimately 
prevent cervical cancer. 
 
Keywords: Cervical cancer, screening programs, human papillomavirus, Portugal.  
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EPIDEMIOLOGICAL DATA 
 
Incidence rates of cervical cancer across Europe are highly variable, with the lowest 
European incidence rate is observed in Finland (3.7 new cases per 100,000 women), while the 
reported incidence rate in Portugal is considerably higher (12.2 new cases per 100,000 women) [1]. A 
cross-sectional population-based study was conducted in mainland Portugal between 2008 and 2009, 
“The Cervical Lesions Observed by Papillomavirus Types – A Research in Europe (CLEOPATRE)” 
[2]. This study constitutes baseline information regarding prevalence of human papillomavirus (HPV) 
infection (overall and age-stratified) and comprises data from 2326 women selected from the five 
different regions across mainland Portugal.  
The overall HPV prevalence observed in the CLEOPATRE study was 19.4% (451/2326; 95% 
CI: 17.8-21.0); the estimated prevalence of HPV infection among Portuguese women aged 18 to 64 
years was 12.7% (95% CI: 11.2-14.4). It was observed a significant association of HPV infection 
with age, where young women (aged < 25 years) evidenced the highest prevalence rates, as expected 
from the described by other studies (Table 1) [2-5]. 
 
Table 1: Prevalence of HPV infection by age group in the CLEOPATRE Portugal Study sample and estimated 
prevalence (weighted) for the general female population of mainland Portugal aged 18 to 64 years 
Age  
Group, 
Years 
Study Sample  Female Population of Mainland Portugal 
No. 
Women 
Tested 
No. Women 
HPV-positive 
% (95% CI) P* 
 
n % (95% CI) P* 
Total 2326 451 19.4 (17.8-21.0) <0.001  3,293,911.6 12.7 (11.2-14.4) <0.001 
  18-19 274 74 27.0 (21.8-32.3)   106,974.1 26.4 (21.5-31.9)  
  20-24 691 199 28.8 (25.4-32.3)   299,096.8 28.7 (25.5-32.2)  
  25-29 458 100 21.8 (18.1-25.6)   365,669.5 21.8 (18.3-25.9)  
  30-39 256 32 12.5 (8.5-16.6)   788,049.2 12.4 (8.9-17.1)  
  40-49 223 22 9.9 (6.0-13.8)   755,443.1 9.6 (6.4-14.2)  
  50-59 228 13 5.7 (2.7-8.7)   675,971.5 5.5 (3.2-9.2)  
  60-64 196 11 5.6 (2.4-8.8)   302,707.4 5.7 (3.2-10.0)  
n, standardized female population of mainland Portugal (weighted value); CI, confidence interval; *Pearson χ 2 test. [2]. 
 
Among HPV-positive women, infection with high-risk HPV (HR-HPV) genotypes was 
identified in 76.5% (345/451) of the cases, and the five most common circulating HR genotypes were 
HPV 16 (19.7%), followed by HPV 31 (11.8%), HPV 53 (11.8%), HPV 51 (9.8%), and HPV 66 
(8.6%), while HPV 18 was only detected in 4.4% of the infected women. This distribution pattern has 
been observed in several other European countries (Table 2) [6-11]. A statistically significant 
association could be established between the prevalence of HR-HPV infection and age (P < 0.001), 
and consequently HR genotypes were more frequent in younger women, in particular for the cohort 
aged 20 to 24 years (23.4%). 
Multiple infections were identified in 7.1% (165/2326) of the studied women, and in 36.6% 
(165/451) of the HPV-positive cases (estimated prevalence, 3.7%). Multiple infections were more 
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frequent in younger women but less frequent in normal cytologies or high-grade cervical lesions [2]. 
Considering the genotypes included in HPV vaccines, HPV 16 was the most frequent (3.8%), 
whereas HPV 6 (1.2%), HPV 18 (0.9%), and HPV 11 (0.4%) were scarce. Infection with at least one 
of these genotypes constitutes 32.6% of the HPV-positive cases, and co-infection with two of these 
genotypes was identified in 2.0% of those. 
 
Table 2: HPV DNA prevalence (% ) in women with high-grade lesions by worl d region 
World  Europe  Portugal  
HPV Type Prevalence   HPV Type Prevalence  HPV Type Prevalence 
16 45.4%  16 51.8%  16 49.7% 
31 8.7%  31 10.0%  31 11.8% 
33 7.3%  33 8.6%  58 11.2% 
58 7.0%  18 6.0%  33 5.9% 
18 6.9%  52 3.6%  51 5.9% 
52 5.1%  73 3.5%  52 5.3% 
35 3.8%  35 3.4%  18 4.7% 
51 3.6%  51 3.0%  35 4.7% 
The grey areas highlight HPV 16 and 18 prevalence rates. [2,12] 
 
In this screening-type population, 93.8% of the women exhibited a normal cytology. 
Stratification according to cytology revealed that HPV infection was detected in 16.5% of the normal 
cytologies (NILM) (estimated prevalence, 12.1%), but increased severity of cervical lesions was 
associated with higher values of HPV detection, namely 21.6% in atypical squamous cells of 
undetermined significance (ASC-US), and 54.5% in low-grade squamous intraepithelial lesion 
(LSIL). A statistically significant association could be established between infection with HR-HPV 
genotypes and cytological abnormalities (P < 0.001) [2]. These results are similar to the described in 
North European countries [4,13], but higher than the expected, considering what was described for 
other neighboring and Mediterranean countries [10,14,15]. 
 
Risk Factors 
CLEOPATRE Portugal Study also investigated potential risk factors for the acquisition of 
HPV infection. Women enrolled in the study reported using contraception (89.1%), a single lifetime 
sexual partner (57.3%), no prior sexual transmitted infections (STI) in the past 12 months (96.0%), 
were not immunocompromised (97.6%), and were currently smokers (22.3%) [16]. 
Young age increased the risk for HPV infection, with an odds ratio (OR) of 6.80 (95% CI: 
0.87-13.90) for women aged 20 to 24 years. In multivariate analysis, women aged 20 to 24 years 
were 3-fold more at risk than women aged 60 to 64 years, as it was described in other studies 
[4,17,18]. Smoking was associated with an increased risk for HPV infection (OR 2.18; 95% CI: 1.73-
2.75), while among current smokers, the risk of HPV infection increased with the number of 
cigarettes smoked. Age at first sexual intercourse (< 14 years) (OR 4.39; 95% CI: 1.37-14.13) and a 
high number of lifetime sexual partners (5-10 partners) (OR 8.58; 95% CI: 5.75-12.82) were both 
strongly associated with HPV infection. Having 5 to 10 sexual partners represented a 5-fold increased 
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risk for HPV infection (OR 5.44; 95% CI: 3.51-843), in multivariate analysis (P < 0.001), as 
described elsewhere [19]. Use of contraception increased the risk for HPV infection (OR 2.12; 95% 
CI: 1.40-3.20), where oral contraceptives induced the higher risk (OR 1.45; 95% CI: 1.04-2.03). 
Having a circumcised sexual partner represented an elevated risk (OR 1.72; 95% CI: 1.27-2.34), as 
opposed to women without STIs in the past 12 months (OR 0.31; 95% CI: 0.18-0.53), where the risk 
was minimal [16]. 
 
 
SCREENING PROGRAMS 
 
Screening strategies imply taking decisions that would be cost-beneficial for reducing 
incidence and mortality rates of cervical cancer. For more than 50 years, cervical cytology 
(conventional Papanicolau (Pap) smear or liquid-based cytology - LBC) has been the standard test for 
screening [20]. In regions where cytology-based programs have been successfully implemented, a 
reduction of 50.0 to 90.0% in cervical cancer incidence rates has been observed [21]. There is now 
substantial and consistent evidence that HPV DNA testing is about 20.0 to 45.0% more sensitive in 
detecting precancerous lesions, when compared to cytology [22-28]. The use of a single HPV DNA 
test could effectively reduce the incidence of cervical cancer within 4 to 5 years [26,28], and the 
mortality rate within 9 years [29], when compared to the impact of the use of a single cytology test. 
This made possible the recommendation of HPV DNA testing to be used as an adjunct to cytology (in 
a co-testing strategy), or as the primary screening test that would be followed by cytology [21]. Also, 
HPV DNA testing may be used in self-collected samples which can be an additional advantage for 
their use in poor clinical settings such as developing countries. In fact, the proven high sensibility of 
HPV DNA testing in detecting high-grade cervical lesions (CIN2+) determined its recommendation 
as primary screening test, especially due to the low sensitivity of the Pap smear test. However, 
repeated HPV genotyping test is needed before the identification of a HR-HPV persistent infection, 
which is the major risk factor for cervical cancer development. Thus, the use of HPV DNA testing as 
a primary screening test is only recommended in women older than 30 years, considering that HPV 
infections in younger women are usually transient and, therefore, clinically irrelevant. HPV DNA 
testing would benefit from specificity increment that might become available in a near future, leading 
to the universal recommendation for the triage of women with cytological abnormalities [22,30,31].  
Data from the CLEOPATRE Portugal Study suggested that vaccination could reduce HPV-
related disease burden in Portugal. However, the expected reduction outcome is difficult to assess as 
screening policies are not equally implemented across the whole country. In fact, differences on 
baseline testing (cytology or HPV DNA test), age and triage testing, and management of HPV-
positive women, differ among country regions. Since 2008, along with the introduction of HPV 
vaccines in the Portuguese national immunization program, different organized population-based 
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cervical cancer screening programs have been implemented by the five regional health 
administrations (ARS) (Fig.1). As it was pointed in 2012 in a report by the General Directorate of 
Health (DGS), the coverage rate is almost 100% in four of the five ARS, but for the remaining it is 
inexistent (ARS Lisboa e Vale do Tejo). This imbalanced geographical distribution can worsen the 
access to HPV opportunistic screening, especially for populations with low-resources that rely 
completely on the free of charge programs provided by the national healthcare system [32]. 
 
Fig. 1: Regional distribution of the five ARS in mainland Portugal [adapted from https://ec.europa.eu/]. 
 
ARS Centro 
The first Portuguese screening program was implemented by the ARS Centro back in 1990, 
which was designed to screen sexually active women aged 25 to 64 years, involving 65 healthcare 
centers. In 2007 the geographical area was expanded to the entire region (109 healthcare centers). It 
is expected to cover 481,000 women, by providing a cytology-based screening (Pap smear) program, 
within a 3-year re-screening interval. The women are recruited by post mail from the database of the 
different healthcare centers. In 2012, this cervical cancer screening program comprehended about 
84,000 cytologies, which corresponded to 58.0% of coverage rate (Fig.2) [33]. 
Cytological findings are classified according to the Bethesda System [34]. Histopathologic 
evaluations are performed in the two regional reference hospitals (Coimbra Portuguese Oncology 
Institute (IPO Coimbra) and Coimbra University Hospitals (HUC)) which apply quality control 
proceedings. For the recommended algorithm, each time a NILM result is obtained these women are 
conducted to re-screening. If an ASC-US result is identified, women are referred to a repeated 
cytological evaluation within six months, and if this test is negative women are conducted to re-
screening; in opposition, a positive result will lead women to colposcopic evaluation. When a 
cytological diagnosis of LSIL or worse is obtained, women are referred to one of the two reference 
regional hospitals for colposcopic evaluation. If minor abnormalities are detected in the biopsy, 
cytology is to be repeated within six months; in opposition to detection of major abnormalities, in 
which excisional treatment of cervical lesions will be performed. 
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Fig. 2: S implified screening algorithm of ARS Centro [33]. 
 
ARS Alentejo 
In 2008 ARS Alentejo implemented a cervical cancer screening program that was designed to 
screen sexually active women aged 30 to 64 years, involving 44 healthcare centers. In 2011, the 
geographical area was expanded, and another four healthcare centers were included, while the age 
range was enlarged to 25 to 64 years. It is expected that this program covers 148,000 women, 
providing a cytology-based screening (LBC) program and an HPV genotyping triage test in women 
with ASC-US. The women are recruited by post mail according to the different healthcare centers 
database. For the period between 2008 and 2012, more than 70,000 cytologies were already 
performed and a coverage rate higher than 80.0% was achieved (Fig.3) [35]. 
 
 
Fig. 3: S implified screening algorithm of ARS Alentejo [35]. The grey areas correspond to changes in the algorithm, 
when compared to the algorithm of ARS Centro (Fig.2). 
 
Cytological findings are classified according to the Bethesda System [34]. Both tests are 
performed in a central laboratory (Evora Central Hospital) which applies quality control proceedings. 
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For the recommended screening algorithm, it is intended to perform two LBC cytologies, one year 
apart, and if two negative cytology results are obtained, the re-screening interval increases to a 3-year 
interval. A negative result implies re-screening after 12 months; in opposition, if one of the 
cytological results reveals ASC-US, an HPV genotyping triage test will be performed, and if the later 
is also positive, women are referred to colposcopy in the central hospital. After colposcopy, if the 
biopsy evaluation reveals minor abnormalities, women are recruited to a new HPV genotyping test 
within 12 months. In the presence of major cervical abnormalities, excisional treatment options are 
undertaken, followed by an HPV genotyping test within 12 months. An HPV genotyping-negative 
result leads women back to re-screening; in opposition to an HPV genotyping-positive result that 
justifies a new referral to colposcopy. Women evidencing LSIL are referred to colposcopy and biopsy 
evaluation, and will undergo adequate procedures (according to the guidelines for ASC-US with an 
HPV-positive test). Women with atypical squamous cells that cannot exclude HSIL (ASC-H) lesions 
are referred to colposcopy and further biopsy evaluation, and will undergo the treatment options 
adequate to high-grade lesions. However, if the biopsy does not reveal cervical lesions, cytology is to 
be reviewed and followed by an HPV genotyping test within 12 months. Women with high-grade 
squamous intraepithelial lesions (HSIL) will undergo excisional treatment followed by an HPV 
genotyping test within 12 months. 
 
ARS Norte 
Up to 2009, opportunistic screening was covering about 40.0% of women living in the area 
covered by ARS Norte; however, women with low-resources were not involved in this system and 
consequently, they would be at higher risk for cervical cancer. With an estimated incidence rate for 
cervical cancer of 3.6 per 100,000 women, and 325 new cases of cervical cancer per year that 
resulted in 65 deaths, ARS Norte decided to implement an organized cytology-based screening 
(LBC) program, using Hybrid Capture® 2 HR HPV DNA Test (HC2) as triage test. Women are 
recruited by post mail, and 103 hea lthcare centers are currently involved, leading to an expected 
coverage rate above 70.0%. Age of women selected for screening ranges between 25 to 60 years with 
a 5-year re-screening interval (corresponding to a total of eight re-screening episodes during each 
woman lifetime) (Fig.4) [36]. 
When NILM cytology is detected, women are conducted to re-screening. In the presence of 
both ASC-US cytology and HPV-negative results, women are called for re-screening within 12 
months. If an HPV HC2-positive outcome or a LSIL cytology result is observed, women are referred 
to colposcopy for a diagnostic evaluation. When minor abnormalities are observed a HC2 triage test 
is performed; in opposition, when major abnormalities are identified, an excisional treatment must be 
done. For an ASC-H/HSIL cytological diagnosis, women are recommended for excisional treatment 
through conization in the central Hospital (Oporto Portuguese Oncology Institute (IPO Porto)) of the 
ARS Norte. 
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Fig. 4: S implified screening algorithm of ARS Norte [36]. The grey areas correspond to changes in the algorithm, 
when compared to the algorithm of ARS Centro (Fig.2). 
 
ARS Algarve 
ARS Algarve implemented a cervical cancer screening pilot program in 2010. The estimated 
incidence and mortality rates for cervical cancer are the highest of the country, implying 15 new 
cases per 100,000 women and 6.8 deaths per 100,000 women, respectively. A cytology-based 
screening (LBC) program was implemented using HPV DNA testing as triage test, and a 3-year re-
screening interval. Women are recruited by the healthcare centers through post mail, and it is 
expected to cover 141,425 women within an age range of 25 to 64 years (50,000 cytologies annually), 
corresponding to a coverage rate of 40.0% (Fig.5) [37]. 
 
 
Fig. 5: S implified screening algorithm of ARS Algarve [37]. The grey areas correspond to changes in the algorithm, 
when compared to the algorithm of ARS Centro (Fig.2). 
 
If NILM cytology is detected on a first screening episode, women are conducted to re-
screening. For an ASC-US cytological result, an HPV DNA test will be performed, and if the later 
comes negative, cytological evaluation will be repeated within six months; if this HPV DNA testing 
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is negative, women return to re-screening. For an ASC-US with an HPV DNA-positive test, women 
are referred to colposcopy at one of the two reference regional hospitals (Barlavento Algarvio 
Hospital (HBA) and Faro Hospital (HF)). In case of detection of minor abnormalities, women repeat 
cytological evaluation within six months; in opposition, when major abnormalities are detected, 
women will undergo excisional treatment followed by HPV DNA testing within 12 months. For a 
cytological evaluation of LSIL or worse (ASC-H, HSIL, cervical cancer) women are referred to 
colposcopy for biopsy evaluation; when biopsy reveals the presence of major abnormalities, women 
undergo excisional treatment. Since the implementation of the pilot screening program, 93.0% of the 
target population has already benefited from the first cytology. In 2013 until April, 20 women have 
been referred to colposcopy with a LSIL cytological diagnosis.  
 
ARS Lisboa e Vale do Tejo 
In 2005, ARS Lisboa e Vale do Tejo estimated the mortality rate associated to cervical cancer 
in 3.4 per 100,000, comprehending a peak of inc idence and mortality for women aged 45 to 54 years. 
Guidelines are still under evaluation for a screening program that expects to involve 893,886 women 
aged 30 to 64 years to be screened (coverage rate of 60.0 to 80.0%), through a cytology-based 
screening (LBC) program every five years (> 160,000 cytologies per year) (Fig.6) [38]. 
 
 
Fig. 6: S implified screening algorithm proposed of ARS Lisboa e Vale do Tejo [38]. The grey areas correspond to 
changes in the algorithm, when compared to the algorithm of ARS Centro (Fig.2). 
 
For ASC-US cytologies it is intended to perform an HPV genotyping triage test (as 
implemented by ARS Alentejo) to allow the discrimination of HPV 16 and 18 considering the 
specific association of these genotypes with precancerous lesions. This strategy will facilitate future 
evaluations of the HPV vaccination program, and will reduce cross-reactions often described for the 
HC2 test (5.0 to 13.0%); it will increase sensibility to CIN2+ detection, without a significant decrease 
in specificity [30,39,40]. HPV genotype detection among ASC-US cases is expected to be higher 
than 50.0%, so that more than 3500 colposcopies will be necessary. The estimated detection rate for 
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LSIL and HSIL lesions is 3.0% and 1.0%, respectively, corresponding to more than 6000 
colposcopies. Also, almost 1000 cases for treatment and follow-up in the reference regional hospital 
in the region (Lisboa Portuguese Oncology Institute (IPO Lisboa)) are expected. This reference 
hospital will be collaborating with ten histopathologic laboratories and two HPV genotyping testing 
reference laboratories (IPO Lisboa and National Institute of Health (INSA)). 
 
 
HPV VACCINATION PROGRAM 
 
The quadrivalent HPV vaccine Gardasil
®
 (Merck & Co., Inc., Whitehouse Station, NJ, USA) 
was commercialized for the first time in Portugal in December 2006 [41]; and from October 2007, the 
bivalent HPV vaccine Cervarix
®
 (GlaxoSmithKline Biologicals, Rixensart, Belgium) also became 
available [42]. Two studies supported the cost-effectiveness of HPV vaccine in Portugal as they 
showed that HPV vaccines would be effective [43,44]. These two HPV vaccines were approved by 
the Portuguese DGS for preventing HPV 6, 11, 16 and 18 infections (including persistent infections), 
and their associated lesions (cervical intraepithelial neoplasia (CIN) grade 1 to 3) and cervical cancer 
[45]. A reduction in the proportion of cytological abnormalities is expected to occur in a short term 
period, after the introduction of HPV vaccination, and, ultimately, a reduction in the number of 
cervical cancer cases is the main objective of this expensive prevention scheme [46]. 
The Portuguese immunization program for HPV was implemented in October 2008 for girls 
aged 13 years; from 2008 to 2011 girls aged 17 years were also given the opportunity to benefit from 
vaccination through a catch-up program. The Portuguese HPV vaccination scheme includes three 
doses which one provided free of charge by the national healthcare system, for covering more than 
70.0% of the target population [45,47]. The decision of including the HPV vaccine in the Portuguese 
immunization program was mainly based on the estimated high cervical cancer incidence and 
mortality rates among Portuguese women, 12.2/100,000 and 3.6/100,000 women, respectively. The 
limited coverage of organized cervical cancer screening programs in mainland Portugal up to 2008 
also contributed for the decision to vaccinate all young Portuguese girls [45,46]. 
Based on worldwide prevalence data, where the oncogenic HPV 16 and 18 genotypes are 
responsible for 70.0 to 75.0% of the cervical cancer cases, a reduction of about the same proportion is 
expected in Portugal [2]. The Portuguese Ministry of Health [http://www.portaldasaude.pt/portal], 
estimates that 80.0% of the 15 years old girls have been already vaccinated, which is near to the 
85.0% coverage goal, but it can still increase considering that HPV vaccine intake is free of charge 
for women under 25 years which had already initiated HPV vaccination program [48]. Despite of the 
concern and efforts of the health authorities, population awareness on cervical cancer is limited, 
namely among university students, who evidence an obvious lack of knowledge on HPV 
transmission, HPV diagnosis and HPV consequences, which may affect the success of HPV 
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vaccination social acceptance [49]. So, improvement of education and screening strategies is needed 
for an effective prevention of HPV-related diseases in Portugal. Vaccinating boys against HPV has 
not been considered cost-effective in Portugal, considering the high coverage rate for adolescent girls 
[50]. 
 
 
DISCUSSION 
 
Worldwide, cervical cancer screening programs are very different within countries that have 
already implemented one, despite the similar recommendations from international practice guidelines 
for Europe and United States of America (USA). The main differences are centered in the age range, 
time to re-screen, primary screening test (cytology versus HPV DNA test), type of testing 
(conventional versus LBC cytology; and HPV DNA versus HPV genotyping tests), and proposed 
algorithm. The bases to elaborate a cervical cancer screening algorithm rely on local baseline 
information regarding HPV infection, and economic cost-effectiveness of the proposed algorithm. 
HPV vaccination programs are almost entirely supported by national health entities so that updated 
information is needed in order to achieve adequate and cost-effective preventive measures. 
Concerning the age range of the Portuguese regional cervical cancer screening programs, all 
ARS implemented the starting age at 25 years (except for ARS Lisboa e Vale do Tejo), and all ARS 
designed screening programs up to 64 years (except ARS Norte). This is the commonest age range 
adopted by several European countries, as for example Finland and United Kingdom (UK), but they 
differ in the re-screening interval. In Finland (screening implemented since the 1960’s), it is 
recommended a 5-year re-screening interval, as it is observed for ARS Norte and ARS Lisboa e Vale 
do Tejo; though in the UK (with an organized screening program since 1988), the re-screening 
interval is variable according to age, so that women aged 25 to 49 years are re-screened every three 
years, and women aged 50 to 64 are re-screened every five years [51; http://www.cancer.fi/; 
http://www.cancerscreening.nhs.uk/cervical/index.html]. This 3-year re-screening interval is also 
adopted by three Portuguese ARS. Worldwide, there are countries that present an enlarged screening 
age range, such as Australia which screen women aged 20 to 70 years, with a 2-year re-screening 
interval (screening implemented since 1991) [http://www.cancerscreening.gov.au/]. In the USA, it 
was also adopted a variable re-screening interval for women aged 21 to 65 years (every three years), 
but if preferred, the women aged 30 to 65 years that want to lengthen the re-screening interval, a co-
testing approach of cytology and HPV DNA testing with a 5-year re-screening interval may be agreed 
[http://www.uspreventiveservicestaskforce.org/uspstf/uspscerv.htm]. 
All cervical cancer screening programs discussed here have a regional approach, but there are 
some variations about the primary screening test within the different programs. In Portugal, only 
ARS Centro proposes the Pap smear in a cytology-based algorithm, as adopted in Finland, which is 
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the most successful European cervical cancer screening program. In fact, in this Northern European 
country, cervical cancer incidence and mortality rates have decreased greatly over these last decades 
(four of five cancers are prevented), so that currently no HPV vaccine has been introduced in the 
Finnish national immunization program [52]. In the UK, cervical cancer screening started by 
performing Pap smears, but in 2003 changed to LBC [http://www.cancerscreening.nhs.uk], though 
Australia and USA still perform the Pap smear as the primary screening test 
[http://www.cancerscreening.gov.au/; http://www.cdc.gov/cancer/cervical/statistics]. 
Pap tests are notoriously insensitive to detect cervical lesions, as they only detect 50.0 to 
75.0% of the cancer cases. However, repeated cytological screening episodes might compensate test’s 
insensitivity, increasing its global performance. Nonetheless, Pap smears feasibility may be restricted 
to developed countries, so that HPV DNA tests can constitute an alternative for primary screening, 
extending the re-screening interval, due to their 90.0 to 95.0% sensitivity to detect precancerous 
cervical lesions. Despite this high sensitivity, HPV DNA tests only detect HPV infection, failing the 
identification of cell abnormalities that precede cervical cancer, which are successfully detected 
through cytology. 
Regarding vaccination, the UK introduced HPV vaccines into the national immunization 
program in 2008 destined to vaccinate young girls aged 12 to 13 years, with a catch-up program for 
girls aged up to 18 years (finished in 2011). Despite it started with the bivalent HPV vaccine, in 2011 
the UK Department of Health deliberated that HPV vaccination program should switch to the 
quadrivalent vaccine (from September 2012), mainly because of the increased costs of the national 
health system to treat the elevated number of genital warts [52; www.patient.co.uk]. Contrary to the 
implemented in Portugal, the HPV vaccination program in UK has a school-based approach. Also, 
the Australian national school-based HPV vaccination program is destined to vaccinate young girls 
aged 12 to 13 years, and has been extended to include young boys since February 2013 (free of 
charge) [http://hpv.health.gov.au/]. HPV vaccination was introduced in the USA in 2006 
(quadrivalent vaccine; in 2009 the bivalent vaccine was introduced) along with a recommendation for 
vaccinating young girls and women aged 11 to 26 years; the quadrivalent HPV vaccine was also 
recommended for young boys and men aged 11 to 26 years [53]. 
HPV vaccines represent the ultimate cervical cancer prevention strategy, but it should take 
several years until a real impact on the decrease of cervical cancer incidence rates can be observed. 
On the other hand, cervical cancer screening must continue, as the majority of sexually active women 
have been exposed to HPV infection prior to the implementation of vaccination schemes, and they 
are at risk of developing cervical cancer [46,54]. 
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ABSTRACT 
Persistent high-risk human papillomavirus (HPV) infection is the major risk factor for 
cervical cancer development. Portugal has one of the highest incidence rates for cervical cancer in 
Europe. The objective was to assess the overall and age-stratified HPV prevalence in an opportunistic 
screening setting to further improve screening policies and management of HPV-infected Portuguese 
women. A total of 2149 samples were selected from different regions in Portugal. Samples were 
stratified by age and cytological groups. HPV DNA detection and genotyping was performed using 
CLART HPV 2 assay. The overall HPV prevalence was 42.2% (906/2149; 95% CI: 40.1-44.2). After 
age stratification of cases, the proportion of HPV infection was higher for the age group 25 to 29 
years, and then decreasing with increasing age. The most frequently detected genotypes were HPV 
16, 31, 53, 51, and 66, and there was a statistically significant association between the prevalence of 
infection with HR-HPV genotypes and age (P = 0.005). HPV DNA testing revealed that 22.6% 
(273/1209) of the samples with normal cytology were HPV-positive; moreover, HPV prevalence 
increased significantly with the severity of lesions (P < 0.001). HPV infection was frequent, since the 
present evaluation relies on opportunistic screening of women who presented clinical diagnosis 
suggestive of HPV infection (potential increase and overstated HPV prevalence). Also, the age-
specific distribution of HPV infection might be useful for detection strategies, by determining how 
and when to act for preventing cervical cancer development.  
Keywords: Human papillomavirus, genotyping, HPV genotype-specific distribution, cervical cancer. 
Chapter 3 – HPV in Opportunistic Screening 
Not Published. 
50 
INTRODUCTION 
 
Human papillomavirus (HPV) is a common sexually transmitted infection (STI) and is 
responsible for a wide range of anogenital diseases that represent a high burden of public health 
disease in both women and men. Approximately 80.0% of sexually active adults will be infected with 
HPV during their lifetime. Worldwide, prevalence of HPV infection is estimated to be from 9.0 to 
13.0%, and in Europe it varies from 3.0 to 15.0%. Most infections are asymptomatic and clear 
spontaneously, but persistent infections can progress to precancerous lesions and cancer [1]. The 
critical factor influencing the likelihood of progression to cervical cancer is the infecting HPV 
genotype. To date, more than 100 HPV genotypes have been identified [2]. According to their 
oncogenic potential, HPV genotypes can be subdivided into low-risk (LR-HPV) genotypes, v.g. HPV 
6 and 11 (mainly found in genital warts), and high-risk (HR-HPV) genotypes, v.g. HPV 16 and 18, 
that are frequently associated with low- or high-grade cervical abnormalities (putative precursors for 
cervical cancer), and invasive cervical cancer [3]. 
Persistent infection with HR-HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 
and 59) is considered a strong predictor of development of high-grade cervical lesions and cervical 
cancer [4,5]. HPV DNA detection tests have proven to be more sensitive than cytology, by revealing 
the presence of multiple HPV infections in women with and without cytological abnormalities. To 
date, 20.0 to 50.0% of HPV-positive women evidenced infection with multiple HPV genotypes [6-8]. 
Co-infection with more than one HPV genotype has been observed more frequently among young 
women and among those with cytological abnormalities [9-13]. However, the clinical importance of 
these multiple HPV infections in cervical cancer development remains unclear. Several studies have 
evidenced that multiple HPV infections seem to be associated with a significantly increased risk of 
high-grade lesions as compared with single infections [10,14,15]. 
Other risk factors that promote carcinogenesis are either biological, such as co-infections 
with other STIs, or behavioral, such as sexual habits. A consistent association has been demonstrated 
between an increased lifetime number of sexual partners and HPV infection among women [16-18]. 
However, different factors, such as young age at first sexual intercourse, use of oral contraceptives, 
and smoking have shown inconsistent associations with HPV infection [17,19-21]. 
In Portugal, cervical cancer is the fourth most frequent cancer in women, and the second most 
frequent cancer in women aged 15 to 44 years of age. The age-standardized incidence rate is 12.2 per 
100,000 women, with 949 new cases of cervical cancer diagnosed per year, and an age-standardized 
mortality rate of 3.6 per 100,000 women, with a total of 346 deaths as a consequence of cervical 
cancer [22]. 
The objective of the present study is to assess the overall and age-stratified prevalence of 
HPV, in normal and abnormal cytological smears, as well as to determine genotype-specific 
Chapter 3 – HPV in Opportunistic Screening 
Not Published. 
51 
proportion of HR-HPV genotypes. This evaluation is intended to gain knowledge and information 
about HPV infection among Portuguese women, in order to further improve screening policies. 
 
 
MATERIAL AND METHODS 
 
Study Design 
A total of 2149 samples were selected for the study from different regions of Portugal, during 
2009 to 2011. The selection criteria included (1) women aged 18 to 65 years; (2) women sexually 
active; and (3) referral from a gynecology clinic. Criteria for exclusion were (1) pregnancy; (2) 
history of atypical cytology, cervical intraepithelial neoplasia (CIN) or treatment for cervical disease 
in the prior 12 months; and (3) having had a hysterectomy. All samples were stratified by age group: 
18-19; 20-24; 25-29; 30-39; 40-49; 50-59; 60-65 years. Eligible women attended to the Human 
Papillomavirus Reference Laboratory at the National Institute of Health (INSA) for opportunistic 
screening and HPV testing, as they evidenced a clinical diagnosis suggestive of HPV infection. The 
study group included a high proportion of women at risk for cervical cancer with a broad range of 
outcomes and an increased rate of disease cases. Cervical cell samples were collected with a 
cytobrush during clinical examination for cytology (Pap smears). Liquid-based cytology (LBC) 
samples were also collected for further HPV testing. Pap smears were classified as normal smears 
(NILM), atypical squamous cells of undetermined significance (ASC-US), atypical squamous cells 
that cannot exclude high-grade lesions (ASC-H), low-grade squamous intraepithelial lesions (LSIL), 
high-grade squamous intraepithelial lesions (HSIL), and invasive cervical cancer (ICC). 
 
Laboratory Methods 
HPV DNA was isolated from 1 ml of cellular suspension using the automated extraction 
system NucliSENS® easyMAG® (bioMérieux, Boxtel, Netherlands), as specified in the 
manufacturer’s instructions. Nucleic acids were eluted in a final volume of 100 µl and stored at -20ºC 
until use for PCR analysis. 
Detection and genotyping of HPV were carried out using the commercial system CLART® 
Papillomavirus Humano 2 (CLART) assay (Genomica, Madrid, Spain) according to the 
manufacturer’s instructions. This methodology uses biotinylated primers that amplify a 450 bp 
fragment within the L1 region, which allows the identification of 35 genotypes (HPV 6, 11, 16, 18, 
26, 31, 33, 35, 39, 40, 42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 
83, 84, 85, and 89). Co-amplification of an 892 bp region of the human housekeeping gene CFTR 
(cystic fibrosis transmembrane conductance regulator) and a 1,202 bp fragment of a transformed 
plasmid, provide a control to ensure DNA extraction adequacy and PCR efficiency, avoiding false-
negative results. HPV genotyping was performed by hybridization in a low-density microarray 
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containing triplicate DNA probes specific to each one of the 35 genotypes included in the assay. 
Semi-quantitative results were obtained in an automatic reader. The clinical sensitivity and specificity 
of CLART assay has been previously established as 96.9% and 71.9%, respectively (Chapter 4) [23]. 
 
Statistical Methods 
For statistical purposes, HPV 16, 18, 26, 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 70, 
73, and 82 were considered to be HR-HPV (including both probable and possible HR genotypes), and 
HPV 6, 11, 40, 42, 43, 44, 54, 61, 62, 71, 72, 81, 83, 84, 85, and 89 were considered to be LR-HPV 
(including undetermined genotypes) according to the classif ication proposed elsewhere [24,25]. 
HPV genotype-specific proportion according to cervical lesions distribution was investigated, 
as well as risk behavior variables for HPV acquisition (age, number of lifetime partners, and use of 
contraceptives). Data was described including mean, standard deviation (SD), median, range and both 
absolute and relative frequencies. The overall and age-stratified prevalence of HPV infection and 
genotype-specific distribution of HPV are presented as relative frequencies with two-sided 95% 
confidence intervals (CI). Bivariate analysis (Pearson χ2 test) was used to (i) evaluate the relationship 
between HPV prevalence and age group or region, (ii) compare the proportion of HPV genotype 
according to the cytological result, and (iii) compare single versus multiple HPV infections.  
To determine the proportion of HR-HPV and LR-HPV genotypes, cases were counted more 
than once whenever they harbored a multiple infection, comprehending a mixture of HR and LR 
genotypes. The proportion of individual HPV genotypes was determined as they were identified 
either in single or in multiple infections. Multiple HPV infections were compared with single HPV 
infections in order to assess the risk for cervical cancer development. The odds ratio (ORs), together 
with two-sided 95% CI, were done using 2 x 2 contingency tables, and the corresponding P value was 
calculated using the chi-square test or, when appropriate, Fisher’s exact test. Statistical analyses were 
performed using SPSS software version 20.0 (IBM Corporation Inc., Armonk, NY, USA). 
 
 
RESULTS 
 
Study Samples 
Almost half of the studied samples (48.9%; 1051/2149) were from Lisbon area (Fig.1). Two 
other large groups of samples were recruited from the north of mainland Portugal (28.2%; 605/2149) 
and from the Azores islands (19.0%; 409/2149); two smaller groups were recruited in the south 
(3.2%; 68/2149) and centre of mainland Portugal (0.7%; 16/2149). Characteristics of the 2149 
samples included in the study are summarized in Table 1. The mean age was 35 years, 4 months (SD: 
10 years; median age 33 years). The majority of women had no prior history of any STI, about half 
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reported having more than one sexual partner during their lifetime, and the use of oral contraceptives 
was more frequent than the use of condom. 
 
Fig. 1: Geographical distribution of the selected cases. 
 
Table 1: Characteristics of study samples 
Characteristic Study Sample (n=2149) 
Age, mean (SD) 35.4 (10.5) 
Age distribution in years, n (%)  
18-19 44 (2.0) 
20-24 256 (11.9) 
25-29 438 (20.4) 
30-39 737 (34.3) 
40-49 422 (19.6) 
50-59 169 (7.9) 
60-65 66 (3.1) 
Data missing* 17 (0.8) 
Prior history of STI, n (%)  
No 1841 (85.7) 
Yes  291 (13.5) 
Data missing* 17 (0.8) 
Lifetime number of sexual partners, n (%)  
1 29 (1.3) 
2 13 (0.6) 
3-5 25 (1.2) 
>=6 2 (0.1) 
Data missing* 2080 (96.8) 
Contraceptive use, n (%)  
Yes  104 (4.8) 
   Oral contraceptive 80 (3.7) 
   Condom 10 (0.5) 
   Other method 14 (0.6) 
No 5 (0.2) 
Data missing* 2040 (94.9) 
*Not determined, unknown. 
 
HPV Prevalence 
The overall HPV prevalence was 42.2% (906/2149; 95% CI: 40.1-44.2) (Fig.2). After age 
stratification of cases, the proportion of HPV infection was higher for age groups 20 to 24 years 
(49.2%, 126/256; 95% CI: 47.1-51.3) and 25 to 29 years (50.5%, 221/438; 95% CI: 48.4-52.6), and 
then decreasing with increasing age. The calculated OR for HPV infection was 1.237 (95% CI:0.693-
2.209; P = 0.491) for women with 20 to 24 years, and was 1.299 (95% CI: 0.748-2.259; P = 0.357) 
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for women aged 25 to 29 years. The calculated HPV prevalence in the study samples by age group is 
presented in Fig.2, where a second peak was observed in women aged 60 to 65 years (43.9%, 29/66; 
95% CI: 41.8-46.0). There was a statistically significant association between HPV prevalence and 
age (P < 0.001). 
 
Age Group, 
years 
No. Women 
Tested 
No. Women 
HPV-positive 
95% CI OR (95% CI) 
Total 2149 906 40.1 – 44.2  
     
     18-19 44 15 32.1 – 36.1 0.660 (0.277 – 1.563) 
     20-24 256 126 47.1 – 51.3 1.237 (0.693 – 2.209) 
     25-29 438 221 48.4 – 52.6 1.299 (0.748 – 2.259) 
     30-39 737 310 40.0 – 44.2 0.926 (0.542 – 1.586) 
     40-49 422 133 29.5 – 33.4 0.587 (0.336 – 1.029) 
     50-59 169 55 30.5 – 34.4 0.616 (0.330 – 1.149) 
     60-65 66 29 41.8 – 46.0 1.00 (reference) 
P*   <0.001  
*Pearson χ2 test. 
Fig. 2: Human papillomavirus prevalence stratification by age group (years), with standard error bars.  
 
Genotype-Specific HPV Prevalence 
Among HPV-positive samples, HR-HPV genotypes were identified in 96% (869/906) of the 
cases. In total, 34 different genotypes (19 HR and 15 LR genotypes) were detected. The most 
common genotypes were HPV 16 (17.5%; 95% CI: 15.9-19.1), HPV 31 (8.1%; 95% CI: 6.9-9.3), 
HPV 53 (4.3%; 95% CI: 3.4-5.2), HPV 51 (4.2%; 95% CI: 3.3-5.1), HPV 18 (3.9%; 95% CI: 3.1-
4.7), and HPV 66 (3.6%; 95% CI: 2.8-4.4) (Table 3). The proportion of HPV 16 among positive 
cases was 41.3% (374/906), while the proportion of HPV 18 among positive cases was only 9.4% 
(85/906). The calculated OR for the development of a high-grade cervical lesion associated to HPV 
16 and/or 18 infection was 2.785 (95% CI: 2.020-3.844; P < 0.001), when compared to other HR-
HPV genotypes. 
HPV genotypes included in bivalent (HPV 16 or 18) and quadrivalent (HPV 6, 11, 16, or 18) 
HPV vaccines were detected in 50.3% (456/906) and 54.0% (489/906) of the HPV-positive cases, 
respectively, and in 21.2% (456/2149; 95% CI: 19.5-22.9) and 22.7% (489/2149; 95% CI: 20.9-24.5) 
of all the study samples, respectively. Among HPV-positive samples, one HPV genotype included in 
the quadrivalent vaccine was detected in 54.0% (489/906) of the cases, while two HPV genotypes 
42,2%
34,1%
49,2% 50,5%
42,1%
31,5% 32,5%
43,9%
0,7%
5,9%
10,3%
14,4%
6,2%
2,6% 1,3%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
Total 18-19 20-24 25-29 30-39 40-49 50-59 60-65
HPV-positive women
overall population
Chapter 3 – HPV in Opportunistic Screening 
Not Published. 
55 
included in the quadrivalent vaccine were detected in 3.0% (27/906) of the cases and only 0.3% 
(3/906) of the cases revealed to be infected by three of the HPV genotypes included in the 
quadrivalent vaccine. There were no cases involving the simultaneous detection of the four vaccine 
HPV genotypes. 
 
Table 3: Distribution of HPV genotypes in positive cases, and prevalence of HPV genotypes in the 
study samples 
HPV  
Genotype 
No. Times That 
Each HPV Was 
Detected (S  + M) 
% of Genotype-
Specific HPV in 
Infected Samples 
(n = 906)† 
% of Genotype-
Specific HPV 
(n = 1600)* 
Prevalence (%) in 
Study Samples 
(n = 2149) 
High-Risk     
16 209 + 168 41.6 23.6 17.5 
18 41 + 44 9.4 5.3 3.9 
26 0 + 2 0.2 0.1 0.01 
31 79 + 95 19.2 10.9 8.1 
33 18 + 47 7.2 4.1 3.0 
35 7 + 23 3.3 1.9 1.4 
39 2 + 21 2.5 1.4 1.1 
45 10 + 28 4.2 2.4 1.7 
51 23 + 68 10.0 5.7 4.2 
52 19 + 52 7.8 4.4 3.3 
53 22 + 70 10.2 5.7 4.3 
56 15 + 26 4.5 2.6 1.9 
58 12 + 34 5.1 2.9 2.1 
59 6 + 40 5.1 2.9 2.1 
66 18 + 58 8.3 4.7 3.6 
68 2 + 24 2.8 1.6 1.2 
70 2 + 25 3.0 1.7 1.3 
73 3 + 15 2.0 1.1 0.8 
82 2 + 19 2.3 1.3 1.0 
Low-Risk     
6 3 + 22 2.8 1.6 1.2 
11 3 + 5 0.9 0.5 0.4 
40 1 + 7 0.9 0.5 0.4 
42 15 + 27 4.6 2.6 1.9 
44 2 + 6 0.9 0.5 0.4 
54 5 + 17 2.4 1.4 1.0 
61 5 + 34 4.3 2.4 1.8 
62 5 + 26 3.4 1.9 1.4 
71 0 + 2 0.2 0.1 0.08 
72 1 + 1 0.2 0.1 0.08 
81 5 + 17 2.1 1.4 0.9 
83 1 + 7 0.9 0.5 0.4 
84 2 + 27 3.2 1.8 1.3 
85 1 + 1 0.2 0.1 0.08 
89 1 + 2 0.3 0.2 0.1 
S, single infections; M, multiple infections; †The sum of percentages is higher than 100% because samples 
could be infected with more than one HPV genotype; *Number of times each genotype was identified 
either on single or multiple infections. HPV genotypes included in the quadrivalent vaccine are highlighted 
in bold. Most common genotypes are underlined.  
 
There was a statistically significant association between the prevalence of infection with HR-
HPV genotypes and age (P = 0.005). Stratification of the results by risk of HPV genotype (HR and 
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LR) and age group, showed that infections with HR-HPV genotypes were more frequent among 
younger age groups (20-24, 25-29, and 30-39 years) (Fig.3). The prevalence of HR-HPV infections 
were highest in women aged 25 to 29 years (48.4%; 95% CI: 43.7-53.0) and LR-HPV infections were 
highest in women aged 18 to 19 years (4.5%; 95% CI: 0.0-10.6), respectively. The prevalence of LR-
HPV genotypes decreased with increasing age. 
 
 
 
Age No. HPV Risk Genotype 
Group, Samples High-Risk  Low-Risk 
Years Tested No. Samples Infected* 95% CI  No. Samples Infected* 95% CI 
Total 2149      
       
     18-19 44 13 16.0 – 43.0  2 0.0 – 10.6 
     20-24 256 120 40.8 – 53.0  6 0.4 – 4.2 
     25-29 438 212 43.7 – 53.0  9 0.7 – 3.4 
     30-39 737 294 36.3 – 43.4  16 1.1 – 3.2 
     40-49 422 128 25.9 – 34.7  5 0.1 – 2.2 
     50-59 169 53 24.4 – 38.3  2 0.0 – 2.8 
     60-65 66 27 29.0 – 52.7  2 0.0 – 7.1 
P†   0.005    
High-risk (HR) group included HPV genotypes of probable high-risk. Low-risk (LR) group included HPV genotypes 
of undetermined risk. CI, confidence interval. *Samples could be infected with HR-HPV and LR-HPV genotypes. 
†Pearson χ2 test. 
Fig. 3: Prevalence stratification in high-risk and low-risk HPV infection by age group (years), with standard error 
bars. 
 
 
HPV Prevalence Related to Cytology 
Normal cytology was observed in 56.3% (1209/2149) of the cases, 15.6% (336/2149) were 
ASC-US, 15.7% (338/2149) were LSIL, 2.3% (49/2149) were ASC-H, 9.2% (197/2149) were HSIL, 
and 0.9% (20/2149) was ICC. HPV DNA testing revealed that 22.6% (273/1209) of the samples with 
normal cytology were HPV-positive (Fig.4); moreover, HPV prevalence increased significantly with 
the severity of lesions (P < 0.001), namely among LSIL (76.9%; 260/338), ASC-H (89.8%; 44/49), 
HSIL (90.4%; 178/197), and ICC (95.0%; 19/20).  
29,5%
46,9% 48,4%
39,9%
30,3% 31,4%
40,9%
4,5%
2,3% 2,1% 2,2% 1,2% 1,2%
3,0%
0,0%
10,0%
20,0%
30,0%
40,0%
50,0%
60,0%
18-19 20-24 25-29 30-39 40-49 50-59 60-65
HR
LR
Chapter 3 – HPV in Opportunistic Screening 
Not Published. 
57 
HR-HPV genotypes were identified in normal cytology cases (20.9%, 253/1209; 95% CI: 
18.6-23.2), while only 1.7% (20/1209; 95% CI: 0.9-2.3) were infected by LR-HPV genotypes. In 
fact, HR-HPV genotypes were highly frequent, compared to LR-HPV genotypes, independently of 
the cytological diagnosis, being responsible for almost all cases of HPV infection (Fig.4). 
Consequently, there was a statistically significant association between infection with HR-HPV 
genotypes and cytological abnormalities (P = 0.007). 
 
 
 
Cytology Prevalence, % (95% CI) (n = 2149)  
Result High-Risk Low-Risk 
   NILM 20.9 (18.6 – 23.2) 1.7 (0.9 – 2.3) 
   ASC-US 37.2 (34.1 – 44.5) 2.1 (0.5 – 3.6) 
   LSIL 73.1 (68.4 – 77.8) 3.8 (1.8 – 5.8) 
   ASC-H 85.7 (75.9 – 95.5) 4.1 (1.4 – 9.6) 
   HSIL 90.4 (86.2 – 94.5) 0.0 
   ICC 90.0 (76.9 – 100.0) 5.0 (0.0 – 14.5) 
P* 0.007  
High-risk (HR) group included HPV genotypes of probable high-risk. Low-risk (LR) group 
included HPV genotypes of undetermined risk. NILM, normal; ASC-US, atypical squamous 
cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; ASC-H, 
atypical squamous cells that cannot exclude HSIL; HSIL, high-grade squamous intraepithelial 
lesion; ICC, invasive cervical cancer. CI, confidence interval. *Pearson χ2 test. 
Fig. 4: Prevalence stratification in high-risk and low-risk HPV infection by cytological diagnosis, with standard error 
bars. 
 
 
When the detection of HPV 16 or 18 was evaluated regarding age and high-grade cervical 
lesions or cervical cancer cases, it was observed that HPV 16 was identified in normal cytologies 
among women with a mean age of 31.8 years (SD: 9.7 years), while for high-grade lesions the mean 
age was 34.7 years (SD: 9.6 years), and for cervical cancer cases was 47.3 years (SD: 16.5 years). For 
HPV 18 it was 32.2 years (SD: 9.2 years), 34.0 years (SD: 7.5 years), and 43.3 years (SD: 13.4 
years), respectively, suggesting a faster progression to cervical cancer when HPV 18 is the infecting 
genotype. Moreover, HPV 16 and 18 are highly associated with the progression from cervical lesions 
to cervical cancer (Fig.5). 
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Fig. 5: Contribution of the most frequent HPV genotypes by cytological diagnosis. 
 
 
Multiple HPV Infections 
Infection with multiple HPV genotypes was identified in 18.1% (388/2149; 95% CI: 16.4-
19.7) of the study samples, representing 42.8% (388/906) of the total HPV-positive cases. While 
57.2% (518/906) of the infections were caused by a single HPV genotype, 217 (23.9%) encompassed 
two HPV genotypes, 113 (12.5%) three genotypes, and 58 (6.4%) at least four genotypes. The most 
common co-infection was exclusively by HR-HPV genotypes (23.4%; 212/906) (HPV 16+31, 3.1%) 
whereas infections comprehending HR-LR and LR-LR HPV genotypes were identified in 18.9% 
(171/906) (HPV 6+16, 1.1%) and 1.0% (9/906) (HPV 61+62, 0.2%), respectively, (representing 
9.9%, 8.0%, 0.4% among the overall studied samples). The prevalence of multiple infections was 
higher among women under 30 years (Fig.6). The lowest prevalence of multiple infections was 
observed in women aged 50 to 59 years (7.1%; 12/169). Consequently, a significant association 
between the presence of multiple infections and young age (P < 0.001) could be established. 
According to cytological diagnosis, multiple HPV infections were less frequent in HPV-
positive cases of normal cytology (9.2%; 111/1209) and ICC (5%; 1/20) (Fig.6). The proportion of 
multiple HPV infections was higher in LSIL cases (40.5%; 137/338). Single HPV infections 
increased with increasing severity of cervical lesions (P < 0.001); the same association could be 
established for HR-HR HPV infections (P < 0.001). Women infected with multiple HPV genotypes 
were not at higher risk for high-grade cervical lesions development than the infected by a single HPV 
genotype (OR 0.495; 95% CI: 0.358-0.685) (P < 0.001). 
 
 
HPV16
HPV31
HPV53HPV51
HPV52
HPV66
HPV18
Other HR
NILM
HPV16
HPV31
HPV53
HPV51
HPV52
HPV66
HPV18 Other HR
ASC-US
HPV16
HPV31
HPV53
HPV51
HPV52
HPV66
HPV18
Other HR
LSIL
HPV16
HPV31
HPV53
HPV51
HPV52
HPV66
HPV18
Other HR
ASC-H
HPV16
HPV31
HPV53
HPV51
HPV52
HPV66 HPV18
Other 
HR
HSIL
HPV16
HPV31
HPV53HPV51
HPV52
HPV66
HPV18
Other 
HR
ICC
Chapter 3 – HPV in Opportunistic Screening 
Not Published. 
59 
 
Category 
No. Samples 
HPV-Positive 
No. Samples 
with Single 
HPV Genotype 
Prevalence of 
Single HPV 
Genotype 
% (95% CI) 
No. Samples with 
Multiple HPV 
Genotypes 
Prevalence of 
Multiple HPV 
Genotypes 
% (95% CI) P* 
Total 906 518 24.1 (22.2 – 25.9) 388 18.1 (16.4 – 19.7) 0.605 
       
     18-19† 15 7 15.9 (3.0 – 28.7) 8 18.2 (6.7 – 29.5) <0.001 
     20-24 126 56 21.9 (16.8 – 26.9) 70 27.3 (21.9 – 32.8)  
     25-29 221 102 23.3 (19.3 – 27.2) 119 27.2 (23.0 – 31.3)  
     30-39 310 184 25.0 (21.8 – 28.1) 126 17.1 (14.4 – 19.8)  
     40-49 133 92 21.8 (17.9 – 25.7) 41 9.7 (6.9 – 12.5)  
     50-59 55 43 25.4 (18.9 – 32.0) 12 7.1 (3.2 – 10.9)  
     60-65 29 18 27.3 (16.5 – 38.0) 11 16.7 (7.7 – 25.6)  
     NILM 273 162 13.4 (11.5 – 15.3) 111 9.2 (7.5 – 10.8) <0.001 
     ASC-US 132 66 19.6 (15.4 – 23.8) 66 19.6 (15.4 – 23.8)  
     LSIL 260 123 36.4 (31.2 – 41.5) 137 40.5 (35.3 – 45.8)  
     ASC-H 44 28 57.1 (43.3 – 71.0) 16 32.7 (19.5 – 45.8)  
     HSIL 178 121 61.4 (54.6 – 68.2) 57 28.9 (22.6 – 35.3)  
     ICC 19 18 90.0 (76.9 – 100.0) 1 5.0 (0.0 – 14.6)  
NILM, normal; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial 
lesion; ASC-H, atypical squamous cells that cannot exclude HSIL; HSIL, high-grade squamous intraepithelial lesion; ICC, 
invasive cervical cancer. †Age group is represented in years. *Pearson χ2 test. 
Fig. 6: Prevalence stratification in single and multiple HPV infections by age and cytological group, with standard 
error bars.  
 
 
DISCUSSION 
 
HPV infection was very common among the population under evaluation, with an overall 
prevalence of 42.2%. Normal cytology cases evidenced HPV infection more frequently (22.6%) than 
the described in an enlarged study held in Portugal (16.5%) [26]. This higher proportion is explained 
by the different characteristics of both studies; in fact, while the present evaluation relies on 
opportunistic screening (potential increase and overstated HPV prevalence), the epidemiological 
evaluation [26] involved a large screening-type sample of Portuguese women. However, 
epidemiologic studies comprehending asymptomatic women of several countries, reported HPV 
infection estimates ranging 2.0% to 44.0% [27], which might reflect methodological differences or 
constitute real different HPV distribution.  
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As in other studies, HPV prevalence was higher in women under 30 years [28]. The peak of 
HPV prevalence is usually observed three years after the onset of sexual activity. The present study 
involved women attending clinics for opportunistic screening that were referred to INSA for HPV 
genotyping, following clinical diagnosis suggestive of HPV infection. This fact may help to 
understand that the peak of HPV prevalence was observed in women a little older than the expected 
(25-29 years), when compared to other studies (peak occurring at 20-24 years), considering that this 
population included a high proportion of women with HPV-related disease [14,20,27]. A second peak 
of HPV prevalence in older women is observed across some world regions, which could be due to 
three main aspects: an impaired immune response caused by hormonal changes at menopause, 
inducing reactivation of latent HPV infections; differences in sexual behaviors; or a cohort effect 
[29,30]. In this study, an increase in women aged 60 to 65 years could be observed, which might be 
related to the relatively small number of cases that were enrolled; moreover, HPV DNA testing in 
women over 60 years is less frequent, being only performed when cervical disease is colposcopically 
observed. 
The most common HPV genotypes were HPV 16, followed by HPV 31, 53, 51, 18, and 66, 
with prevalence rates ranging from 17.5% to 3.6%, which is mainly in accordance with other 
Portuguese published data [31]. In a comparison study comprehending single and multiple infections, 
HPV 66 and 58 were found among the most prevalent genotypes, while HPV 18 was poorly detected 
[31]. In the present study, the higher disease rate, along with the high number of older women, may 
affect HPV genotype distribution, especially for HPV 18 which is more associated with an aggressive 
behavior and a rapid progression for cervical cancer [32]. In fact, the mean age at diagnosis of high-
grade lesions associated to HPV 16 or 18 infections was 34.7 years and 34.0 years, respectively, 
while for cervical cancer was 47.3 years and 43.3 years, respectively. In the present study, HPV 16 
was the most frequent genotype (51.6%; 112/217) followed by HPV 18 (14.7%; 32/217) among high-
grade lesions and ICC cases. The prevalence of these two genotypes increased with the severity of 
cervical neoplasia, which is in line with previous reports [33-35]. These two oncogenic genotypes are 
responsible for more than 65.0% of high-grade cervical lesions, so HPV vaccines may become 
responsible for a high decrease on HPV 16/18-associated diseases in Portugal [26]. HPV 16 was the 
most commonly detected genotype independently of cytological diagnosis and age, while HPV 18 
was more frequent among women older than 30 years and it was mainly identified in precancerous 
lesions and cervical cancer, suggesting a higher risk for progression linked to HPV 18 infection as 
recently suggested by others [35,36]. 
The high prevalence of HPV 31, 53, 51 and 66 found has been described by other authors 
[12,37,38]. Recent migrations from regions where incidence rates for those HPV genotypes are high, 
such as Brazil and sub-Saharan Africa, might explain the circulating proportions of these genotypes 
among Portuguese women, and support the need for continuously evaluate genotype-specific HPV 
distributions, as putatively rare HR-HPV genotypes might become frequent, and health measures may 
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have to be implemented in accordance to those molecular epidemiological changes. However, HPV 
31 seems to be widespread across Europe and HPV 51 and 53 have been consistently reported in 
several Southern European studies [38-41]. 
Multiple HPV infections were detected in 18.1% of the studied samples, representing 42.8% 
of the HPV-positive cases. The proportion of multiple genotypes was higher than the previously 
reported for a similar population [31]. These infections were detected more frequently in young 
women, who could have higher number of sexual partners. In fact, young age is more often 
associated with an increased rate of multiple HPV infections, suggesting a demographic and 
behavioral influence in HPV acquisition, mostly probably through multiple sexual contacts 
[8,10,13,33]. According to cytological diagnosis, multiple HPV infections were more frequent in 
abnormal smears and low-grade cervical lesions, and decreased among high-grade cervical lesions, 
possibly indicating that co-infection with multiple genotypes are common and occur independently of 
the severity of cytological diagnosis. The presence of multiple HPV infections was not significantly 
associated with the development of high-grade cervical lesions, suggesting that might not constitute a 
risk factor for carcinogenesis [11,42,43]. The data reported here contradicts what was reported in 
another Portuguese study, where multiple HPV infections were associated with persistency and 
seemed to represent a higher risk for the development of precancerous lesions [31]. In fact, more 
important than the influence of the presence of multiple HPV genotypes, might be the individual 
oncogenic potential of each infecting genotype, as in this study HR-HPV infection represented an 
increased risk for cervical cancer development.  
This study highlights the importance of HPV genotype evaluation in opportunistic screening 
and furnishes baseline data that will contribute for the optimization of routine screening policies for 
Portuguese women. Also, the definition of age-specific distribution for HPV infection might help 
HPV detection strategies, by determining how and when to act for preventing cervical cancer 
development. 
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ABSTRACT 
Persistent infection by high-risk human papillomavirus (HR-HPV) is the necessary cause of 
cervical cancer. The use of HPV detection in cervical screening programs can improve the ability to 
identify women at risk of cervical cancer. Therefore, the use of adequate methods is essential. The 
aim of this study was to evaluate the clinical performance of different HPV tests in comparison with 
the Hybrid Capture® 2 High-Risk HPV DNA Test (HC2), using a clinical cut-off of cervical 
intraepithelial neoplasia grade 2 or worse. Considering the 731 samples included in this study, HR-
HPV positivity rates were similar among DNA tests (HC2: 71.7%; CLART: 69.6%; Cobas® 4800 
HPV: 69.8%; Abbott RealTime High-Risk HPV: 68.2%). Overall, the agreement between DNA tests 
was comparable (> 0.860). For the HPV RNA testing, the positivity rate was lower compared to 
DNA testing (APTIMA® HPV: 65.4%; NucliSENS® EasyQ® HPV: 49.5%). HPV DNA tests 
showed a clinical sensitivity over 93%, while RNA tests were less sensitive to detect cervical disease 
(79.4%). However, RNA testing increased the clinical specificity (77.2%) when compared to DNA 
testing (49.2%). Moreover, specificity increased greatly for each assay evaluated when only HPV 16 
and 18 detection was considered (> 80.0%). In conclusion, the HPV DNA tests under evaluation may 
be considered efficient, sensitive and reproducible, evidencing similar performance to HC2 test. RNA 
tests revealed as more specific, improving the management of HPV-infected women, and may 
discriminate the clinically relevant HPV infections in routine practice. 
Keywords: Human papillomavirus, genotyping, DNA testing, clinical practice, cervical cancer. 
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INTRODUCTION 
 
Epidemiological studies have established that certain human papillomavirus (HPV) 
genotypes are aetiologically related to cervical cancer development [1-3]. More than 120 HPV 
genotypes have been identified, of which, approximately 40 can infect the human genital tract 
mucosa. According to the oncogenic potential, these HPV genotypes can be classified into high-risk 
(HR), associated with high-grade cervical lesions and cervical cancer, and low-risk (LR), found 
mainly in benign lesions [4,5]. Most infections will clear spontaneously, but persistent infection with 
HR-HPV genotypes has been considered a strong predictor of the development of high-grade cervical 
intraepithelial neoplasia (CIN) and cervical cancer [6,7]. 
In areas where the Papanicolau (Pap) smear is the primary screening method, the unnoticed 
development of high-grade cervical lesions may be attributed to the low reproducibility and 
sensitivity of the Pap test [8]. Several studies have shown that the combined use of cytology and HPV 
DNA testing in women above 30 years old can improve the sensitivity and the negative predictive 
value (NPV) of routine screening. HPV DNA testing may also provide reassurance to extended re-
screening intervals, and can be cost-effective in the prevention of the development of high-grade 
cervical lesions in women with cytological abnormalities. Several HPV assays with various levels of 
sensitivity and specificity have been made available lately. However, clinical validation is required 
prior to the use as a “stand-alone” method in cervical cancer screening programs. As an example, 
tests with significantly higher sensitivity than the Hybrid Capture® 2 High-Risk HPV DNA Test 
(HC2; Qiagen, Gaithersburg, MD, USA) for the detection of HPV DNA could detect latent infections 
that are clinically irrelevant, which may lead to overtreatment of women [9,10]. Recently, an assay 
based on PCR and hybridization, the CLART® Papillomavirus Humano 2 (CLART; Genomica, 
Madrid, Spain) was developed for the detection and genotyping of 35 HPV genotypes (20 HR-HPV 
and 15 LR-HPV), either in single or multiple infections. 
Some studies on clinical validation of HPV DNA testing have gather evidences that a single 
positive result either for HPV 16 or 18 provides a high predictive value for CIN grade 2 or worse 
(≥CIN2) [11,12]. These results supported the clinical importance of HPV 16 and/or 18 infections and 
raised the emergence of HPV DNA screening tests including the specific identification of HPV 16 
and 18, which are referred to as ‘HR-HPV DNA detection assays with concurrent or reflex HPV 16 
and HPV 18 genotyping’ [13]. Two of these commercial systems are fully automated, and they are 
based in a multiplex real-time PCR methodology that identifies HPV 16 and 18 with concurrent 
detection of twelve other HPV genotypes simultaneously (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 
66, and 68): the Cobas® 4800 HPV (Roche Molecular Systems, Inc, Pleasanton, CA, USA) and the 
Abbott RealTime High-Risk (HR) HPV (Abbott Molecular, Des Plaines, IL, USA). 
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Regarding HPV RNA testing, there are two commercial systems targeting mRNA detection: 
the APTIMA® HPV (Hologic Gen-Probe Incorporated, San Diego, CA, USA), and the NucliSENS® 
EasyQ® HPV (bioMérieux SA, Marcy l’Etoile, France). The APTIMA® HPV assay detects 
qualitatively the presence of mRNA of at least one of 14 HR-HPV genotypes (HPV 16, 18, 31, 33, 
35, 39, 45, 51, 52, 56, 58, 59, 66, and 68). This mRNA assay, while increasing the specificity and the 
positive predictive value (PPV), can also achieve sensitivity and NPV values similar to HPV DNA 
testing, so that it may be used in routine cervical cancer screening programs as an adjunct to the 
widely used cytology approach [14-16]. The NucliSENS® EasyQ® HPV semi-quantifies the over-
expression of E6 and E7 genes for five HR-HPV genotypes (HPV 16, 18, 31, 33, and 45). The higher 
specificity of this mRNA assay would reduce false positives, v.g. it excludes transient infections, so 
that this assay could be used as a triage test for HPV DNA-positive women, reducing the colposcopy 
referral in cytological abnormalities and therefore improving patient management [17,18]. 
The aim of this study was to evaluate the performance of different HPV tests [CLART® 
Papillomavirus Humano 2 (CLART; Genomica, Madrid, Spain); Cobas® 4800 HPV (Roche 
Molecular Systems, Inc, P leasanton, CA, USA); Abbott RealTime High-Risk (HR) HPV (Abbott 
Molecular, Des Plaines, IL, USA); APTIMA® HPV (Hologic Gen-Probe Incorporated, San Diego, 
CA, USA); NucliSENS® EasyQ® HPV (bioMérieux SA, Marcy l’Etoile, France)] in comparison to 
the clinically validated Hybrid Capture® 2 High-Risk HPV DNA Test (HC2; Qiagen, Gaithersburg, 
MD, USA) test in cervical samples for which histological results were available. The clinical 
performance was also evaluated by histological grade, using a clinical cut-off of CIN grade 2 or 
worse (≥ CIN2). 
To simplify the reading of the text, from this section on, manufacturers address will not be 
displayed. 
 
 
MATERIAL AND METHODS 
 
Study Design 
The study population comprised 731 archived cervical DNA samples selected from an 
enlarged longitudinal study (Chapter 3), with the following selection criteria: (1) age range of 18 to 
65 years; (2) sexually active life; and (3) referral from a gynecological clinic. Criteria for exclusion 
were (1) pregnancy; (2) history of atypical cytology, CIN lesions or treatment for cervical disease in 
the prior 12 months; and (3) having had a hysterectomy. DNA samples were obtained from residual 
liquid-based cytology (LBC) as previously described (Chapter 3). 
The final diagnosis, based on histological examination of biopsy samples obtained at 
colposcopy, was made available for the purposes of the present evaluation. Table 1 summarizes the 
characteristics of women from whom specimens were obtained. As suggested by Wentzensen et al. 
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[19] and according to histology, 386 out of the 731 samples (52.8%) were considered to have CIN 
grade 1 or less (≤ CIN1, regarded as controls), while 345 (47.2%) were diagnosed as CIN grade 2 or 
worse (≥ CIN2, regarded as cases). 
 
Laboratory Methods 
HPV DNA was isolated from 1 ml of cellular suspension using the automated extraction 
system NucliSENS® easyMAG® (bioMérieux, Boxtel, Netherlands), as specified in the 
manufacturer’s instructions. Nucleic acids were eluted in a final volume of 100 µl and stored at -20ºC 
until use for PCR analysis. This DNA extraction was used in CLART and NucliSENS® EasyQ® 
HPV assays. 
All samples were tested by HC2, CLART and NucliSENS® EasyQ® HPV assays. 
Furthermore, 725 (99.2%) were tested by both Cobas® 4800 HPV and Abbott RealTime HR HPV 
assays, and 719 (98.4%) samples were tested by APTIMA® HPV assay. Each HPV test was carried 
out independently of each other according to the manufacturer’s instructions. 
 
Table 1: Characteristics of study samples 
Characteristic, n (%) Study Sample (n=731) 
Age of HPV-infected women, mean (SD) 35.0 (10.4) 
Age distribution in years  
18-19 6 (0.8) 
20-24 88 (12.0) 
25-29 170 (23.3) 
30-39 267 (36.5) 
40-49 123 (16.8) 
50-59 48 (6.6) 
60-65 29 (3.9) 
Cytology results  
NILM 216 (29.4) 
ASC-US 133 (18.2) 
LSIL 178 (24.4) 
HSIL 188 (25.7) 
ICC 16 (2.2) 
Histological results  
Normal 263 (36.0) 
CIN1 128 (17.5) 
CIN2 193 (26.4) 
CIN3 139 (19.0) 
ICC 8 (1.1) 
Clinical diagnosis (cytology + biopsy)  
≤ CIN1 386 (52.8) 
≥ CIN2 345 (47.2) 
  
≤ CIN2 578 (79.1) 
≥ CIN3 153 (20.9) 
NILM, normal cytology; ASC-US, atypical squamous cells of 
undetermined significance; LSIL, low-grade squamous intraepithelial 
lesion; HSIL, high-grade squamous intraepithelial lesion; ICC, invasive 
cervical cancer; CIN, cervical intraepithelial neoplasia grade 1-3. 
 
Hybrid Capture® 2 High-Risk HPV DNA Test (HC2) 
The HC2 test is a sandwich capture molecular hybridization assay that uses a signal 
amplification detection method based on chemiluminescence to detect 13 HR-HPV genotypes (HPV 
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16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, and 68). The resultant DNA:RNA hybrids are captured on a 
microplate, and the emitted light is measured in a luminometer as relative light units (RLU). Samples 
were considered as positive if the ratio RLU/cut-off was ≥ 1.0 (equivalent to 1.0 pg HPV DNA/ml). 
In the present study, cut-off values between 1 and 2.5 were confirmed by retesting with HC2 before 
being considered as positives. 
 
CLART® Papillomavirus Humano 2 (CLART) 
The CLART test uses biotinylated consensus primers that amplify a 450 bp fragment within 
the HPV L1 region. To avoid false-negative results, co-amplification of an 892 bp region of the 
human housekeeping gene CFTR (cystic fibrosis transmembrane conductance regulator) and of a 
1,202 bp fragment of a transformed plasmid is performed, to ensure DNA extraction adequacy and 
PCR efficiency. HPV genotyping is performed by hybridization in a low-density microarray 
containing triplicate DNA probes specific to 35 genotypes (HPV 6, 11, 16, 18, 26, 31, 33, 35, 39, 40, 
42, 43, 44, 45, 51, 52, 53, 54, 56, 58, 59, 61, 62, 66, 68, 70, 71, 72, 73, 81, 82, 83, 84, 85, and 89). 
Semi-quantitative results were obtained in an automatic reader. A detailed evaluation of the clinical 
performance of this methodology is presented in Paper II (Chapter 4). 
 
Cobas® 4800 HPV 
The Cobas® 4800 HPV test is a fully automated qualitative multiplex assay that provides 
HPV 16 and 18 genotyping, while concurrently detects other 12 HR-HPV genotypes in a pooled 
result (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), either in single or multiple infections. 
This assay uses the human β-globin gene as an internal control to assess specimen quality. The 
system comprehends a sample preparation robotic platform (cobas x 480 instrument; DNA extraction 
and real-time PCR platting) and a real-time PCR apparatus (cobas z 480 analyser) performing up to 
96 tests per run, for the amplification and detection of L1 gene. 
 
Abbott RealTime High-Risk (HR) HPV 
The Abbott RealTime HR HPV test is a qualitative multiplex real-time PCR performed in a 
fully automated platform (m2000 system) for the detection of HPV 16 and 18, along with 12 other 
HR-HPV genotypes in a pooled result (HPV 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), either 
in single or multiple infections. The test comprehends homogeneous target amplification of L1 gene 
using single-stranded linear probes, performing up to 96 tests per run. In addition, the endogenous 
human β-globin gene is used as an internal control for sample validity.  
 
APTIMA® HPV 
The APTIMA® HPV test is a transcription-mediated amplification-based assay, which 
allows the detection of E6/E7 mRNA transcripts of 14 HR-HPV genotypes in a pooled result (HPV 
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16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 66, and 68), and includes an unspecified non-infectious 
RNA transcript internal control to ensure sample adequacy (details on the internal control are Hologic 
confidential). The test is based on mRNA target capture by specific oligomers linked to magnetic 
microparticles followed by a transcription-mediated amplification and by production of labeled 
RNA:DNA hybrids emitting chemiluminescence reported as a signal-to-cutoff ratio, in which ≥ 0.5 
determines positivity.  
Hologic Gen-Probe Incorporated provides platforms including several levels of automation, 
from a semi-automated Direct-Tube Sampling (DTS; used in the present study) to TIGRIS DTS 
(fully automated). 
 
NucliSENS® EasyQ® HPV 
The NucliSENS® EasyQ® HPV is a nucleic acid sequence-based amplification (NASBA) 
system based on isothermal amplification of E6/E7 mRNA from high-risk HPV 16, 18, 31, 33, and 
45, through different molecular beacon probes. Integrity of RNA in the specimen is confirmed by 
using a probe directed against the human U1 small nuclear ribonucleoprotein-specific mRNA (U1A). 
The use of two fluorescent dyes, 6-carboxy fluorescein (6-FAM) for HPV genotypes 16, 31 and 33, 
and 6-carboxy X-rhodamine (6-ROX) for HPV genotypes 18 and 45, and for U1A protein, allows 
simultaneous duplex amplification. The detailed evaluation of the clinical performance of this 
methodology is presented in Paper III (Chapter 6). 
 
Statistical Methods 
The histological diagnosis defining cervical intraepithelial neoplasia grade 2 or worse 
(≥CIN2) as a disease endpoint was used to evaluate the clinical performance of the different tests. 
Eligible samples corresponded to an opportunistic screening population, with a clinical diagnosis 
suggestive of HPV infection. Although not a routine screening population, the advantage was a broad 
range of outcomes and a high disease rate, which would enable accurate evaluation of sensitivity and 
specificity in a relatively small sample. 
The HC2 test was used as the reference standard method as it encompasses a clinically 
defined cut-off value. Considering data harmonization, a CLART-positive result was considered: (1) 
when one (or more) of the following 13 HR-HPV genotypes (HPV 16, 18, 31, 33, 35, 39, 45, 51, 52, 
56, 58, 59, and 68) (CLART-13) was present for further comparison with HC2 and APTIMA® HPV; 
(2) when one (or more) of the following 5 HR-HPV genotypes (HPV 16, 18, 31, 33, and 45) 
(CLART-5) was present for further comparison with NucliSENS® EasyQ® HPV; and (3) a HPV 16 
and/or 18-positive reflex result was considered when HPV 16 or 18 were detected concurrently with 
one (or more) of the following 12 HR-HPV genotypes (HPV 31, 33, 35, 39, 45, 51, 52 56, 58, 59, 66, 
and 68) (CLART-16/18) for further comparison with Cobas® 4800 HPV and Abbott RealTime HR 
HPV. 
Chapter 5 – HPV Testing 
Not Published. 
81 
The sensitivity, specificity, NPV, and PPV of each assay were calculated using 2 x 2 
contingency tables with 95% confidence intervals (95% CI). Agreement between assays was assessed 
by Cohen’s kappa (κ) statistics, where values ranging from 0.00 to 0.20 were considered as indicating 
poor agreement; 0.21 to 0.40 indicating fair agreement; 0.41 to 0.60 indicating moderate agreement; 
0.61 to 0.80 indicating good agreement; and 0.81 to 1.00 indicating very good to perfect agreement. 
All P values were obtained using the Fisher’s exact test or McNemar χ2 for comparison of matched-
pair samples. A two-sided P values < 0.05 was considered statistically significant. All analyses were 
performed by using the IBM SPSS Statistics version 20.0 (IBM Corporation Inc., Armonk, NY, 
USA). 
 
 
RESULTS 
 
HPV testing results are presented in Table 2. 
 
Table 2: HPV testing results 
HPV Test, n (%) Study Sample (n=731) 
HC2  
Negative 207 (28.3) 
Positive 524 (71.7) 
CLART   
Negative 222 (30.4) 
   CLART-13 Positive 502 (68.7) 
   CLART-5 Positive 440 (60.2) 
   CLART-16/18 Positive 299 (40.9) 
Cobas® 4800 HPV  
Negative 219 (30.2) 
Positive 506 (69.8) 
   HR-Positive 210 (29.0) 
   16/18-Positive 296 (40.8) 
Data missing* 6 
Abbott RealTime HR HPV  
Negative 230 (31.7) 
Positive 495 (68.2) 
   HR-Positive 209 (28.8) 
   16/18-Positive 286 (39.4) 
Data missing* 6 
APTIMA® HPV  
Negative 249 (34.6) 
Positive 470 (65.4) 
Data missing* 12 
NucliSENS® EasyQ® HPV  
Negative 369 (50.5) 
Positive 362 (49.5) 
   16/18-Positive 256 (35.0) 
HR, high-risk; * Not determined, unknown. 
 
Overall, HR-HPV genotypes were detected in 524 cases (71.7%) using the reference test, 
HC2, which provided the highest positivity rate. CLART test positivity rate was 69.6% (509/731; 
including HPV 68 in addition to the 13 HR-HPV genotypes detected by HC2). Cobas® 4800 HPV 
test positivity rate was 69.8% (509/725), whereas 40.8% (296/725) corresponded to HPV 16 and 18 
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infections. Abbott RealTime HR HPV positivity rate was 68.2% (495/725), of which 39.4% 
(286/725) were HPV 16 and 18 infections. Regarding HPV RNA testing, APTIMA® HPV tested 
positive for 65.4% (470/719) of the cases, and NucliSENS® EasyQ® HPV detected 362 positive 
results (49.5%), of which 35.0% (256/731) corresponded to HPV 16 and 18 infections (Table 2). 
 
The performance of the different tests for disease cases (≥ CIN2) was in accordance with 
histological findings and comparable sensitivities could be observed: HC2, 95.1% (95% CI: 92.3-
96.9); CLART, 94.5% (95% CI: 91.6-96.5) (94.2% for CLART-13; 88.1% for CLART-5; and 65.8% 
for CLART-16/18); Cobas® 4800 HPV, 94.7% (95% CI: 91.9-96.7) (66.2% for Cobas-16/18); 
Abbott RealTime HR HPV, 93.6% (95% CI: 90.5-95.7) (65.0% for Abbott-16/18); APTIMA® HPV, 
93.5% (95% CI: 90.4-95.7); and NucliSENS® EasyQ® HPV, 79.4% (95% CI: 74.8-83.4) (61.2% for 
NucliSENS-16/18) (Table 3). 
 
The specificity of all tests was also comparable, ranging from 49.2% (95% CI: 44.3-54.2) for 
HC2 to 60.1% (95% CI: 55.0-64.9) for APTIMA® HPV test. NucliSENS® EasyQ® HPV was the 
test evidencing the highest specificity (77.2%; 95% CI: 72.8-81.1). For each assay, specificity 
increased greatly when only HPV 16 and 18 detection was considered (> 80.0%). No significant 
statistical differences were found among the different assays, in terms of sensitivity, specificity, and 
NPV (P = 0.662) (Fig.1). 
 
 
Fig.1: ROC Curves for CIN grade 2 or worse (≥ CIN2) disease endpoint and CIN grade 3 or worse (≥ CIN3) disease 
endpoint. 
 
Overall, the agreement between the HC2 and CLART-13 was considerable (κ = 0.869, 95% 
CI: 0.830-0.909; concordance: 94.5% ± 1.7), as well as between the assays HC2 and Cobas® 4800 
HPV (κ = 0.887, 95% CI: 0.850-0.924; concordance: 95.3% ± 3.6), and between HC2 and Abbott 
RealTime HR HPV (κ = 0.866, 95% CI: 0.826-0.906; concordance: 94.3% ± 1.7). 
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Table 3: Clinical performance of different HPV tests for ≥ CIN2 based in Pap smear and biopsy diagnosis of 731 samples 
 Clinical Diagnosis     
 ≤ CIN1 
(n = 386) 
≥ CIN2 
(n = 345) 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
HC2 (n = 731) 
P 
N 
Positivity (%) 
 
196 
190 
50.8 
 
328 
17 
95.1 
 
95.1 
(92.3 – 96.9) 
 
49.2 
(44.3-54.2) 
 
62.6 
(58.3-66.8) 
 
91.8 
(87.2-95.1) 
CLART (n = 731)  
P 
N 
Positivity (%) 
 
183 
203 
47.4 
 
326 
19 
94.5 
 
94.5 
(91.6 – 96.5) 
 
52.6 
(47.6-57.5) 
 
64.1 
(59.7-68.2) 
 
91.4 
(86.9-94.8) 
CLART-13 (n = 731) 
P 
N 
Positivity (%) 
 
177 
209 
45.8 
 
325 
20 
94.2 
 
94.2 
(91.2-96.2) 
 
54.2 
(49.2-59.2) 
 
64.7 
(60.4-68.9) 
 
91.3 
(86.8-94.6) 
CLART-5 (n = 731) 
P 
N 
Positivity (%) 
 
136 
250 
35.2 
 
304 
41 
88.1 
 
88.1 
(84.3-91.1) 
 
64.8 
(59.9-69.4) 
 
69.1 
(64.5-73.4) 
 
85.9 
(81.4-89.7) 
CLART-16/18 (n = 731) 
P 
N 
Positivity (%) 
 
72 
314 
18.7 
 
227 
118 
65.8 
 
65.8 
(60.6-70.6) 
 
81.3 
(77.2-84.9) 
 
75.9 
(70.7-80.7) 
 
72.7 
(68.2-76.8) 
Cobas® 4800 HPV (n = 725)  
P 
N 
Positivity (%) 
 
181 
201 
47.4 
 
325 
18 
94.7 
 
94.7 
(91.9 – 96.7) 
 
52.6 
(47.6-57.6) 
 
64.2 
(59.9-68.4) 
 
91.8 
(87.3-95.1) 
Cobas-16/18 (n = 725) 
P 
N 
Positivity (%) 
 
69 
313 
18.1 
 
227 
116 
66.2 
 
66.2 
(61.0-71.0) 
 
81.9 
(77.8-85.5) 
 
76.7 
(71.4-81.4) 
 
73.0 
(68.5-77.1) 
Abbott RealTime HR HPV (n = 725) 
P 
N 
Positivity (%) 
 
174 
208 
45.5 
 
321 
22 
93.6 
 
93.6 
(90.5 – 95.7) 
 
54.5 
(49.4-59.4) 
 
64.9 
(60.5-69.1) 
 
90.4 
(85.9-93.9) 
Abbott-16/18 (n = 725) 
P 
N 
Positivity (%) 
 
63 
319 
16.5 
 
223 
120 
65.0 
 
65.0 
(59.8-69.9) 
 
83.5 
(79.5-86.9) 
 
78.0 
(72.7-82.6) 
 
72.7 
(68.2-76.8) 
APTIMA® HPV (n = 719)  
P 
N 
Positivity (%) 
 
151 
227 
39.9 
 
319 
22 
93.5 
 
93.5 
(90.4 – 95.7) 
 
60.1 
(55.0-64.9) 
 
67.9 
(63.4-72.1) 
 
91.2 
(86.9-94.4) 
NucliSENS® EasyQ® HPV (n = 731) 
P 
N 
Positivity (%) 
 
88 
298 
22.8 
 
274 
71 
79.4 
 
79.4 
(74.8 – 83.4) 
 
77.2 
(72.8-81.1) 
 
75.7 
(70.9-80.0) 
 
80.8 
(76.4-84.7) 
NucliSENS-16/18 (n = 731) 
P 
N 
Positivity (%) 
 
45 
341 
11.7 
 
211 
134 
61.2 
 
61.2 
(55.9-66.2) 
 
88.3 
(84.8-91.2) 
 
82.4 
(77.2-86.9) 
 
71.8 
(67.5-75.8) 
≤ CIN1, cervical intraepithelial neoplasia grade 1 or less; ≥ CIN2, cervical intraepithelial neoplasia grade 2 or worse; PPV, positive 
predictive value; NPV, negative predictive value; CI, confidence interval; P, HPV positive; N, HPV negative.  
 
When comparing HC2 with HPV DNA tests providing a positive result for fewer genotypes, 
the agreement decreased greatly, ranging between κ = 0.712 and κ = 0.251 (data not shown). 
Regarding the comparison between HC2 with HPV RNA tests, a considerable agreement could be 
observed with APTIMA® HPV (κ = 0.779; 95% CI: 0.730-0.828; concordance: 90.4% ± 2.1), but it 
was less obvious with NucliSENS® EasyQ® HPV for which a moderate kappa value was determined 
(κ = 0.542; 95% CI: 0.488-0.597; concordance: 62.5% ± 3.5). 
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Table 4: Clinical performance of different HPV tests for ≥ CIN3 based in Pap smear and biopsy diagnosis of 731 samples 
 Clinical Diagnosis     
 ≤ CIN2 
(n = 578) 
≥ CIN3 
(n = 153) 
Sensitivity (%) 
(95% CI) 
Specificity (%) 
(95% CI) 
PPV (%) 
(95% CI) 
NPV (%) 
(95% CI) 
HC2 (n = 731) 
P 
N 
Positivity (%) 
 
378 
200 
65.4 
 
146 
7 
95.4 
 
95.4 
(90.9 – 97.8) 
 
34.6 
(30.8-38.6) 
 
27.9 
(24.1-31.9) 
 
96.6 
(93.2-98.6) 
CLART (n = 731) 
P 
N 
Positivity (%) 
 
365 
213 
63.2 
 
144 
9 
94.1 
 
94.1 
(89.2 – 96.9) 
 
36.8 
(33.0-40.9) 
 
28.3 
(24.4-32.4) 
 
95.9 
(92.4-98.1) 
CLART-13 (n = 731) 
P 
N 
Positivity (%) 
 
359 
219 
62.1 
 
143 
10 
93.5 
 
93.5 
(88.4-96.4) 
 
37.9 
(34.0-41.9) 
 
28.5 
(24.6-32.6) 
 
95.6 
(92.1-97.9) 
CLART-5 (n = 731) 
P 
N 
Positivity (%) 
 
305 
273 
52.8 
 
135 
18 
88.2 
 
88.2 
(82.2-92.4) 
 
47.2 
(43.2-51.3) 
 
30.7 
(26.4-35.2) 
 
93.8 
(90.4-96.3) 
CLART-16/18 (n = 731) 
P 
N 
Positivity (%) 
 
190 
388 
32.9 
 
109 
44 
71.2 
 
71.2 
(63.6-77.8) 
 
67.1 
(63.2-70.8) 
 
36.4 
(31.0-42.2) 
 
89.8 
(86.6-92.5) 
Cobas® 4800 HPV (n = 725)  
P 
N 
Positivity (%) 
 
364 
208 
63.6 
 
142 
11 
92.8 
 
92.8 
(87.6 – 95.9) 
 
36.4 
(32.5-40.4) 
 
28.1 
(24.2-32.2) 
 
95.0 
(91.2-97.5) 
Cobas-16/18 (n = 725) 
P 
N 
Positivity (%) 
 
184 
388 
32.2 
 
112 
41 
73.2 
 
73.2 
(65.7-79.6) 
 
67.8 
(63.9-71.5) 
 
37.8 
(32.3-43.6) 
 
90.4 
(87.3-93.1) 
Abbott RealTime HR HPV (n = 725) 
P 
N 
Positivity (%) 
 
352 
220 
61.5 
 
143 
10 
93.5 
 
93.5 
(88.4 – 96.1) 
 
38.5 
(34.6-42.5) 
 
28.9 
(24.9-33.1) 
 
95.6 
(92.1-97.9) 
Abbott-16/18 (n = 725) 
P 
N 
Positivity (%) 
 
175 
397 
30.6 
 
111 
42 
72.6 
 
72.6 
(65.0-79.0) 
 
69.4 
(65.5-73.0) 
 
38.8 
(33.1-44.7) 
 
90.4 
(87.3-93.0) 
APTIMA® HPV (n = 719)  
P 
N 
Positivity (%) 
 
332 
236 
58.5 
 
138 
13 
91.4 
 
91.4 
(85.8 – 94.9) 
 
41.5 
(37.6-45.7) 
 
29.4 
(25.3-33.7) 
 
94.5 
(91.2-97.2) 
NucliSENS® EasyQ® HPV (n = 731) 
P 
N 
Positivity (%) 
 
241 
337 
41.7 
 
121 
32 
79.1 
 
79.1 
(72.0 – 84.8) 
 
58.3 
(54.2-62.3) 
 
33.4 
(28.6-38.5) 
 
91.3 
(88.0-94.0) 
NucliSENS-16/18 (n = 731) 
P 
N 
Positivity (%) 
 
154 
424 
26.6 
 
102 
51 
66.7 
 
66.7 
(58.9-73.7) 
 
73.4 
(69.6-76.8) 
 
39.8 
(33.8-46.1) 
 
89.3 
(86.1-91.9) 
≤ CIN2, cervical intraepithelial neoplasia grade 2 or less; ≥ CIN3, cervical intraepithelial neoplasia grade 3 or worse; PPV, p ositive 
predictive value; NPV, negative predictive value; CI, confidence interval; P, HPV positive; N, HPV negative.  
 
When evaluating the clinical performance of the several tests for CIN grade 3 or worse 
(≥CIN3) cases, some differences could be observed towards the results obtained for ≥ CIN2 disease 
endpoint. The overall sensitivity of all tests was maintained (HC2: 95.4%; CLART: 94.1%; Cobas® 
4800 HPV: 92.8%; Abbott RealTime HR HPV: 93.5%; APTIMA® HPV: 91.4%; NucliSENS® 
Chapter 5 – HPV Testing 
Not Published. 
85 
EasyQ® HPV: 79.1%), but a corresponding decrease in specificity could be observed (Table 4) 
(Fig.1).  
 
 
DISCUSSION 
 
HR-HPV infection is a necessary step in cervical cancer development, and consequently, 
HPV DNA detection constitutes a promising target for primary screening of this potentia lly fatal 
neoplasia [20-23]. In general, HPV DNA testing is considered as having higher sensitivity and lesser 
specificity than cytology [24]. However, HPV DNA tests have been validated only for women older 
than 30 years, as an adjunct to cytological screening [14], and their applicability to screening depends 
on intrinsic characteristics of each population. In the absence of a large evaluation of HPV DNA tests 
in the Portuguese population, it was considered imperative to determine their performance. Similarly, 
it was considered necessary to evaluate HPV mRNA tests on a Portuguese cervical sample collection , 
for which clinical histological findings were available. Moreover, considering that most HR-HPV 
infections clear spontaneously, the main question regarding the evaluation of any HPV test does not 
rely completely on its innate capacity for detecting HPV, but rather on its sensitivity and specificity 
towards the detection of high-grade cervical lesions (≥ CIN2) in order to be of real clinical 
usefulness. In fact, very sensitive tests will detect a large number of latent infections that are, for the 
most, clinically irrelevant, leading to overtreatment of women hosting transient HPV infections 
[9,10]. Also, it has been suggested that latent infections, putatively comprehend a low number of viral 
copies; accordingly, an HPV threshold below which HPV infection would not be clinically relevant 
should be established [25,26].  
In current clinical practice, the most expanded and clinically validated HPV detection method 
is HC2, becoming considered as the reference standard against which all new HPV assays are 
evaluated [10], and for this reason, HC2 was chosen as the reference test in the present study. 
However, it is known that HC2 cross-reacts with non-oncogenic genotypes, thus potentially 
contributing to a reduction in specificity [27-29]. HC2 methodology is very laborious and time-
consuming, as well as does not distinguish the HPV genotypes detected. Consequently, several new 
tests have became commercially available, including fully automated platforms that allow testing 
simultaneously large numbers of samples in about five hours. The aim of this study was to evaluate 
the performance of different HPV tests in comparison to HC2 test in cervical samples for which 
histological results were available .Furthermore, the clinical performance was evaluated by 
histological grade, using a clinical cut-off of CIN grade 2 or worse (≥ CIN2). 
In the present study, HC2 and CLART-13 tests showed an identical clinical performance, 
with a clinical sensitivity of 95.0%. Regarding the specificity and the NPV, the results of the HC2 
and CLART-13 tests were also similar (> 49.0% for specificity and > 91.0% for NPV). In the control 
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group (CIN grade 1 or less; ≤ CIN1), the positivity rate ranged from 39.9% to 50.8%, which can 
explain the low clinical specificity (49.2% for HC2; 54.2% for CLART-13), when compared to the 
specificity (70.5%) described by other authors [10,30] in screening populations where a positivity 
rate of 29.5% was detected, and 38.0% of specificity among another screening/disease population 
with 62.0% of HPV infection [16,31,32]. Compared to HC2, CLART test presents reproducibility 
characteristics that HC2 lacks [24]. Furthermore, this methodology is able to detect and identify 35 
HPV genotypes within a single test, either in single or multiple infections, which is useful for 
individual risk stratification in women persistently infected by HR-HPV genotypes, as well as for 
epidemiological evaluations included in vaccination trials and for monitoring the efficacy of HPV 
vaccines [33]. 
CLART is better designed for epidemiological studies and HPV vaccination efficacy 
assessment, due to its technical approach of full genotyping of 35 HPV genotypes, either in single or 
multiple infections, within a single test. For large clinical settings might not be feasible, since it is 
more expensive when compared to other commercial systems evaluated through the present study 
Also, it has been described that HPV full genotyping has some technical issues that can produce loss 
of clinical sensitivity or reproducibility, namely primer competition in the amplification of the 
specific target [34]. 
The HPV infecting genotype is determinant for the carcinogenesis process. Worldwide, HPV 
16 and 18 genotypes have been considered responsible for more than 70.0% of all cervical cancers 
and have been given prognostic value [11,35-37]. For this reason, the detection of HR-HPV, in 
particular of HPV 16 and 18, should be addressed in cervical cancer screening programs and 
algorithms, and it is expectable that the new generation of HPV tests discriminate these two 
oncogenic genotypes [11,12,14].  
The Cobas® 4800 HPV test was designed for cervical cancer primary screening by the reflex 
genotyping of HPV 16 and 18 with concurrent detection of other 13 HR-HPV genotypes. This reflex 
genotyping that discriminates HPV 16 and 18 was considered very suitable for risk assessment in 
women with negative cytology but HR-HPV-positive [38]. In the present study, the Cobas® 4800 
HPV test showed a high performance (higher sensitivity and specificity) for the disease endpoint 
≥CIN2, when compared with HC2. In addition to specificity, sensitivity, and reproducibility, its fully 
automation provides a more suitable approach than HC2 for large scale screening studies. Moreover, 
within a single test, this methodology concurrently distinguishes HPV 16 and 18 from the remaining 
HR-HPV genotypes, which adds prognostic value to the HR-HPV infection diagnosis, due to the 
major contribution of these two genotypes in cervical cancer development. 
The clinical sensitivity of Abbott RealTime HR HPV was very high (93.6%) across the 
different histological grades, especially for women with CIN2 or worse (≥ CIN2), but also high 
specificity, PPV, NPV and concordance (even when stratified by age). Compared to HC2, this 
methodology comprehends a fully automated system, which makes it suitable to large-scale cervical 
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cancer screening evaluations as proposed for Cobas® 4800 HPV test, as well as being more attractive 
than the manual procedure of HC2. 
The APTIMA® HPV has been designed, and further approved, for screening of women over 
21 years with ASC-US cytological diagnosis for reducing the need to colposcopy referral, and for 
assessing the presence or absence of HR-HPV in women 30 years or older as an adjunct to cytology. 
This methodology exhibited a high performance regarding sensitivity and NPV, 93.5% and 91.2%, 
respectively, with similar results when compared to HPV DNA testing, once again avoiding over-
testing of HPV-infected women. Also, in a clinical trial of routine cervical cancer screening (CLEAR 
trial), APTIMA® HPV minimized about one quarter the false-positivity rate in comparison to HC2 
[39]. However, this methodology does not discriminate the two most oncogenic HPV 16 and 18, in 
opposition to Cobas® 4800 HPV and Abbott RealTime HR HPV. 
NucliSENS® EasyQ® HPV was launched prior to APTIMA® HPV, targeting only five HR-
HPV genotypes, with the purpose of identifying the over expression of E6 and E7 mRNA in 
persistent infections. This methodology presented the highest specificity from all the tests under 
evaluation, being suitable for triage of HPV-infected women. Despite the fact that they are both HPV 
mRNA tests, they do not display the same applicability in a routine clinical setting. The NucliSENS® 
EasyQ® HPV is far more specific and can be of value during later stages of infection as a reflex test, 
namely in ASC-US or LSIL cytological diagnosis to estimate their risk of progression, as evaluated 
elsewhere [18]. 
In conclusion, and despite the difficulties of comparing the clinical performance of different 
HPV tests (comprehending diversified HPV genotypes), all the methodologies evaluated through the 
present study provided promising results, compared to HC2. Overall, CLART may be considered 
more useful for epidemiological studies, while NucliSENS® EasyQ® HPV test can be more 
appropriate to triage of HPV-positive women to potentially discriminate clinically relevant infections. 
The remaining evaluated tests (HC2, Cobas® 4800 HPV, Abbott RealTime HR HPV, APTIMA® 
HPV) are more suited for primary cervical cancer screening contexts due to their high sensitivity. In 
particular, Cobas® 4800 HPV and Abbott RealTime HR HPV, because of additional automation 
characteristics, should be useful for large screening studies. Also, the higher specificity of 
NucliSENS® EasyQ® HPV might avoid the discomfort and clinical consequences of colposcopy and 
invasive treatments. 
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ABSTRACT 
Infection with high-risk human papillomavirus (HPV) is considered to play a central role in 
cervical carcinogenesis. Molecular markers may increase HPV detection specificity and predict the 
risk of disease progression. Viral load has been proposed as a marker for progression to cervical 
precancerous lesions but it has been confirmed only to HPV 16. The aim of this study was to evaluate 
the clinical significance of the viral load of HPV 16 and 18. Cervical smears from 499 HPV 16 and/or 
18-positive women (117 with normal cytology, 84 with ASC-US, 134 with LSIL, 149 with HSIL, 
and 15 with ICC) were evaluated. Viral load was determined through real-time PCR by quantitation 
of the E6 gene for HPV 16 and 18, while the albumin gene was used as a housekeeping gene to 
estimate the number of human cells. HPV 16 and 18 viral load increased with severity of cervical 
abnormality (P < 0.001 and P < 0.001, respectively). Regarding HPV 18 cases, mean viral load 
increased highly in LSIL cases, when compared to normal cytologies, but decreased in high-grade 
lesions; this finding might be related to the predisposition of this genotype to infect glandular cells, 
which are less detectable through cytology. These results show that viral load quantitation for HPV 
16 and 18 may constitute an important biomarker in predicting cervical cancer development, and in 
improving patient management among women infected with these oncogenic HPV genotypes. 
 
 
Keywords: Cervical cancer, human papillomavirus, molecular marker, viral load, risk assessment. 
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INTRODUCTION 
 
Worldwide, cervical cancer is the second most common cancer among women, and virtually 
all cervical cancers are related to human papillomavirus (HPV) infection [1,2]. HPV 16 and 18 
genotypes are the most frequently related to cervical cancer and are responsible for more than 70.0% 
of the cases [3-5]. HPV 18 is more frequently detected in adenocarcinoma and adenosquamous 
carcinoma, while HPV 16 is more often associated to squamous cell carcinoma [6,7].  
It has been well established that persistent high-risk HPV infection is the major risk factor for 
cervical cancer [8-11]. The average time from HPV infection to development of cervical cancer is 10 
to 15 years, and the likelihood of progression from infection to disease increases with age [2]. In 
Portugal, cervical cancer incidence rate has been estimated in 12.2/100,000 and the mortality rate in 
3.6/100,000 [12]. HPV 16 is the most frequently detected genotype among Portuguese women 
independently of the cytological grade (19.7%), while for HPV 18 a much lower prevalence was 
determined (4.4%) [13]. 
Several potential markers of premalignant lesions development and cervical cancer have been 
evaluated, among which HPV viral load has been described as a prognostic marker for cervical 
intraepithelial neoplasia (CIN) development [14-17]. Several studies have shown that high HPV 
DNA load is associated with persistence of HPV infection and with an increased risk for the 
development of cervical intraepithelial neoplasia grade 2 or worse (CIN2+) and invasive cervical 
carcinoma (ICC) [16-21]. Therefore, viral load assessment together with HPV 16/18 testing may help 
to identify women at risk of CIN2+ or ICC development [22]. However, the clinical value of viral 
load is not consistent across studies, which may reflect, in part, the use of different quantitation 
assays [23,24].  
Since HPV DNA testing has become available, and has demonstrated high sensitivity and 
reproducibility, it was recommended that HPV DNA tests could be integrated in cervical cancer 
screening programs and in the management of women at risk of premalignant lesions development 
[10]. However, it is still controversial if the primary screening test should be the cytology or the HPV 
DNA test [16,17,25]. In this perspective, it is essential to perform an adequate triage
5
 of HPV-
positive women. Determining the clinical significance of potential biomarkers (which are more 
specific) may be useful to a further risk assessment evaluation and improved management of HPV-
infected women. The aim of this study was to determine the predictive value of HPV viral load 
quantitation for cervical cancer development, and assess its clinical prognostic significance among 
Portuguese women infected by HPV 16 and 18 genotypes. 
 
                                                 
5
 Term applied to selection of women with abnormal cytology using HPV DNA test for better risk evaluation in a screening 
program. 
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MATERIALS AND METHODS 
 
Biological Samples 
Frozen DNA aliquots (n = 499) from cervical samples that had been previously genotyped by 
CLART® Papillomavirus Humano 2 (Genomica, Madrid, Spain) were selected for the present study, 
comprising 361 cases positive for HPV 16, 138 cases positive for HPV 18, among which 17 were 
positive for both genotypes. This subset group was selected from an enlarged prospective study, as 
previously described (Chapter 3). The samples were stratified according to host characteristics into 
seven age groups (18-19; 20-24; 25-29; 30-39; 40-49; 50-59; 60-65), and in five cytological 
categories (NILM, normal cytology; ASC-US, atypical squamous cells of undetermined significance; 
LSIL, low-grade squamous intraepithelial neoplasia; HSIL, high-grade intraepithelial neoplasia; and 
ICC, invasive cervical carcinoma), which corresponded to five histological categories (normal, 
negative histology; CIN1-3, cervical intraepithelial neoplasia grade 1 to 3; and ICC, invasive cervical 
carcinoma). Cytological and histological diagnoses had been previously confirmed by experienced 
pathologists and made available to the Human Papillomavirus Reference Laboratory at the National 
Institute of Health (INSA) for opportunistic screening and HPV testing (Chapter 3). Therefore, no 
patient was sampled solely for the purpose of this research study. Women or clinician were not 
contacted with any result, other than HPV testing, nor would it be used to influence their 
management. 
 
Real-time quantitative PCR 
HPV 16 and 18 viral loads were assessed by real-time PCR amplification of the E6 gene, 
using the human housekeeping albumin gene as a reference for the estimation of the number of 
human host cells, as previously described [26]. Briefly, real-time quantitative PCR was carried out in 
a 96-well reaction 0.2 ml microplate on an ABI Prism 7500 Sequence Detection System (Applied 
Biosystems, Foster City, CA, USA). For each sample, absolute quantitation of E6 and albumin genes 
was performed in a duplex real-time PCR reaction, where each sample was tested in duplicate 
simultaneously in the same plate. Commercially available standards with the complete viral genomes 
cloned into plasmids (HPV 16 Genome for Real Time Standards and HPV 18 Genome for Real Time 
Standards; CLONIT, Milano, Italy) were diluted in sterile water from 200,000 copies in a 2-fold 8-
dilution series. Standards were carried out in duplicate in every plate, as well as a negative control. 
The reaction was performed in a 25 µl mixture containing TaqMan® Gene Expression Master Mix 
(Invitrogen Corporation, Carlsbad, CA, USA), 400nM of forward and reverse primers for both E6 
and albumin genes, and 2 µl of each DNA sample was added to the reaction mixture. Amplification 
conditions were as follows: 2 min at 50ºC, 10 min at 95ºC, a two-step cycle at 95ºC for 10 secs, and 
60ºC for 1 min, for a total of 45 cycles. 
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Viral load is expressed as the number of HPV 16 and 18 copies per million of normal human 
cells according to the following formula: 
            
          
         
   
                    
                        
 
       
 
Statistical Methods 
The histological result was applied as the gold-standard in assessing the predictive value of 
the viral load in cervical cancer development using the cytological result as baseline. Multiple 
infections with HPV 16 and 18 were counted has duplicates. Quantitative results from the real-time 
PCR amplification were log transformed for correlation analyses and for graphical display. Mann-
Whitney tests were used to determine differences in viral load between samples of normal cytology 
(reference group) and samples with CIN (test group). The Kruskal-Wallis non-parametric methods 
were used to discriminate differences in HPV viral load among the different cytological and 
histological categories. A two-sided P value ≤ 0.05 was considered statistically significant. All 
analyses were performed by using the IBM SPSS Statistics version 20.0 (IBM Corporation Inc., 
Armonk, NY, USA). 
 
 
RESULTS 
 
Study Population 
The samples selected for viral load determination were stratified according to age and clinical 
diagnosis (Table 1). Regarding the HPV 16-positive samples, the mean age ranged between 31.8 ± 
9.6 and 47.2 ± 16.5 (mean age ± standard deviation (SD)), when comparing normal histology to 
squamous cell carcinoma cases, respectively. Regarding HPV 18-positive samples, the mean age 
ranged between 32.2 ± 11.1 and 43.2 ± 13.4, for normal histology and adenocarcinoma cases, 
respectively.  
 
Viral Load Quantitation 
The mean viral load stratified by age and cytology is presented in Table 2. Overall, the value 
of the mean viral load for HPV 16 was 2.7x10
8
 (± 3.6x10
9
), among which 1.1x10
7
 (± 1.5x10
7
) was 
determined in ICC cases. For HPV 18, the mean viral load value was 7.1x10
9
 (± 8.1x10
10
), among 
which 3.8x10
9
 (± 9.9x10
9
) was determined for ICC cases. Moreover, for HPV 16 there was a 
statistical significant association between viral load and older women (≥ 30 years) (P < 0.001), in 
opposition to HPV 18-positive cases where no statistical association was identified (P = 0.221) 
(Table 2). 
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Table 1: Characteristics of the studied samples 
 
Cases (%) 
(N=499) 
HPV 16-positive (%) 
(n=361) 
HPV 18-positive (%) 
(n=138) 
Age (mean; SD) 32.9 ± 9.9
†
 32.6 ± 9.9 32.6 ± 8.3* 
18-19 9 (1.9) 5 (1.4) 4 (3.3) 
20-24 79 (16.4) 59 (16.3) 20 (16.4) 
25-29 136 (28.2) 104 (28.8) 32 (26.2) 
30-39 167 (34.6) 126 (34.9) 41 (33.6) 
40-49 60 (12.4) 42 (11.6) 18 (14.8) 
50-59 17 (3.5) 12 (3.3) 5 (4.1) 
60-65 15 (3.1) 13 (3.6) 2 (1.6) 
nd 16 0 16 
Cytology    
NILM 117 (23.4) 78 (21.6) 39 (28.3) 
ASC-US 84 (16.8) 53 (14.7) 31 (22.4) 
LSIL 134 (26.9) 100 (27.0) 34 (24.6) 
HSIL 149 (29.9) 122 (33.8) 27 (19.6) 
ICC 15 (3.0) 8 (2.2) 7 (5.1) 
Histology    
Normal 45 (9.0) 45 (12.5) 0 (0.0) 
CIN1 143 (28.7) 90 (24.9) 53 (38.4) 
CIN2 194 (38.9) 129 (35.7) 65 (47.1) 
CIN3 109 (21.8) 93 (25.8) 16 (11.6) 
ICC 8 (1.6) 4 (1.1) 4 (2.9) 
NILM, normal cytology; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-
grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; ICC, cervical 
carcinoma, including adenocarcinoma; CIN, cervical intraepithelial neoplasia grade 1 to 3; †, n=483; *, 
n=122; nd, not determined. 
 
Viral load values for HPV 16 and 18 varied among the different clinical cytological or 
histological categories (P < 0.001). The mean viral load for HPV 16 was significantly higher in HSIL 
(P < 0.001), when compared to normal cytology. HPV 16 viral load increased with the severity of 
cervical lesion, but a decrease was observed in ICC cases. Considering the histological diagnosis, the 
HPV 16 mean viral load increased from negative histologies to CIN1 and CIN2 cases (P = 0.029), 
and then decreased slightly in CIN3 and ICC cases. From HPV 16-positive cases, 55.4% (200/361) 
corresponded to single infections, and the remaining 44.6% (161/361) were co-infections with HPV 
16 and other high-risk genotypes, namely HPV 31 (15.5%; 25/161) and HPV 51 (13.0%; 21/161). 
However, the mean viral load of HPV 16 was not statistically associated to clinical diagnosis, 
whether it was single or multiple infections (P = 0.174) (Fig.1). 
 
For HPV 18 viral load, significantly higher values were observed in LSIL (P = 0.001), when 
compared to normal cytology. However, HPV 18 high viral load was not associated with HSIL and 
ICC cases, as it was observed a slight decrease in the mean values (P = 0.516) (Table 2). Considering 
the histological diagnosis, the mean viral load for HPV 18 was consistent among CIN lesions, and 
then decreasing in ICC cases (P = 0.112) (Fig.1). From HPV 18-positive cases, 55.1% (76/138) 
corresponded to single infections, and the remaining 44.9% (62/138) were co-infections with HPV 18 
and other high-risk genotypes, namely HPV 16 (27.4%; 17/62) and HPV 31 (17.7%; 11/62). 
Moreover, the mean viral load of HPV 18 was not associated with the clinical diagnosis for single 
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infections, when analyzed in comparison to HPV 18 multiple infections that were statistically 
significant (P = 0.003) (data not shown). Fig. 2 show logarithmic mean viral load values for HPV 16 
and 18 by cytological/histological categories. 
 
 
Table 2: Mean viral load for HPV 16 and 18 stratified by age and cytological diagnosis 
 Overall*  ≤ 30 years  > 30 years 
HPV 16 
(n = 361) 
HPV 18 
(n = 138) 
 HPV 16 
(n = 182) 
HPV 18 
(n = 60) 
 HPV 16 
(n = 179) 
HPV 18 
(n = 62) 
Cytological Group         
NILM (n = 117)         
Number of cases  78 39  45 24  33 15 
Mean viral load 
(± SD) 
2.3x106  
(± 9.7x106) 
5.5x105  
(± 1.8x106) 
 
6.4x105  
(± 1.5x106) 
5.7x107  
(± 2.3x108) 
 2.7x108  
(± 1.0x109) 
2.8x104  
(± 4.1x104) 
ASC-US (n = 84)         
Number of cases  53 31  32 13  21 18 
Mean viral load 
(± SD) 
3.7x106  
(± 1.1x107) 
6.5x104  
(± 1.1x105) 
 
3.2x106  
(± 1.0x107) 
7.8x104  
(± 1.4x105) 
 4.5x106  
(± 1.2x107) 
5.6x104  
(± 8.2x104) 
LSIL (n = 134)         
Number of cases  100 34  63 17  37 17 
Mean viral load 
(± SD) 
1.1x108  
(± 6.6x108) 
1.2x107  
(± 4.4x107) 
 
1.3x107  
(± 3.4x107) 
2.1x107  
(± 6.0x107) 
 2.8x108  
(± 1.1x109) 
2.6x106  
(± 4.1x106) 
HSIL (n = 149)         
Number of cases  122 27  40 6  82 8 
Mean viral load 
(± SD) 
6.9x108  
(± 6.3x109) 
3.4x106  
(± 7.6x106) 
 
7.0x107  
(± 2.1x108) 
4.6x106  
(± 3.9x106) 
 9.9x108  
(± 7.7x109) 
2.3x106  
(± 2.9x106) 
ICC (n = 15)         
Number of cases  8 7  2 0  6 4 
Mean viral load 
(± SD) 
1.1x107  
(± 1.5x107) 
1.5x106  
(± 3.7x106) 
 
3.5x107  
(± 5.4x107) 
- 
 3.1x106  
(± 3.5x106) 
3.0x106  
(± 5.2x106) 
Histological Group         
Normal (n = 45)         
Number of cases  45 0  31 0  14 0 
Mean viral load 
(± SD) 
1.5x105  
(± 3.2x105) 
-  
1.3x105  
(± 3.4x105) 
- 
 1.7x105  
(± 2.9x105) 
- 
CIN1 (n = 143)         
Number of cases  90 53  48 28  42 25 
Mean viral load 
(± SD) 
1.3x108  
(± 6.6x108) 
8.4x106  
(± 3.7x107) 
 
2.5x107  
(± 1.2x108) 
6.5x107  
(± 2.2x108) 
 2.6x108  
(± 9.6x108) 
5.2x105  
(± 2.3x106) 
CIN2 (n = 193)         
Number of cases  128 65  62 29  66 30 
Mean viral load 
(± SD) 
1.3x108  
(± 6.5x108) 
3.8x106  
(± 1.4x107) 
 
2.7x107  
(± 1.1x108) 
6.4x106  
(± 2.1x107) 
 2.3x108  
(± 8.7x108) 
1.2x106  
(± 2.7x106) 
CIN3 (n = 110)         
Number of cases  94 16  41 3  53 6 
Mean viral load 
(± SD) 
4.8x107  
(± 1.7x108) 
2.8x106  
(± 3.6x106) 
 
2.9x107  
(± 1.2x108) 
5.6x106  
(± 5.1x106) 
 6.1x107  
(± 1.9x108) 
3.1x106  
(± 3.8x106) 
ICC (n = 8)         
Number of cases  4 4  0 0  4 1 
Mean viral load 
(± SD) 
3.8x106  
(± 4.4x106) 
3.4x104  
(± 3.3x104) 
 - - 
 3.8x106  
(± 4.4x106) 
2.6x1010  
(-) 
NILM, normal cytology; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous  
intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; ICC, cervical carcinoma, including adenocarcinoma; 
CIN1-3, cervical intraepithelial neoplasia grade 1 to 3; SD, standard deviation; *, Overall mean viral load included 16 samples 
without age information.  
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Multiple infections simultaneously harboring HPV 16 and 18 were identified in 17 samples 
(3 NILM, 2 ASC-US, 7 LSIL, and 5 HSIL). Overall, the viral load was higher for HPV 16, when 
compared to HPV 18 in these multiple infections, with no statistical significance (P = 0.163). 
 
 
Fig. 1: Distribution of HPV 16 and 18 viral load by cytological and histological grade. NILM, normal cytology; ASC-
US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, 
high-grade squamous intraepithelial lesion; ICC, cervical carcinoma, including adenocarcinoma; CIN, cervical 
intraepithelial neoplasia grade 1 to 3. Filled symbols correspond to HPV 16 case s and empty symbols correspond to 
HPV 18 cases. 
 
 
 
Fig. 2: Comparison of HPV 16 (up) and HPV 18 (bottom) viral load according to clinical diagnosis. Data is presented 
as T-plots, representing the 5th and 95th percentiles. NILM, normal cytology; ASC-US, atypical squamous cells of 
undetermined significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous 
intraepithelial lesion; ICC, cervical carcinoma; CIN, cervical intraepithelial neoplasia grade 1 to 3. 
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DISCUSSION 
 
Viral persistence is required for cervical cancer carcinogenesis, and increased risk has been 
associated with early high viral loads [27,28]. Studies that evidenced an increase in viral load 
measurements during HPV infection have shown an association with a modest increased risk of 
developing cytological abnormalities [29-33]. HPV 16 is the only genotype for which viral load may 
predict viral persistence and progression to cervical cancer [16,21,34]. The aim of this study was to 
identify the clinical significance of HPV 16 and 18 viral loads as a potential biomarker for cervical 
cancer development, by applying a real-time quantitative PCR approach that constitutes the gold 
standard for HPV viral load quantitation. 
Although the significance of HPV viral load is specific of the infecting genotype, the 
quantitation of HPV load may clarify between clearance and persistence regarding HPV-infected 
women. Several methods have been described for HPV quantitation, all considering a real-time 
quantitative PCR approach [35-40]. In fact, the advances in molecular biology technologies not only 
exposed the importance of HPV viral load quantitation but also revealed appropriate for the 
determination of the prognostic significance of several viral genes, so that these methodologies have 
been tested for HPV epidemiological and clinical purposes. However, real-time techniques may be 
quite expensive especially beacuse they are based on TaqMan® oligoprobes (Invitrogen Corporation, 
Carlsbad, CA, USA) and limited/specific for each HPV genotype [40]. The importance of this 
biomarker in cervical carcinogenesis has prompted many evaluations but the prognostic value is still 
under investigation. In this assessment, the TaqMan® technology was used due to its high specificity, 
and because it enables the possibility of duplex real-time quantitation. While many authors 
established an association between HPV viral load and the cytological diagnosis [28,38,41-46], in 
this study the histological result was applied as the gold-standard to assess the clinical significance of 
HPV viral load in cervical disease. It was intended to understand if high viral loads were more 
frequent among high-grade cervical lesions (CIN2 or worse), and, if so, to evaluate the applicability 
of this methodology to clinical settings while reducing colposcopy and biopsy referral. Recurring 
only to the cytological sample one can predict the risk of persistent infection and cervical lesions 
development, while eliminating the need for unnecessary invasive procedures that induce anxiety and 
morbidity to HPV-infected women. 
An association between HPV 16 viral load and cervical cancer development has been 
established in this study. However, it is hard to determine whether such an association could be 
extended to less carcinogenic and less prevalent genotypes [47]. The present study evidenced an 
association between the severity of cervical lesions and HPV 16 and 18 viral loads, which is in 
agreement with other studies [26,48,49]. Regarding HPV 16-positive cases, the mean viral load 
increased significantly with the severity of cervical lesion. In fact, considering that the higher values 
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were observed among high-grade cervical lesions, viral load quantitation could be considered an 
important molecular marker for the clinical evaluation of HPV 16 infections. It was only observed a 
decreased amount of HPV 16 viral load among ICC cases, suggesting that after invasion and cancer 
development, viral load may be no longer necessary to maintain cervical cancer progression. HPV 16 
viral load was significantly higher among LSIL cases, when compared to ASC-US cases, suggesting 
an increased risk for persistence, which is a recognized risk factor for cervical cancer development.  
For HPV 18, it was observed an increase in the mean viral load values from normal 
cytologies to LSIL lesions, and then a decrease among HSIL and ICC cases. This could suggest that 
the higher viral loads determined in low-grade cervical lesions may favor the persistence of HPV 
infection and its progression to high-grade cervical lesions and cervical cancer. However, considering 
that among HSIL and ICC cases the mean HPV 18 viral load decreased, one could consider that 
during the final stages of carcinogenesis, viral load might not be the major factor related to cervical 
cancer development. In fact, the decrease in viral load values among high-grade lesions has been 
previously proposed [47,50,51]. The predisposition of HPV 18 for infecting glandular cells and its 
detection in adenocarcinomas that are more difficult to detect cytologically could also explain these 
findings. Moreover, the age range from normal histology to adenocarcinoma was 11 years, 
suggesting a more rapid progression to cervical cancer, when compared to HPV 16-positive cases 
(15.4 years) [6]. 
It was proposed by Saunier et al. [52] a cut-off value of 22,000 copies/10
3
 cells for HPV 16 
viral load, in which values higher than the cut-off corresponded to an associated risk for cervical 
lesion development. In the present study, using this cut-off, 46 HPV 16-positive cases (12.7%) (1 
normal, 9 CIN1, 25 CIN2, and 11 CIN3), and eight (5.8%) of HPV 18-positive cases (5 CIN1, 2 
CIN2, and 1 ICC), could be considered at risk. Assuming that a cervical lesion develops following 
infection by one specific genotype (one virus-one lesion concept), genotype-specific quantitation 
could be required to determine the true clinical significance of HPV 16 and 18 viral loads as it was 
performed in this study [53,54]. 
Multiple HPV infections have been considered as a risk factor for the development of h igh-
grade cervical lesions [55,56]. In the present study, a high proportion of women infected with HPV 
16 and 18 were also co-infected with other high-risk HPV genotypes, namely HPV 31, 33 and 51. 
However, differences in HPV 16 and 18 viral loads were not observed between women co-infected or 
not co-infected with other high-risk HPV genotypes. The methodology used in this study is specific 
of each genotype, only quantifying HPV 16 or 18, with statistical significant association between 
multiple infections and HPV 18 viral load. It is of note that among cases with co-infection by HPV 
16+18, the HPV 16 viral load was constantly higher than the quantified for HPV 18 in the same 
sample. 
The results of the present study suggest that the determination of a high viral load during the 
early stages of HPV 16 and 18 infections may be an important risk predictor of malignant 
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progression, and women with high HPV 16 and 18 viral loads should be closely monitored because 
of their major aggressive potential. In conclusion, viral load quantitation constitutes a valuable 
biomarker for predicting the risk of cervical cancer development, improving patient management. 
 
 
ACKNOWLEDGMENTS 
AG is grateful to FCT (Fundação para a Ciência e Tecnologia) for her PhD studentship 
(Ref.: SFRH/BD/47044/2008). The authors declare that there are no conflicts of interest. 
 
 
REFERENCES 
 
1. Walboomers JM, Jacobs MV, Manos MM, Bosch FX, Kummer JA, Shah KV, et al. Human 
papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189(1):12-
19. 
2. Muñoz N, Castellsagué X, de Gonzalez AB, Gissmann L. Chapter 1: HPV in the etiology of human 
cancer. Vaccine 2006;24(Suppl 3):1-10. 
3. Bosch FX, Lorincz A, Muñoz N, Meijer CJ, Shah KV. The causal relat ion between human 
papillomavirus and cervical cancer. J Clin Pathol 2002;55(4):244-265. 
4. Clifford G, Franceschi S, Diaz M, Muñoz N, Villa LL. Chapter 3: HPV type-distribution in women 
with and without cervical neoplastic diseases. Vaccine 2006;24(Suppl 3):26-34. 
5. Smith JS, Lindsay L, Hoots B, Keys J, Franceschi S, Winer R, et al. Human papillomavirus type 
distribution in invasive cervical cancer and high-grade cervical lesions: a meta-analysis update. Int J 
Cancer 2007;121(3):621-632. 
6. Woodman CB, Collins S, Rollason TP, Winter H, Bailey A, Yates M, et al. Human papillomavirus 
type 18 and rapid ly progressing cervical intraepithelial neoplasia. Lancet 2003;361(9351):40-43. 
7. Yoshida T, Sano T, Oyama T, Kanuma T, Fukuda T. Prevalence, viral load, and physical status of 
HPV 16 and 18 in cervical adenosquamous carcinoma. Virchows Arch 2009;455(3):253-259. 
8. Ho GY, Burk RD, Klein S, Kadish AS, Chang CJ, Palan P, et al. Persistent genital human 
papillomavirus infection as a risk factor for persistent cervical dysplasia. J Nat l Cancer Inst 
1995;87(18):1365-1371. 
9. Nobbenhuis MA, Walboomers JM, Helmerhorst TJ, Rozendaal L, Remmink AJ, Risse EK, et al. 
Relation of human papillomavirus status to cervical lesions and consequences for cervical-cancer 
screening: a prospective study. Lancet 1999;354(9172):20-25. 
10. Briolat J, Dalstein V, Saunier M, Joseph K, Caudrov S, Prétet JL, et al. HPV prevalence, viral load and 
physical state of HPV-16 in cervical smears of patients with different grades of CIN. Int J Cancer 
2007;121(10):2198-2204. 
11. Sargent A, Bailey A, Turner A, A lmonte M, Gilham C, Baysson H, et al. Optimal threshold for a 
positive hybrid capture 2 test for detection of human papillomavirus: data from the ARTISTIC trial. J 
Clin Microbio l 2010;48(2):554-558. 
12. GLOBOCAN 2008. Lyon: International Agency for Research on Cancer. 2010. [Available at: 
http://globocan.iarc.fr/]. 
13. Pista A, de Oliveira CF, Cunha MJ, Paixao MT, Real O; CLEOPATRE Portugal Study Group. 
Prevalence of human papillomavirus infect ion in women in Portugal: the CLEOPATR E Portugal 
Study. Int J Gynecol Cancer 2011;21(6):1150-1158. 
Chapter 7 – Viral Load 
Not Published. 
113 
14. Castle PE, Sch iffman M, Scott DR, Sherman ME, Glass AG, Rush BB, et al. Semiquantitative human 
papillomavirus type 16 viral load and the prospective risk of cervical precancer and cancer. Cancer 
Epidemio l Biomarkers Prev 2005;14(5):1311-1314. 
15. Moberg M, Gustavsson I, Wilander E, Gyllensten U. High viral loads of human papillomavirus predict 
risk of invasive cervical carcinoma. Br J Cancer 2005;92(5):891-894. 
16. Boulet GA, Benoy IH, Depuydt CE, Horvath CA, Aerts M, Hens N, et al. Human papillomavirus 16 
load and E2/E6 ratio in HPV16-positive women: biomarkers for cervical intraepithelial neoplasia ≥ 2 
in a liquid -based cytology setting? Cancer Epidemio l Biomarkers Prev 2009;18(11):2992-2999. 
17. Hesselink AT, Berkhof J, Heideman DA, Bulkmans NW, van Tellingen JE, Meijer CJ, et al. High-risk 
human papillomavirus DNA load in a population-based cervical screening cohort in relation to the 
detection of high-grade cervical intraepithelial neoplasia and cervical cancer. Int J Cancer 
2009;124(2):381-386. 
18. Jossefsson AM, Magnusson PK, Ylitalo N, Sorensen P, Qwarforth-Tubbin P, Andersen PK, et al. Viral 
load of human papillomavirus 16 as a determinant for development of cervical carcinoma in situ: a 
nested case-control study. Lancet 2000;355(9222):2189-2193. 
19. Ylitalo N, Sorensen P, Jossefsson AM, Magnusson PK, Andersen PK, Pontén J, et al. Consistent high 
viral load of human papillomavirus 16 and risk of cervical carcinoma in situ: a nested case -control 
study. Lancet 2000;355(9222):2194-2198. 
20. Fiander AN, Hart KW, Hibbitts SJ, Rieck GC, Tristram AJ, Beukenholdt RW, et al. Variat ion in 
human papillomavirus type-16 viral load within different histological grades of cervical neoplasia. J 
Med Virol 2007;79(9):1366-1369. 
21. Gravitt PE, Kovacic MB, Herrero R, Schiffman M, Bratti C, Hildesheim A, et al. High load for most 
high risk human papillomavirus genotypes is associated with prevalent cervical cancer precursors but 
only HPV16 load predicts the development of incident disease. Int J Cancer 2007a;121(12):2787-
2793. 
22. Stevens SJ, Verkuijlen SA, Bru le AJ, Middeldorp JM. Comparison of quantitative competitive PCR 
with LightCycler-based PCR for measuring Epstein-Barr virus DNA load in clinical specimens. J Clin 
Microbiol 2002;40(11):3986-3992. 
23. Gravitt PE, Burk RD, Lorincz A, Herrero  R, Hildesheim A, Sherman  ME, et al. A comparison 
between real-t ime polymerase chain reaction and hybrid capture 2 for human papillomavirus DNA 
quantitation. Cancer Epidemiol Biomarkers Prev 2003;12(6):477-484. 
24. Prétet JL, Dalstein V, Monnier-Benoit S, Delpeut S, Mougin C. High risk HPV load estimated by 
Hybrid Capture II correlates with HPV16 load measured by real-time PCR in cervical smears of 
HPV16-infected women. J Clin Viro l 2004;31(2):140-147. 
25. Grce M, Matovina M, Milutin-Gasperov N, Sabol I. Advances in cervical cancer control and future 
perspectives. Coll Antropol 2010;34(2):731-736. 
26. Carcopino X, Henry M, Benmoura D, Fallabreques AS, Richet H, Boubli L, et al. Determination of 
HPV type 16 and 18 viral load in cervical smears of women referred to colposcopy. J Med Virol 
2006;78(8):1131-1140. 
27. Kjaer SK, van den Brule AJ, Paull G, Svare EI, Sherman ME, Thomsen BL, et al. Type specific 
persistence of high risk human papillomavirus (HPV) as indicator of high grade cervical squamous 
intraepithelial lesions in young women: population based prospective follow -up study. BMJ 
2002;325(7364):572. 
28. Dalstein V, Riethmuller D, Prétet JL, Le Bail CK, Sautière JL, Carbillet JP, et al. Persistence and load 
of high-risk HPV are pred ictors for development of high-grade cervical lesions: a longitudinal French 
cohort study. Int J Cancer 2003;106(3):396-403. 
29. Kjaer S, Hogdall E, Frederikssen K, Munk C, van den Brule A, Svare E, et al. The absolute risk of 
cervical abnormalities in high-risk human papillomavirus-positive, cytologically normal women over a 
10-year period. Cancer Res 2006;66(21):10630-10636. 
30. Monnier-Benoit S, Dalstein V, Riethmuller D, Lalaoui N, Mougin C, Prétet JL. Dynamics of HPV16 
DNA load reflect the natural history of cervical HPV-associated lesions. J Clin Viro l 2006;35(3):270-
277. 
Chapter 7 – Viral Load 
Not Published. 
114 
31. Plummer M, Schiffman M, Castle PE, Maucort-Boulch D, Wheeler CM, ALTS Group. A 2-year 
prospective study of human papillomavirus persistence among women with a cytological diagnosis of 
atypical squamous cells of undetermined significance or low-grade squamous intraepithelial lesion. J 
Infect Dis 2007;195(11):1582-1589. 
32. Rodriguez AC, Schiffman M, Herrero R, Wacholder S, Hildesheim A, Castle PE, et al. Rapid 
clearance of human papillomavirus and implications for clinical focus on persistent infections. J Natl 
Cancer Inst 2008;100(7):513-517. 
33. Constandinou-Williams C, Collins SI, Roberts S, Young LS, Woodman CB, Murray PG. Is human 
papillomavirus viral load a clinically useful predictive marker? A longitudinal study. Cancer 
Epidemio l Biomarkers Prev 2010;19(3):832-837. 
34. Xi LF, Hughes JP, Castle PE, Edelstein ZR, Wang C, Galloway DA, et al. Viral load in the natural 
history of human papillomavirus type 16 infection: a nested case-control study. J Infect Dis 
2011;203(10):1425-1433. 
35. Sun CA, Liu JF, Wu DM, Nieh S, Yu CP, Chu TY. Viral load of h igh risk human papillomavirus in 
cervical squamous intraepithelial lesions. Int J Gynaecol Obstet 2002;76(1):41-47. 
36. Hernandez-Hernandez DM, Ornelas-Bernal L, Guido-Jimenez M, Apresa-Garcia T, Alvarado-Cabrero 
I, Salcedo-Vargas M, et al. Association between high-risk human papillomavirus DNA load and 
precursor lesions of cervical cancer in Mexican women. Gynecol Oncol 2003;90(2):310 -317. 
37. Weissenborn SJ, Funke AM, Hellmich M, Mallmann P, Fuchs PG, Pfister HJ, et al. Oncogenic human 
papillomavirus DNA loads in human immunodeficiency virus -positive women with high-grade 
cervical lesions are strongly elevated. J Clin Microb iol 2003;41(6):2763-2767. 
38. Snijders PJ, Hogewoning CJ, Hesselink AT, Berkhof J, Voorhorst FJ, Bleeker MC, et al. 
Determination of viral load thresholds in cervical scarpings to rule out CIN 3 in HPV16, 18, 31, and 
33-positive women with normal cytology. Int J Cancer 2006;119(5):1102-1107. 
39. Broccolo F, Cocuzza CE. Automated extract ion and quantification of oncogenic HPV genotypes from 
cervical samples by a real-t ime PCR-based system. J Virol Methods 2008;148(1-2):48-57. 
40. de Araujo MR, De Marco L, Santos CF, Rubira-Bullen IR, Ronco G, Pennini I, et al. GP5+/6+ SYBR 
Green methodology for simultaneous screening and quantification of human papillomavirus. J Clin 
Virol 2009;45(2):90-95. 
41. Van Duin M, Snijders PJ, Schrijnemakers HFJ, Voorhorst FJ, Rozendaal L, Nobbenhuis AE, et al. 
Human papillomavirus 16 load in normal and abnormal cervical scrapes: an indicator of CIN II/III and 
viral clearance. Int J Cancer 2002;98(4):590-595. 
42. Ho CM, Cheng WF, Chu TY, Chen CA, Chuang MH, Chang SF, et al. Human papillomavirus load 
changes in low-grade squamous intraepithelial lesions of the uterine cervix. Br J Cancer 
2006;95(10):1384-1389. 
43. Kulmala SM, Syrjanen SM, Gyllenstein UB, Shabalova IP, Petrovichev N, Tosi P, et al. Early 
integration of high copy HPV16 detectable in women with normal and low grade cerv ical cytology and 
histology. J Clin Pathol 2006;59(5):513-517. 
44. Lai HC, Peng MY, Nieh S, Yu CP, Chang CC; Lin YW, et al. Differential viral loads of human 
papillomavirus 16 and 58 in fections in the spectrum of cerv ical carcinogenesis. Int J Gynecol Cancer 
2006;16(2):730-735. 
45. Payan C, Ducancelle A, Aboubaker MH, Caer J, Tapia M, Chauvin A, et al. Human papillomavirus 
quantification in urine and cervical samples by using the Mx4000 and LightCycler general real time 
PCR systems. J Clin Microbio l 2007;45(3):897-901. 
46. Yoshida T, Sano T, Kanuma T, Owada N, Sakurai S, Fukuda T, et al. Quantitative real-t ime 
polymerase chain reaction analysis of the type distribution, viral load, and physical status of human 
papillomavirus in liquid-based cytology samples from cerv ical lesions. Int J Gynecol Cancer 
2007;18(1):121-127. 
47. Wentzensen N, Gravitt PE, Long R, Schiffman M, Dunn ST, Carreon JD,  et al. Human papillomavirus 
load measured by Linear Array correlates with quantitative PCR in cerv ical cytology specimens. J Clin 
Microbiol 2012;50(5):1564-1570. 
Chapter 7 – Viral Load 
Not Published. 
115 
48. Lo KW, Yeung SW, Cheung TH, Siu NS, Kahn T, Wong YF. Quantitative analysis of human 
papillomavirus type 16 in cervical neoplasm: a study in Chinese population. J Clin Viro l 
2005;34(1):76-80. 
49. Gravitt PE, Coutlée F, Iftner T, Sellors JW, Quint WG, Wheeler CM. New technologies in cerv ical 
cancer screening. Vaccine 2008;26(Suppl 10):42-52. 
50. Kovacic MB, Castle PE, Herrero R, Sch iffman M, Sherman ME, Wacholder S, et al. Relationships of 
human papillomavirus type, qualitative viral load, and age with cytologic abnormality. Cancer Res 
2006;66(20):10112-10119. 
51. Schiffman M, Wentzensen N, Wacholder S, Kinney W, Gage JC, Castle PE. Human papillomavirus 
testing in the prevention of cervical cancer. J Nat l Cancer Inst 2011;103(5):368-383. 
52. Saunier M, Monnier.Benoit S, Mauny F, Dalstein V, Brio lat J, Riethmuller D, et al. Analysis of human 
papillomavirus type 16 (HPV16) DNA load and physical state for identification of HPV 16 -infected 
women with high-grade lesions or cervical carcinoma. J Clin Microbio l 2008;46(11):3678-3685. 
53. Sherman ME, Wang SS, Wheeler CM, Rich L, Gravitt PE, Tarone R, et al. Determinants of human 
papillomavirus load among women with histological cervical intraep ithelial neoplasia 3: dominant 
impact of surrounding low-grade lesions. Cancer Epidemio l Biomarkers Prev 2003;12(10):1038-1044. 
54. Gravitt PE, van Doorn LJ, Quint W, Schiffman M, Hildesheim A, Glass AG, et al. Human 
papillomavirus (HPV) genotyping using paired exfoliated cervicovaginal cells and paraffin -embedded 
tissues to highlight difficult ies in attributing HPV types to specific lesions. J Clin Microbio l 
2007b;45(10):3245-3250. 
55. Trottier H, Mahmud S, Costa MC, Sobrinho JP, Duarte-Franco E, Rohan TE, et al. Human 
papillomavirus infect ions with mult iple types and risk o f cerv ical neoplasia. Cancer Epidemio l 
Biomarkers Prev 2006;15(7):1274-1280. 
56. Spinillo A, Dal Bello B, Gardella B, Roccio M, Dacco’ MD, Silini EM. Multiple human 
papillomavirus infect ion and high grade cervical intraepithelial neoplasia among women with 
cytological diagnosis of atypical squamous cells of undetermined  significance or low grade squamous 
intraepithelial lesions. Gynecol Oncol 2009;113(1):115-119. 
 
 
 
  
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 8 
 
 
 
 
Ana Gradíssimo*, Cândida Delgado*, Nuno Verdasca, Ângela Pista
 
 
Contributions of the Authors: 
Ana Gradíssimo was responsible for the research, writing and organization of this paper. She was 
also responsible for the data analysis, including figures and tables, as well as laboratory work, namely 
DNA extraction, HPV genotyping and real-time PCR amplification.  
Cândida Delgado was responsible for the implementation of this methodology. She also contributed 
with proofreading and data analysis. 
Nuno Verdasca contributed with proofreading and image rearrangements. He also conducted 
laboratory work, including DNA extraction and HPV genotyping. 
Ângela Pista contributed with proofreading and scientific guidance. 
 
*, contributed equally to this work. 
 
  
 
 
 
 
Chapter 8 – Physical Status 
Updated from Gradissimo et al., 2013. 
119 
ORIGINAL ARTICLE 
 
Prognostic value of human papillomavirus types 16 and 18 DNA physical 
status in cervical intraepithelial neoplasia 
 
A. Gradíssimo Oliveira
1,†
, C. Delgado
2,†
, N. Verdasca
1
 and Â. Pista
3
 
1
 National Reference Laboratory for Sexually Transmitted Diseases - Human Papillomavirus and Genital 
Herpesvirus, Department of Infectious Diseases, National Institute of Health, Lisbon, Portugal; 
2
 Department of 
Bioinformatics and Computational Biology, Instituto de Tecnologia Química e Biológica, Universidade Nova 
de Lisboa, Oeiras, Portugal; 
3
 Department of In fectious Diseases, National Institute of Health, Lisbon, Portugal. 
†
, These authors participated equally in the study. 
 
 
Corresponding Author: 
Ana Gradíssimo. Departamento de Doenças Infecciosas, Instituto Nacional de Saúde Doutor Ricardo Jorge I.P., 
Av. Padre Cruz, 1649-016 Lisboa, Portugal. Telephone: +351 217519213. Fax: +351 217526498. E-mail: 
ana.oliveira@insa.min-saude.pt. 
 
Running Title: Physical status of HPV 16 and 18. 
 
ABSTRACT 
Human papillomavirus (HPV) integration into the host genome is a critical event for cervical 
carcinogenesis. The aim of this study was to assess the value of the physical status of HPV 16 and 18 
DNA as a disease marker for cervical cancer development. A subset of 499 DNA samples previously 
genotyped as HPV 16 or 18 was selected, comprehending 45 (9.0%) samples from normal histology 
cases, while 143 (28.7%) were from CIN1, 194 (38.9%) from CIN2, 109 (21.8%) from CIN3 and 
eight (1.6%) from ICC. The physical status of both HPV genotypes was assessed by calculating the 
E2/E6 ratio through real-time quantitative PCR. Among HPV 16 infections, 19.7% (71/361) were 
found in the episomal form, 74.0% (267/361) presented concomitant forms, and 6.4% (23/361) were 
in the linear form. Regarding HPV 18 infections, 13.0% (18/138) were episomal, 55.8% (77/138) 
presented concomitant forms, and 31.2% (43/138) were in the linear state. There was a statistically 
significant association between HPV 16 and 18 DNA integration status and disease state (P < 0.001). 
Furthermore, especially for HPV 18, the determination of the DNA physical status may become a 
useful biomarker in predicting cervical cancer risk development, where a lower E2/E6 ratio would be 
more frequent among precancerous lesions. 
Keywords: Cervical cancer, human papillomavirus 18, molecular marker, physical status, risk 
assessment. 
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INTRODUCTION 
 
Infection by human papillomavirus (HPV) is aetiologically linked to cervical cancer 
development [1,2]. HPV 16 and 18 genotypes are the most carcinogenic, with a higher prevalence in 
cervical cancer cases worldwide [3-5]. Portugal has one of the highest incidence rates registered in 
Europe (12.2/100,000), as well as a high mortality rate (3.6/100,000) [6]. HPV 16 is the most 
frequently detected genotype independently of the cytological grade (19.7%), while HPV 18 has a 
low prevalence in Portuguese women (4.4%) [7]. 
Most HPV-related cervical intraepithelial precursor lesions are known to regress 
spontaneously, which implies that although HPV is a necessary cause for cervical cancer 
development, additional factors must play a role in the progression of those lesions. Many studies 
have focused on the identification of virological markers that could be predictive of the progression 
from cervical intraepithelial lesions to cervical cancer, but also act as an adjunct molecular approach 
to identify HPV-infected women at risk for cervical cancer development [8-11]. 
Integration of the viral DNA into the host cell genome could constitute a virological marker, 
as it is often considered as a pre-requisite for the development of malignant lesions. On the other 
hand, the physical status of HPV DNA (episomal, linear or concomitant/mixed forms) has been 
considered as a marker of disease progression [12-14], and the absolute quantitation of E2 and E6 
genes by real-time PCR, followed by the calculation of the E2/E6 ratio has been proposed for the 
identification of the different forms of the viral DNA [15]. 
The HPV viral integration into the host genome results from a viral genome disruption, 
during which occurs a partial loss of the E2 gene, promoting the linearization and integration of the 
viral genome, which will induce deregulated production of E6 and E7 oncoproteins [16,17]. 
Therefore, the discrimination of the integrated forms in HPV-positive cases could offer a more 
specific target of disease risk. In addition, recent data suggest that integration frequency in pre- and 
malignant lesions varies according to HPV genotype, where the estimates of integration vary from 
5.0% to 100.0% in high-grade cervical lesions (HSIL) to no evidence of integration, namely among 
low-grade cervical lesions (LSIL) [18-20]. 
The aim of this study was to investigate the level of integration of HPV 18 and its association 
with progression from cervical intraepithelial neoplasia (CIN) to the development of invasive cervical 
cancer (ICC), in comparison with HPV 16. The value of the determination of physical status for both 
HPV 16 and 18 genotypes, as a virological marker for cervical cancer development will also be 
evaluated. 
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MATERIALS AND METHODS 
 
Biological Samples 
Frozen DNA aliquots (n = 499) obtained from cervical samples, previously genotyped as 
HPV 16 (n = 361) and HPV 18 (n = 138) were selected for HPV integration evaluation from an 
enlarged prospective study (Chapter 3). Data concerning the cytological and histological evaluations, 
as well as age from HPV-infected women were made available for the purposes of this study. As 
previously described (Chapter 7), the age of HPV 16-infected women varied from 18 to 65 years 
(mean age 32.6 ± 9.9 years; median 30 years). Histological grade comprehended 12.5% (45/361) with 
negative histology, 24.9% (90/361) with CIN1, 35.7% (129/361) with CIN2, 25.8% (93/361) with 
CIN3 and 1.1% (4/361) with ICC. Age of HPV 18-infected women varied from 18 to 64 years (mean 
age 32.6 ± 8.3 years; median 31 years). All these women presented histological abnormalities: 38.4% 
(53/138) CIN1, 47.1% (65/138) CIN2, 11.6% (16/138) CIN3, and 2.9% (4/138) adenocarcinomas 
(Chapter 7). 
 
HPV 16 and 18 DNA physical status assessment 
The physical status of HPV 16 and 18 DNA was assessed by real-time PCR amplification of 
E2 and E6 genes, as previously described [21]. Real-time quantitative PCR was carried out in a 96-
well reaction plate on an ABI Prism 7500 Sequence Detection System (Applied Biosystems, Foster 
City, CA, USA). For each sample, absolute quantitation of E2 and E6 genes was performed in 
duplicate, and simultaneously in the same plate. Commercially available standards with the complete 
viral genomes cloned into plasmids (HPV 16 Genome for Real Time Standards and HPV 18 Genome 
for Real Time Standards; CLONIT, Milano, Italy) were diluted in sterile water from 200,000 copies 
in a 2-fold 8-dilution series. Standards were carried out in duplicate in every plate, as well as a 
negative control. The reaction was performed in a 25 µl mixture containing 1x SYBR® GreenER™ 
qPCR Supermix for ABI PRISM® (Invitrogen Corporation, Carlsbad, CA, USA), 400nM of forward 
and reverse primers for E2 and E6 regions [22], and 5 µl of DNA from each sample was added to the 
reaction mixture. Amplification conditions were as follows: 10 min at 95ºC, a two-step cycle at 95ºC 
for 10 secs, and 60ºC for 1 min, for a total of 40 cycles. HPV 16 and 18 DNA physical status was 
assessed following the ratio calculation determined by Zhang et al. [23]. 
 
Statistical Methods 
The histological result was applied as the reference standard in assessing the predictive value 
of the physical status in cervical cancer development using the cytological result as baseline. Mann-
Whitney and Kruskal-Wallis non-parametric methods were used to discriminate differences in HPV 
DNA physical status among the different cytological and histological categories. Student’s t-test 
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analysis was performed to measure the difference between the mean E2/E6 ratios for both genotypes 
through the clinical diagnosis categories. A two-sided P value ≤ 0.05 was considered statistically 
significant. All analyses were performed by using the IBM SPSS Statistics version 20.0 (IBM 
Corporation Inc., Armonk, NY, USA). 
 
 
RESULTS 
 
Regarding the real-time PCR methodology used for calculating E2/E6 ratio, both sets of 
primers have demonstrated specificity for HPV 16 and HPV 18 E2 and E6 genes, as no cross-reaction 
was observed for samples harboring other high-risk HPV genotypes. The standard curve evidenced a 
dynamic linear range with very good correlation (R
2
 > 0.9914 for HPV 16 and R
2
 > 0.9935 for HPV 
18). For both genotypes, the PCR amplification efficiencies for E2 and E6 genes were > 92.3%. 
 
Concomitant forms of HPV 16 were observed in 74.0% (267/361) of the cases whereas it was 
episomal or linear in 19.7% (71/361) and 6.4% (23/361) of the cases, respectively. The mean age of 
patients infected with HPV 16 episomal forms (32.4 ± 11.3 years) was lower than the determined for 
the HPV 16 linear forms (36.5 ± 11.5 years), but no statistical significance (P = 0.073) could be 
established (Fig.1). 
 
 
Fig. 1: Distribution of HPV 16 DNA physical status by cytological and histological grade. The percentage bars are 
presented with standard error bars. NILM, normal cytology; ASC-US, atypical squamous cells of undetermined 
significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; 
ICC, cervical carcinoma; CIN, cervical intraepithelial neoplasia grade 1 to 3. 
 
Considering the clinical diagnosis, the presence of HPV 16 linear forms increased with 
increasing disease grade, while episomal forms were more frequently detected in normal cytologies 
(NILM) (41.0%; 32/78), and the concomitant forms, although detected in a higher proportion 
(>70.0%), their detection was independent of disease grade (P = 0.232) (Fig.1). As for histological 
results, 57.8% (26/45) of the HPV 16 episomal forms were detected in negative histologies, and their 
frequency diminished with increasing disease grade (only one out of four ICC cases). Concomitant 
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forms were highly detected independently of the disease grade but they were more frequent among 
CIN lesions (> 70%), and they were only present in one out of four ICC cases (P = 0.006). 
Concerning E2/E6 ratio, no differences were found between normal histologies and CIN3 lesions 
(0.632 ± 0.236), whereas a significant association was identified between low E2/E6 ratios and ICC 
(P < 0.001) (Fig.2). 
 
 
Fig. 2: Comparison of HPV 16 E2/E6 ratio according to the different clinical diagnosis. Data is presented as T-plots, 
representing the 5th and 95th percentiles. NILM, normal cytology; ASC-US, atypical squamous cells of undetermined 
significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; 
ICC Cervical carcinoma; CIN, cervical intraepithelial neoplasia grade 1 to 3. 
 
Concomitant forms of HPV 18 were observed in 55.8% (77/138) of the cases whereas it was 
linear or episomal in 31.2% (43/138) and 13.0% (18/138) of the cases, respectively. The mean age of 
patients infected with HPV 18 episomal forms (32.6 ± 9.7 years) was lower than the determined for 
HPV 18 linear forms (33.8 ± 10.3 years), but no statistical significance (P = 0.393) could be 
established (Fig.3). 
 
 
Fig. 3: Distribution of HPV 18 DNA physical status by cytological and histological grade. The percentage bars are 
presented with standard error bars. NILM, normal cytology; ASC-US, atypical squamous cells of undetermined 
significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; 
ICC, cervical carcinoma, including adenocarcinoma; CIN, cervical intraepithelial neoplasia grade 1 to 3. 
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Considering the cytological diagnosis, the concomitant form was the most frequently 
detected in every lesion group (> 60.0%) whereas the episomal was detected in about 15.0% of the 
cases from each cytological category. There was an increasing proportion of linear forms detected 
according to the severity of lesion grade, reaching 100.0% among adenocarcinoma cases (P < 0.001; 
Fig.3). As for histology results, 26.4% (14/53) of the episomal forms were detected in CIN1 cases, 
decreasing to 6.2% (4/65) among CIN2 cases and none was detected in CIN3 lesions or ICC cases. 
The proportion of concomitant forms also decreased from 66.0% (35/53) to 25.0% (4/16) among 
CIN1 to CIN3 lesions, respectively. In opposition, the proportion of linear forms increased from 
7.5% (4/53) in CIN1 lesions and 35.4% (23/65) in CIN2 lesions, to 75.0% (12/16) among CIN3 
lesions; all adenocarcinomas (n = 4) presented linear HPV 18 forms (P < 0.001; Fig.3). Considering 
E2/E6 ratio, there was a significant linear decrease of the ratio associated with the severity of lesion 
grade (0.054 ± 0.112; P = 0.001) (Fig.4).  
 
Fig. 4: Comparison of HPV 18 E2/E6 ratio according to the different clinical diagnosis. Data is presented as T-plots, 
representing the 5th and 95th percentiles. NILM, normal cytology; ASC-US, atypical squamous cells of undetermined 
significance; LSIL, low-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesion; 
ICC Cervical carcinoma, including adenocarcinoma; CIN, cervical intraepithelial neoplasia grade 1 to 3. 
 
 
DISCUSSION 
 
HPV DNA physical status has been claimed to be a useful biomarker, namely due to its 
prognostic significance for cervical cancer development, and it might be predictive of lesion 
progression among women infected with high-risk HPV genotypes [13,14]. This study aimed to 
evaluate the physical status of HPV 16 and 18 DNA as a biomarker for cervical cancer development. 
To fulfill this purpose, a previously described real-time quantitative PCR approach was used [21,22]. 
Although the real-time PCR methodology applied in the present study may be considered a suitable 
methodology for the management of HPV-infected women, special attention should be addressed to 
circulating variants of oncogenic HPV genotypes. In fact, during preliminary stages of the present 
study, the HPV 16 physical status determination required some adjustments regarding the set of 
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primers, as real-time PCR failed to detect the cervical cancer-associated African and Asian-American 
variants [24], further identified by E6 gene sequencing. Some authors reported a PCR in-house 
approach [25-28], followed by agarose gel analysis, which, in comparison with the adopted 
methodology, has demonstrated to be subjective and far less specific. Also, PCR in-house procedures 
are laborious, time-consuming and require large quantities of DNA to correctly estimate the physical 
status of the viral DNA, in contrast to real-time quantitative PCR. 
Real-time PCR methodologies have demonstrated to be adequate for the determination of 
HPV DNA physical status, namely when using paraffin-embedded tissues for which the major 
problem is the use of a correct DNA extraction procedure. However, these methodologies fail to 
distinguish the number of episomal genomes from integrated viral genomes. HPV DNA integration is 
thought to be a single event that occurs surrounded by a probable high number of epissomal 
genomes, which may influence the sensitivity of real-time PCR methodologies in detecting integrated 
forms [29,30]. Even so, the E2/E6 ratio may provide a fairly good estimation of this relation if the 
exclusively episomal forms (quantitation of E2 gene) are subtracted from the overall quantitation of 
E6 gene (corresponding to integrated forms + episomal forms). In the present study, real-time PCR 
confirmed to be an appropriate methodology since no cross-reactions were observed in multiple 
infections involving HPV 16 and/or 18, and other high-risk HPV genotypes. Furthermore, by 
applying the histological diagnosis as the gold-standard for assessment of the prognostic significance 
of the ‘physical status’ biomarker, it is possible to understand the involvement of this event in 
cervical disease through a correspondence between the integrated genomes and the histologically 
confirmed high-grade lesions. The cytological diagnosis in which the HPV DNA physical status is 
determined provides useful information regarding its potential use for diagnostic purposes in a 
clinical setting.  
High-risk HPV is often found integrated into the host cell genome, which is considered 
critical for the malignant transformation of host cells. Some authors [17,20,21] have shown that HPV 
integration occurs at the early stages of cervical cancer development, as this biological feature can be 
detected in all CIN stages. Studies focused on HPV 16 showed that the proportions of linear DNA 
increased with lesion grade; however, for other carcinogenic HPV data is still scarce, namely for 
HPV 18 [15,31-34]. 
In the present study, the percentage of concomitant and linear forms (82.2%; 410/499) for 
both genotypes is consistent with the described by other authors [14,15,17,21,32,34], and it 
corroborates, especially for HPV 16, that integration may be an early event during carcinogenesis. In 
fact, concomitant forms were the most frequently detected, independently of the disease grade. Yet, 
the fact that even in CIN2 cases or worse episomal forms were detected could indicate that HPV 16 
integration might not be essential for malignant transformation. Nonetheless, only eight cases of ICC 
were studied, among which one presented the HPV 16 DNA in the linear form, whereas the 
remaining seven presented the DNA whether in concomitant or episomal forms. Considering the 
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mean E2/E6 ratio, the values were similar independently of the severity of the cervical lesion, from 
normal histology to CIN3 lesions; however, among ICC cases the E2/E6 ratio was significantly 
lower. 
Previous studies [26,32] determined that the frequency rate of exclusively episomal forms of 
HPV 18 ranged from 9.8% and 36.7% in ICC. These findings suggest that unknown factors, other 
than integration, are likely to be involved in the induction or maintenance of HPV 18 E6 expression 
during cervical carcinogenesis. However, and despite the low number of adenocarcinoma cases 
involved in the present study, none presented the episomal form, which agrees with the higher 
aggressiveness of HPV 18 previously proposed by Woodman et al. [35]. On the other hand, the 
proportion of HPV 18 linear forms increased significantly with the disease grade and a linear relation 
between E2/E6 ratio and disease grade was observed, as evidenced by a shift from the exclusively 
episomal form to the exclusively linear form according to the severity of the disease. In fact, 
integration of the HPV 18 DNA into the host cell appears to be a crucial and determining event 
during cervical carcinogenesis, strongly associated to cervical cancer development. All together, 
more significantly than to HPV 16, the determination of the physical status of HPV 18 DNA 
constitutes a useful biomarker, as it could predict the risk of cervical cancer development, where 
lower E2/E6 ratios would be clinically associated with prevalent precancerous lesion.  
Considering the systematic analysis proposed by Saunier et al. [17] in which a cut-off value 
for E2/E6 ratio lower than 0.520 represents a higher risk for the development of high-grade lesions, 
in this study, 35.2% (127/361) of the HPV 16-positive and 63.8% (88/138) of HPV 18-positive cases 
identified through the present study would be at risk of cervical cancer development. The majority of 
these cases at risk corresponded to high-grade cervical lesions (CIN2 or worse) for both genotypes, 
meaning that there is a good correlation between the determination of the HPV DNA physical status 
and the histological diagnosis. In a clinical scenario where low-grade cervical lesions might regress 
spontaneously within the first years of infection, it is important to rationally manage HPV 16/18-
positive women, avoiding unnecessary aggressive treatments, which could increase morbidity, but 
rather improve diagnosis and risk assessment, namely by using molecular markers as the evaluated in 
this study. However, research on the mechanisms and corresponding biomarkers associated with 
neoplastic progression, remains an important priority for future screening test improvements.  
The findings reported here clearly evidence a tendency where HPV 18 DNA integration may 
be a crucial event in malignant cervical cancer development, and for this reason, women presenting 
integrated DNA together with abnormal cytology should be closely monitored. Regarding HPV 16 
integration, it seems to be an early event and its involvement in the malignant transformation of host 
cells is less suggestive, which could mean that other virological, host or environmental factors should 
play a more effective role on cervical cancer development. 
Despite some limitations of the present cross-sectional study, that precludes the 
determination of the longitudinal clinical relevance of HPV physical status as a biomarker, namely 
Chapter 8 – Physical Status 
Updated from Gradissimo et al., 2013. 
127 
the low number of ICC cases, attention should be addressed to HPV 18 physical status as a predictive 
biomarker of cervical cancer for future patient management and cervical cancer prevention, helping 
to distinguish the clinical relevance of HPV infection. These limitations evidence the need for larger 
studies involving women infected by the different HPV carcinogenic genotypes at different clinical 
stages. 
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ABSTRACT 
Cervical cancer prevention strategies are based on assumptions and projections of estimates 
for HPV infection dynamics. In this context, mathematical models provide a useful tool to estimate 
scenarios and strategies effectiveness. Here, the aim was to develop a mathematical model applicable 
to genital HPV infection, to further estimate different HPV infection scenarios based on opportunistic 
and routine epidemiological data, and to formulate predictions putatively useful for the 
implementation of cervical cancer prevention strategies more adequate to Portuguese women. A 
simple compartmental Markov model was developed comprehending six mutually exclusive disease 
states in order to simulate a simplified path of the HPV natural history towards cervical 
carcinogenesis. The evolution was explored in an opportunistic screening-type population (Chapter 3) 
and compared with a routine screening-type population (CLEOPATRE Study). This study design led 
to an initial stratification of all women through the various disease states at the entry of the model. 
Different scenarios of HPV vaccination coverage rate (85% and 100%) for women aged 18 to 25 
years were also simulated. The predicted progression curves evidenced a 32.5% decrease on HPV 16 
and 18 infections for the ‘Study Population’, and a decrease also on HR HPV infections, with a 
corresponding lower proportion of cervical lesions, contributing to a decrease of around 10% in high-
grade cervical lesions. The estimates also evidenced some impact of routine screening programs over 
cervical cancer prevention rates (60.0%). 
Keywords: Cervical cancer, human papillomavirus, prevention strategies, mathematical modeling. 
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INTRODUCTION 
 
Human papillomavirus (HPV) infection is a determinant factor for the development of 
cervical cancer [1,2]. As reported from the International Agency for Research on Cancer (IARC), the 
oncogenic HPV 16 and 18 are the most prevalent genotypes associated to invasive cervical cancer 
(ICC) cases [3-5]. In addition, HPV contributes to the development of numerous cancer-related 
diseases, including anogenital carcinomas (vulvar, vaginal, anal, penile) [6-8], as well as head and 
neck squamous cell carcinomas [9-12], where HPV 16 and 18 are also the most carcinogenic 
genotypes. Also, highly recurrent benign diseases, such as genital warts, are caused by HPV 6 and 11 
genotypes (almost 90.0% of the cases) [12,13]. 
Two vaccines against HPV infections have been released, namely Gardasil
®
 (Merck & Co., 
Inc., Whitehouse Station, NJ, USA) in 2006, often referred to as the quadrivalent vaccine and 
Cervarix
®
 (GlaxoSmithKline Biologicals, Rixensart, Belgium) in 2007, also referred to as the 
bivalent vaccine. Gardasil
®
 targets the oncogenic HPV 16 and 18 genotypes and two non-oncogenic 
HPV genotypes (6 and 11). Cervarix
®
 targets the same two oncogenic HPV genotypes (16 and 18) 
but no non-oncogenic HPV genotype, and is formulated with a novel adjuvant, ASO4, which is 
intended to boost the immune response [14,15]. For Cervarix
®
, the findings from randomized clinical 
trial studies evidenced an efficacy of 100% in preventing HPV 16/18-associated cervical 
intraepithelial neoplasia (CIN) lesions [16-18]. For Gardasil
®
, the efficacy is greater than 90.0% in 
preventing HPV 6/11/16/18-associated CIN lesions, adenocarcinoma, genital warts, or vulvar and 
vaginal intraepithelial neoplasia (VIN or VaIN, respectively) [19]. 
Cervical cancer prevention strategies are dependent of country-specific information regarding 
the dynamics of HPV infection, so that epidemiological data is essential for the formulation of 
adequate measures and prevention programs, including HPV vaccination programs, regardless of 
vaccines clinical efficacy and safety [20,21]. In this context, mathematical models constitute useful 
tools to estimate scenarios and strategies effectiveness. Through the combination of results from 
randomized clinical trials, and from biologic and epidemiologic studies, mathematical models would 
be able to predict and address the main questions underlying each HPV infection prevention strategy. 
However, these models are based on assumptions and estimates, which may bring uncertainty [19]. 
Regarding HPV infection, this uncertainty is of some importance, mainly due to the complexity of 
the model, relying on the natural history of HPV infection, which includes several stages of infection 
and disease progression that are variable within each specific genotype. Also, the baseline 
information that would define model parameters is difficult to estimate; in fact, studies on age- and 
genotype-specific epidemiology and transmission rates are still scarce. Moreover, as it was 
considered for HPV vaccine randomized clinical trials, the use of ICC cases to estimate progression 
rates cannot be carried out for ethical reasons. 
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Epidemiological data on HPV infection among Portuguese women have been recently 
published [22,23]. One study involved normal cytology cases from routine screening-like population 
[22], while the other was a retrospective study focused on HPV genotype-specific detection in 
precancerous lesions and cervical cancer cases [23]. In the present study, the aim was to develop a 
mathematical model applied to genital HPV infection, to further estimate different HPV infection 
scenarios based on epidemiological data from opportunistic and routine settings, and to formulate 
predictions putatively useful for the implementation of cervical cancer prevention strategies more 
adequate to Portuguese women. 
 
 
MATERIAL AND METHODS 
 
Study Design 
The model was developed to be applied on two different populations, one involving 
characteristics of opportunistic screening (‘Study Population’) and another involving routine 
screening (‘Reference Population’) of women sexually active aged 18 to 65 years. The ‘Study 
Population’ was composed by a cohort of 2149 women distributed along the defined diseases states 
of the model at baseline according to data collected in Chapter 3. The ‘Reference Population’ 
corresponded to a cohort of 2326 women that participated in the CLEOPATRE Portugal Study [22], 
and were also distributed along the disease states of the defined model. For the purposes of the aimed 
model, it was considered that both populations would be followed through their lifetimes. 
Additionally, the simulations were carried out on a theoretical population (‘Hypothetical 
Population’) which consisted in 2149 women (for approximation to ‘Study Population’ scenarios), 
aged 18 years and HPV-negative at baseline, to explore the maximum impact of HPV vaccination in 
a population not exposed to HPV infection (approximately 1.0% of young female population 
vaccinated). 
 
Model structure 
A simple compartmental model of the natural history of HPV infection into ICC was 
developed incorporating transitions between five mutually exclusive disease states, defined to 
describe each woman’s clinical condition: HPV-negative (susceptible; ‘HPV-ve’); HPV-positive 
(infected); low-grade cervical lesion (‘LSIL’); high-grade cervical lesion (‘HSIL’); and ‘ICC’. The 
‘HPV-positive’ state was further divided into two different states: HPV 16/18-positive (‘HPV 
16/18+ve’); and high-risk (HR) HPV-positive (‘HR HPV+ve’), to incorporate estimates of HPV 
genotype-specific infection rates. Low-risk HPV infection was ignored in the model because the 
previous determined proportion was too low (4.0 %) (Chapter 3) and it was associated with HR HPV 
infection in the vast majority of the cases. In addition, for each incremental year in the model, the 
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cohort was subjected to an age-dependent probability of acquiring HPV. Viral infection was defined 
proportionally as either detectable (‘HPV-positive’) or undetectable (‘HPV-negative’), and disease 
states were defined using the Bethesda classification system (SIL lesions) [24,25]. Similarly to what 
is applied to Markov models, in this study, the conditional distribution of the outcomes given a 
disease state depends on prior outcome observations only. 
To define model parameters, several data were collected across different studies. The 
transition probabilities used to “move” women through the disease states over time were extrapolated 
from published studies [20,24,26-28], and further explained in the following sections. Whenever 
deemed necessary, the probabilities were adjusted by the modeler on the assumption that each 
probability is disease state-specific; however, this adjustment may carry some bias to the model. The 
time lapse defined to run the model was 30 years (arbitrary decision of the modeler) and was divided 
into equal increments per year, referred to as Markov cycles, during which women transitioned from 
one disease state to another. Each year, women may get infected with HPV (any of the sub-groups 
previously defined), develop SIL lesions, progress to a higher grade SIL or cancer, regress from a 
higher to a lower grade SIL or normal epithelium (infected state), or clear the infected state. In each 
cycle, women can die from any cause other than cervical cancer (‘Dead’) (age- and sex-related all-
cause mortality adjusted rate) [29]. 
Simulations were carried out using R software version 2.12.1 (R Project for Statistical 
Computing, http://www.r-project.org/). The predictive outcome of the model was assessed by the 
generation of age-specific progression curves predicted over time for HPV 16/18 infection, HR HPV 
infection, LSIL and HSIL lesions, for further comparison with published data. 
The model was used to address the following questions: 
1. Given the current status of the ‘Study Population’, the most effective approach would be 
to prevent HPV infection or to treat clinical symptoms? 
a. Which would be the evolution for the ‘Study Population’ , without any clinical 
procedure? 
b. To what extent HPV vaccination would contribute to the prevention of HPV-
associated cervical lesions in the ‘Study Population’? 
c. How does HPV vaccination impact on the prevention of HPV 16 and 18 
infections in the ‘Study Population’ for a coverage rate of 85%? 
2. For each disease state, what would be the main differences between routine screening-
based and opportunistic screening-based populations? 
a. How would the routine screening impact on HPV infection dynamics for a 
‘Reference Population’? 
b. Different coverage rates (85% versus 100%) of HPV vaccination would impact 
on the ‘Reference Population’? 
3. How would be HPV vaccination effective in a population not exposed to HPV infection? 
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To address question 1, different scenarios were estimated for the population studied in 
Chapter 3 comprehending no clinical intervention (question 1a), or the possibility to vaccinate 
women below 25 years without HPV 16 and 18 infection (questions 1b and 1c) for a coverage rate of 
85% [30] or 100%. These scenarios were further evaluated to propose the best strategy to provide 
effective health-care to the ‘Study Population’. The outcomes were based on the estimates of the 
proportion of HPV infection (in the two sub-groups) and the proportion of HPV-associated LSIL, 
HSIL and ICC cases for the overall population. At baseline, women entered the model at their current 
disease state, as determined in Chapter 3. 
To address question 2, the simulations were carried out in a ‘Reference Population’ from an 
epidemiological study in Portugal (CLEOPATRE Study), including non-vaccination (question 2a), or 
the possibility to vaccinate women below 25 years without HPV 16 and 18 infection (question 2b) for 
a coverage rate of 85% and 100%. The estimates were further compared with the estimates obtained 
for the ‘Study Population’ to assess the main differences between the two populations.  
To address question 3, a theoretical population, as referred in the Study Design, was tested to 
assess differences for the HPV vaccination impact regarding the ‘Study Population’. 
 
Natural History 
Contrary to other studies [20,26-28,31,32], women from both populations were distributed 
along the different disease states at baseline, assuming different proportions in the beginning of the 
simulations. Several conditions were assumed as static, while others were allowed to vary, based on 
epidemiological cohort published data: 
 All cases of cervical cancer depend on a prior HPV infection and on a prior cervical lesion 
(LSIL and HSIL), and sequential transitions are obligatory between disease states through the 
designed model, given that HPV is the causative agent for cervical cancer [1,2]. 
 Clearance of HPV infection is defined as an undetectable HPV DNA result following a 
previous detection of an HPV genotype in the same woman by using the same diagnostic test. 
 Acquisition of HPV infection was based on age-specific incidence rates and defined into two 
age groups (18-25 and 26-65 years), assuming that young women tend to present higher 
infection rates [33,34].  
 Clearance time of HPV infection was defined as age-specific into two age groups (18-25 and 
26-65 years), where young women present no detectable HPV DNA in almost 90.0% of the 
cases after two years upon initial infection [35]. 
 Clearance rates are dependent of specific genotypes, v.g. HPV 16 presents a longer 
persistency of infection and consequently a higher risk of SIL development (around 40.0% in 
five years) [36]. This supports the evidence that HPV genotype is the most significant risk 
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factor for cervical cancer development, as the majority of HSIL lesions and ICC cases are 
associated to high-risk HPV infection, namely HPV 16 and 18 [5]. 
 Acquisition of HPV infection and SIL development was defined as genotype-specific and 
was divided into two groups (‘HPV 16/18’, and ‘HR HPV’), given the increased risk linked 
to HPV 16 and 18. Additionally, this stratification allowed the assessment of the impact of 
HPV vaccination for the populations under evaluation.  
 Transition probabilities for developing LSIL and HSIL lesions were defined as age-specific 
into two age groups (18-25 and 26-65 years), since young women present higher incidence 
estimates for SIL lesions (HSIL is identified after two years of the onset of an high-risk HPV 
infection) [35,37,38]. In addition, young women present lower rates of progression from SIL 
lesions to ICC cases (approximately one percent per year) [39,40]. 
 ICC development rates were assumed as 12.0 to 31.0% of precancerous lesions (if left 
untreated) [39,41,42]. 
 
Vaccination 
The base-case scenario of the assumed genital HPV infection model includes a simulation of 
non-vaccination, which was further compared to additional scenarios of vaccine coverage rates (85% 
and 100%), to explore the impact of HPV vaccination in both women populations. The possibility to 
be vaccinated was only allowed by the modeler to women aged below 25 years. Estimates were 
generated considering the overall population and further comparisons were performed 
comprehending three different HPV vaccination scenarios (0%, 85% and 100%) within each 
population. Predictions were estimated based on the following assumptions: i) vaccine duration is 
lifelong; ii) 100% reduction in susceptibility to HPV 16 and 18 infections (vaccine efficacy); and iii) 
variable proportion of women protected following vaccination, coverage level, of 100% or 85.0% (as 
observed by the General Directorate of Health (DGS) in Portugal – Chapter 2) [30]. Moreover, no 
cross-protection data was included, regarding protection conferred from HPV vaccines to prevent 
infection by other HR HPV genotypes. 
 
 
RESULTS 
 
Overview 
All the possible transitions that correspond to HPV natural history are depicted in Fig.1, with 
the assumed transitions represented by solid lines and the ignored transitions by dotted lines, 
constituting the final genital HPV infection model assumed for the simulations.  
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Fig.1: Genital HPV infection model diagram. The model assumes the inclusion of six mutually exclusive disease 
states: ‘HPV-ve’, HPV-negative; ‘HPV 16/18+ve’, HPV-positive for genotypes 16 and 18; ‘HR HPV+ve’, HPV-
positive for high-risk genotypes; ‘LSIL’, low-grade cervical lesions; ‘HSIL’, high-grade cervical lesions; ‘ICC’, 
cervical cancer. For all disease states is included an age-dependent probability of death by causes other than cervical 
cancer (‘Dead’ state) (dashed lines). Disease states ‘ICC’ and ‘Dead’ are called as absorbing states, as women remain 
in this states for the remainder of the simulations. The transitions represented in solid black lines correspond to the 
transitions included in the simulations, whereas the dotted black lines correspond to transitions not included in the 
simulations. The arrows represented in both ways correspond to acquisition vs clearance of HPV infection (all sub-
groups), or progression vs regression of cervical lesions. The circular arrows correspond to the probability to remain 
in the same disease state in one Markov cycle (one year). No transitions were allowed between the two different 
genotype-specific sub-groups. 
 
Formula and Parameters 
The model was based on the following formula: 
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    is the number of women in age group     included in the disease state   for the time   
(measured in years); whereas:           (as the number of disease progression states defined). 
The transition probabilities are defined as    
   
 that corresponded to the annual probability for 
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The calculations were carried out as follows: 
   
     
   
          
         
         
   
   
    
   
   
   
   
    
   
  
The probabilities used in the transition matrixes are presented in Table 1. 
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Acquisition Clearance Maintenance
'HPV-ve' vs 'HPV 16/18+ve' 0.0980 (18-25 years) 0.5297 (18-25 years)
0.0500 (26-65 years) 0.2797 (26-65 years)
'HPV-ve' vs 'HR HPV+ve' 0.1140 (18-25 years)
0.0570 (26-65 years)
'HPV-ve'† - - Assumed
'HPV 16/18+ve'† - - 0.2500 (18-65 years)
'HR HPV+ve'† - - 0.2000 (18-65 years)
Progression Regression Maintenance
'HPV 16/18+ve' vs 'LSIL' 0.0900 (18-25 years)
0.3500 (26-65 years)
'HR HPV+ve' vs 'LSIL' 0.0900 (18-25 years)
0.0600 (26-65 years)
'LSIL' vs 'HSIL' 0.0350 (18-25 years)
0.1500 (26-65 years)
'LSIL'† 0.0600 (18-65 years)
'HSIL' vs 'ICC'* 0.0300 (18-25 years)
0.1500 (26-65 years)
'HSIL'† - - 0.0800 (18-65 years)
Death by other cause 0.0002 (15-19 years)
0.0003 (20-24 years)
0.0003 (25-29 years)
0.0005 (30-34 years)
0.0008 (35-39 years)
0.0012 (40-44 years)
0.0016 (45-49 years)
0.0024 (50-54 years)
0.0035 (55-59 years)
0.0055 (60-64 years)
0.0088 (65-69 years)
0.0161 (70-74 years)
Table 1: Transition probabilities included in the genital HPV infection model
0.9000 (18-65 years)
-
-
0.0800 (18-65 years) -
Probability
Transition Reference
-
0.6297 (18-65 years) -
[26,34,36,37,43-45]
HPV-ve', HPV-negative; 'HPV 16/18+ve', HPV-positive for genotypes 16 and 18; 'HR HPV+ve', HPV-positive for high-risk genotypes;
'LSIL', low-grade cervical lesions; 'HSIL' high-grade cervical lesions; 'ICC', cervical cancer; *, regression probability of HSIL was not
considered since excisional treatment is mandatory; †, disease state of infection or SIL lesion unchanged for each Markov cycle.
- -
[46-48]
[37,44,49,50]
- - [29]
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Population Stratification into Disease States 
Of the 2149 women studied in Chapter 3 (‘Study Population’), 384 women (17.9%) were 
included in the 18 to 25 years age group, and the remaining 1765 women (82.1%) corresponded to 
the 26 to 65 years age group. Considering the ‘Reference Population’ (2326 women), 965 (41.5%) 
were included in the 18 to 25 years age group, and the remaining 1361 (58.5%) corresponded to the 
26 to 65 years age group. For the ‘Hypothetical Population’ all women (n=2149) were aged 18 years 
and included in ‘HPV-ve’ disease state. The final stratification into disease states of the populations 
is presented in Table 2.  
 
Table 2: Stratification of the two populations included in the model predictions, by disease state 
Disease State 
‘Study Population’,  
n (%) 
Age Group, years 
 ‘Reference Population’,  
n (%) 
Age Group, years 
 ‘Hypothetical Population’, 
n (%) 
Age Group, years 
18-25 26-65  18-25 26-65  18-65 
‘HPV-ve’  215 (56.0) 1036 (58.7)  861 (89.2) 1010 (74.2)  2149 (100) 
‘HPV 16/18+ve’ 39 (10.2) 127 (7.2)  27 (2.8) 127 (9.3)  0 (0.0) 
‘HR HPV+ve’  39 (10.2) 193 (10.9)  47 (4.9) 188 (13.8)  0 (0.0) 
‘LSIL’  71 (18.5) 189 (10.7)  30 (3.1) 30 (2.2)  0 (0.0) 
‘HSIL’  20 (5.2) 201 (11.4)  0 (0.0) 6 (0.4)  0 (0.0) 
‘ICC’ 0 (0.0) 19 (1.1)  0 (0.0) 0 (0.0)  0 (0.0) 
‘HPV-ve’, HPV-negative; ‘HPV 16/18+ve’, HPV-positive for genotypes 16 and 18; ‘HR HPV+ve’, HPV-positive for 
high-risk genotypes; ‘LSIL’, low-grade cervical lesions; ‘HSIL’, high-grade cervical lesions; ‘ICC’, cervical cancer.  
 
For multiple HPV infections, whenever HPV 16 and/or 18 were detected in co-infections 
with other high-risk genotypes, women were included in the ‘HPV 16/18+ve’ disease state, because 
of the major contribution of these genotypes for SIL lesions development and cervical cancer. 
Model predictions were calculated for two age groups (18-25 and 26-65 years), since 
transition probabilities varied according to age. All women were summed in relation to the year of 
simulation to obtain the graphic representations presented in Fig.2.  
 
Age-specific Prevalence Curves Predicted 
‘Study Population’ 
Considering the ‘HPV 16/18+ve’ disease state, the highest proportion of cases would be 
observed within the first six years (7.8%; 166 women), and then declining over time until around 
5.3% (100 women). Since women from all ages were included at the same time in the model, this 
peak would be linked to transient infections in younger women, as well as persistent HPV 16 and 18 
infections in older women. Regarding the comparison between the different coverage rate scenarios 
on HPV vaccination (85% and 100%), a reduction of 32.5% would occur within the first years (5.2%; 
112 women). As represented in Fig.2, both vaccination scenarios are nearly coincident, meaning that 
85% of coverage rate would induce the same reduction outcome as 100% of vaccinated women aged 
18 to 25 years. 
The estimates obtained for ‘HR HPV+ve’ disease state evidenced an expected increased 
proportion of HR HPV-positive cases within the first two to f ive years, with a proportion of 9.8% 
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(209 women), and then declining over time until around 5.6% (105 women). The proportion of HR 
HPV genotypes would be maintained around 5.0% after 10 years, and it would be expected to 
represent persistent infections. Regarding the different scenarios for coverage rate of HPV 
vaccination (85% and 100%), no reduction would be expected. This scenario has probably been 
influenced by the initial assumption where no cross-protection was included in the simulations, 
inducing an unchangeable HR HPV infection estimate (regardless of the HPV vaccination scenario).  
The highest proportion for low-grade cervical lesions would be registered in the first years 
(15.7%; 337 women), and would decrease over time until around 3.0% (58 women). Similarly to HR 
HPV infections, no reduction would be expected, when HPV vaccination was considered for women 
aged 18 to 25 years (regardless of the two coverage rates estimated). This outcome has probably been 
influenced by the initial stratification of women at the entry of the model, so that the expected 
reduction of low-grade cervical lesions, due to the decrease of HPV 16 and 18 infections, is 
somewhat diluted within the population’s estimates. For high-grade cervical lesions, the proportion of 
cases would decrease within the first years to a minimal 2.8% (61 women) of cases, affecting women 
of all ages. When HPV vaccination was considered, again no reduction would be expected, due to the 
baseline stratification of women in the model. Additionally, for the estimates of cervical cancer cases, 
an increasing proportion of cases over time would be predictable in the ‘Study Population’. This 
outcome results from the assumption on Markov models where the estimate of ‘ICC’ disease state is 
dependable on the prior outcome registered in the previous Markov cycle for both ‘ICC’ and ‘HSIL’ 
disease states. Due to ethical reasons, cervical cancer is not the endpoint on HPV vaccination clinical 
trial studies; thus, this increase was to be expected. 
 
‘Reference Population’ 
For the base-case scenario (non-vaccination), the estimates for the proportion of HPV 16 and 
18 infections would reach the peak also within the first six years (7.8%; 181 women) and then slowly 
decreasing over time until around 4.4% (133 women). This  increase proportion would be linked 
either to transient infections in younger women, or to persistent infections in older women. Since it 
was not possible to represent the simulations according to age, it is difficult to visualize an age-
specific distribution of HPV-infected women. Given the initial stratification of the ‘Reference 
Population’ at the entry of the model, and as it was estimated a decrease after the initial years, it is 
most likely that this peak would be attributable to transient infections. If HPV vaccination was 
considered, a reduction of 42.7% would be observed for HPV 16 and 18 infections, when compared 
to the non-vaccination scenario (regardless of the coverage rate). 
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Fig.2: Representations of the different scenarios regarding HPV vaccination: 0%, 85% and 100%. ‘HPV 16/18’, HP V-
positive for genotypes 16 and 18; ‘HR HPV’, HPV-positive for high-risk genotypes; ‘LSIL’, low-grade cervical lesions; 
‘HSIL’, high-grade cervical lesions; ‘ICC’, cervical cancer. Blue arrows signal the degree of reduction observed in the 
progression curves. 
Chapter 9 – Mathematical Modeling 
Not Published. 
148 
The estimates of HR HPV infections in the non-vaccination scenario would reach a peak 
within the first six to eight years (9.0%; 235 women) and then slowly decreasing over time. Similarly 
to what was described for HPV 16 and 18 infections, it is more likely to be linked to transient 
infections, while the remainder proportion of cases after 10 years would represent persistent 
infections. For the comparison between vaccination scenarios, no reduction could be estimated in HR 
HPV infections. This outcome is also related to the absence of cross-protection influence from HPV 
vaccination. 
The proportion of low-grade cervical lesions should remain stable over time, varying between 
3.1% (60 women) and 2.2% (56 women), with no expected significant variation. This outcome would 
also induce a low colposcopy referral. The comparison of the HPV vaccination scenarios evidenced 
no estimated reduction in the proportion of cases, which could be related to the bias effect described 
for the ‘Study Population’. Similarly, the proportion of high-grade cervical lesions would remain 
stable at a minimal proportion of 0.9% over time (with increasing age). This fact would be related to 
the low proportion of resulting high-grade cervical lesions due to the proportion estimated namely for 
HPV 16 and 18 infections. No reduction would be expected in the proportion of high-grade cervical 
lesions, if considering HPV vaccination of women aged 18 to 25 years (Fig.2). Also, cervical cancer 
estimates evidenced a proportion of cases of 1.6% (38 women), with no estimated impact after the 
comparison of HPV vaccination scenarios. 
 
Comparison between populations 
An opportunistic screening-type population would evidence an elevated proportion of HPV 
16 and 18 infection cases, when compared to a routine screening-type population. For HR HPV 
infections, an increased proportion of 18.1% of cases would be observed for the routine screening-
type population, when compared to the opportunistic screening-type population. 
Regarding cervical lesions, the routine screening-type population would evidence 58.8% 
fewer cases of low-grade cervical lesions, with a corresponding decrease for colposcopy referral, in 
relation to the opportunistic screening-type population (for the first years). Differences between the 
two populations evidenced that the proportion of high-grade cervical lesions would remain stable at a 
minimal proportion of 0.9% over time for the ‘Reference Population’ (with increasing age). This fact 
would be linked to the low proportion of resulting high-grade cervical lesions due to the low 
proportion registered mainly for HPV 16 and 18 infections. Between the two populations, the 
opportunistic screening-type population would represent an increased proportion of 4.9% of cervical 
cancer cases, when compared to the routine screening-type population (1.6%). 
 
Expected impact of HPV vaccination in a population not exposed to HPV infection 
In opposition to the described for both populations, if HPV vaccination was to be taken by 
HPV-negative women (therefore not exposed to HPV infection), its expected impact would be 
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significantly higher. As shown in Fig.2, for HPV 16 and 18 infections, a reduction of 98.6% of cases 
was estimated, considering the 100% coverage rate HPV vaccination scenario. This high reduction 
would represent 80.8% fewer low-grade cervical lesions, 81.3% fewer high-grade cervical lesions, 
and ultimately, about 80.0% fewer cervical cancer cases. Regarding the differences between the two 
coverage rates, in the 85% HPV vaccination scenario, it was estimated a reduction of 82.3% in HPV 
16 and 18 infections, 71.8% in low-grade cervical lesions, 75.0% in high-grade cervical lesions, and 
66.7% in cervical cancer cases. 
For the estimates of a non-vaccination scenario, HPV 16 and 18 infections would be expected 
to reach a proportion of 10.3% (220 women), while HR HPV infections could be estimated in 11.3% 
(242 women) within the first ten years. The proportions of both sub-groups of HPV-infected women 
would decrease to a stable proportion of 5.9% (‘HPV 16/18’) and 6.2% (‘HR HPV’), which would be 
attributable to persistent infections, inducing the estimated low-grade and high-grade cervical lesions 
(3.4% and 0.6%, respectively). The significant decrease in the proportion of these sub-groups 
evidenced in Fig.2 for the ‘Hypothetical Population’ is consistent with the change between age 
groups, revealing a bias effect in the estimates. 
 
 
DISCUSSION 
 
The use of mathematical models has increased since the 1950’s to assess the evolution of 
specific illnesses such as malaria and measles [51]. The structure of such models constitutes in the 
compartmentalization of the population into disease states, mutually exclusive, defined by the health 
state of the individuals towards the specific infection – susceptible, exposed, infected, and recovered 
– , while the transition between the different disease states is defined by infection, clearance, 
progression and regression rates. In sexually transmitted infections some questions must be 
addressed, such as HPV infection, like narrowing the developed model to the sexually active 
individuals, and involving gender separation, since the development of neoplasia is very distinct 
between male and female individuals. 
Mathematical models can be used as tools for decision making by estimating the outcome 
associated with different public health-care interventions, considered as cost-effectiveness analysis 
when deciding a more efficient use of resources [24]. Regarding genital HPV infection, a cost-
effectiveness analysis may estimate the impact of a specific intervention, v.g. HPV vaccination 
program, as it was aimed in the present study. The health outcomes from the model are compared to a 
non-vaccination scenario, providing useful data for choosing one strategy over another, and 
extending the knowledge from epidemiological studies to real-world situations [52,53]. 
For viral infections such as influenza, the vaccination impact is almost immediate and may be 
observed by the absence of flu in vaccinated individuals during the next cold season. Other vaccines 
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are administered to children to avoid serious pediatric infections, such as rubella or measles, so that 
the efficacy of vaccination as a preventive measure for some viral infections is observed in a short-
term period. Alternatively, for HPV infection, the effect of a worldwide vaccination can hardly be 
observed in less than 50 to 70 years, thus, global estimates on cervical cancer reduction would only 
be significantly recognized by 2109 [32]. 
Although HPV infection has a high prevalence worldwide, the majority of infections are 
transient, especially in young women [3]. Being a sexually transmitted infection, it is easy to perceive 
that sexual behaviors are important risk factors for HPV acquisition, so that it would be meaningful 
to modulate the risk behaviors, v.g. sexual contacts between individuals, for HPV infection and 
estimate their impact on HPV prevalence. However, due to social and moral constraints this 
information is not available. Therefore, the presented genital HPV infection model is based on the 
natural history of HPV infection and cervical lesions development, in order to predict changes in 
HPV prevalence among Portuguese women by the introduction of HPV vaccines. 
The aim was to keep the model as simple as possible without sacrificing important elements 
of the natural history of HPV infection. The presented model assumes an age-dependent progression 
and regression rates, either for HPV infection or cervical lesion cases, which is in accordance with 
most studies [20,24,27,49,54], and is based on the assumption that the age of HPV-infected women 
influence the susceptibility to acquire HPV infection, or to develop subsequent cervical lesions (by 
the decrease of immunological mechanisms) [55]. Estimates of progression and regression rates of 
HPV infection are often subjected to variability due to differences in the study design, including 
characteristics of the populations and HPV testing assays. This variability is also present in transition 
probabilities presented for SIL lesions. However, it is difficult to convert rates into probabilities that 
accurately reflect the natural history of HPV infection and its associated cervical lesions. Also, 
differences in terminology affect further research, since various studies report transitions between 
CIN1 to CIN3 that may be difficult to translate into LSIL and HSIL estimates [54]. The cytological 
SIL terminology was chosen for the assumed model because it was developed to describe differences 
between two different populations subjected to different health-care measures. Considering the 
Portuguese screening programs based on cytology testing (Chapter 2), the disease states 
correspondent to cervical lesions were designated into SIL lesions (LSIL and HSIL). 
 
Question 1 “Given the current status of the ‘Study Population’, the most effective approach 
would be to prevent HPV infection or to treat clinical symptoms?” was addressed as a way of 
predicting how to proceed to reduce the burden of HPV-associated cervical lesions in the ‘Study 
Population’, which presented a high proportion of oncogenic HPV genotypes strongly associated to 
high-grade cervical lesions (Chapter 3). This scenario would imply a considerable use of treatment 
options due to the cytological characterization of the population; however, HPV vaccination could be 
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considered as an effective approach to women below 25 years if a significant reduction on SIL 
lesions could be estimated (that would result of a reduced HPV-positive cases). 
A non-vaccination scenario was first estimated evidencing an evolution of the ‘Study 
Population’ over 30 years (question 1a – “Which would be the evolution for the ‘Study Population’, 
without any clinical procedure?”). The model has provided some insight on possible outcomes, 
regardless of its simplicity. Fig.2 evidences that a decrease of HPV 16 and 18 infections is to be 
expected, as for HR HPV infections (smaller decrease than for HPV 16 and 18). This reduction in the 
proportion of infection cases would represent a lower risk for the development of high-grade cervical 
lesions, and subsequently for the development of cervical cancer. The importance of these oncogenic 
genotypes in cervical cancer cases has been extensively evidenced, so that the potential decrease on 
HPV 16 and 18-positive cases would restrain colposcopies (and further clinical procedures) to a 
manageable number. In fact, it was estimated that the proportion of high-grade cervical lesions would 
become so low over time that they would imply fewer treatment interventions. 
For HR HPV infections, all oncogenic non-vaccine genotypes were combined into a single 
disease state (‘HR HPV+ve’) because detailed information on individual genotypes is still lacking, 
and were further compared to an opposite disease state of HPV 16 and 18 infections, constituting two 
separate sub-groups for the HPV-infected state. However, this method has been shown to 
overestimate the infectivity of HR HPV genotypes, hence contributing for an underestimation of 
vaccine impact [32,56]. In fact, the comparison between both sub-groups of infection evidenced a 
slightly higher proportion of cases for HR HPV infection. The estimated outcomes evidenced a small 
decrease after the first years to a stable proportion of HR HPV infection cases around 5.0%. This 
proportion of cases probably represents persistent infections that would correspond to putatively low 
proportions of low- and high-grade cervical lesions in the ‘Study Population’. Regardless of the 
augmented proportions determined for these women in Chapter 3, no significant improvement in the 
management of HPV-infected women would be needed in a near future, despite the absence of a 
routine screening program for these women. 
Regarding cervical cancer estimates, the simulations showed an increase that would be 
expectable due to a mathematical artifact. In reality, less HPV-positive cases would mean less 
precancerous cervical lesions, and fewer cervical cancer cases. So, when estimating prevention 
scenarios, it is more important to observe variations for high-grade cervical lesions than for cervical 
cancer itself, and consequently, the projections concerning precancerous lesions may be more useful 
for deciding the best approach to define any clinical strategy or intervention [54,57]. 
Results might have been influenced by the population dimensions which are too small to 
induce significant variations. Moreover, the initial stratification of women at the entry of the model 
influenced the projections, when comparing to published data, where additional variations could be 
observed for the studied scenarios [20,24,45,49,54,58-61]. Various studies on mathematical modeling 
applied to HPV infection are based in theoretical populations involving only ‘HPV-ve’ individuals at 
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the entry of the model, and comprehending a number of women large enough (v.g. 50.000 women) to 
induce significant variations and reliable projections [26-29,54,57]. However, and based on 
epidemiological data, whenever the adequacy between the theoretical simulations and real-world 
populations is assured, the estimates may be assumed [19,20], as it was observed for the present 
study. 
To address question 1b – “To what extent HPV vaccination would contribute to the 
prevention of HPV-associated cervical lesions in the study population?” – different scenarios were 
estimated by varying the HPV vaccination coverage rate (85% and 100%). In the first scenario the 
coverage rate for women aged 18 to 25 years would be the aimed by the Portuguese DGS (85%) [30], 
and in the second, the coverage rate for the same age group would be total (100%). These scenarios 
were further compared to the estimates obtained in question 1a. As evidenced by Fig.2, a reduction of 
32.5% would be expected for HPV 16 and 18 infections, assuming that women aged 18 to 25 years 
would be vaccinated, if they were not infected by these oncogenic genotypes at baseline. No 
reference was made regarding which vaccine was taken, since only HPV 16 and 18 infections were 
modeled and both vaccines available could have been taken [55]. This estimated reduction is lower 
than expected, and may be linked to the initial stratification of women at the entry of the model. In 
fact, almost no variation was observed in the estimates of HR HPV infections, implying that even for 
the different scenarios of HPV vaccination, no reduction would be expected. This result is in 
accordance with the assumptions of the model, since no multiple infections between ‘HPV 16/18’ and 
‘HR HPV’ sub-groups were allowed, and no cross-protection data was included in the design of the 
model. Furthermore, the ‘Study Population’ was constituted by a relatively low number of women 
(N=2149), which restricts the estimates of the model in fewer variations and lower reduction 
outcomes, as described by others [26,45,54]. Nonetheless, an interesting outcome was obtained, 
which was the almost coincident estimates for both 85% and 100% HPV vaccination coverage rates, 
which brings up question 1c – “How does HPV vaccination impact on the prevention of HPV 16 and 
18 infections in the ‘Study Population’ for a coverage rate of 85%?”. This means that the 85% 
coverage rate proposed by the Portuguese DGS would induce the same prevention outcome than the 
100% coverage rate. This result may also evidence some degree of herd immunity in the female 
population, which is desirable to achieve better results [55,62]. 
To address question 2 – “For each disease state what would be the main differences state 
between routine screening-based and opportunistic screening-based populations?” – the estimated 
scenarios between the ‘Study Population’ and the ‘Reference Population’ were compared. First, on 
“How would the routine screening impact on HPV infection dynamics for a ‘Reference 
Population’?” (question 2a), the estimates for a routine screening-based population were analyzed. 
The proportion of HPV 16 and 18 positive cases was estimated to increase in the first years and then 
decrease to a constant proportion of less than 5.0%. The initial increase would represent transient 
infections, while the remaining 5.0% would probably represent persistent infections affecting o lder 
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women, and requiring follow-up either by cytology, colposcopy, HPV testing or specific molecular 
markers. For HR HPV infections, a high proportion would be maintained during the first years and 
then slowly decreasing. Again, the remaining proportion of HR HPV infection cases over time would 
represent persistent infections with a putative impact on the development of cervical lesions. 
For the ‘Reference Population’, only the constant proportion of HPV-positive cases during 
the whole modeling period (30 years), would represent an increased risk for the development of 
cervical lesions. The estimates point to a low proportion of low-grade cervical lesions, and even a 
lower proportion of high-grade cervical lesions. Consequently, this routine screening-based 
population would evidence a lower proportion of cervical cancer cases, which is in accordance with 
the expected prevention provided by a screening program [20,24,55]. Furthermore, for question 2b – 
“Different coverage rates (85% versus 100%) of HPV vaccination would impact on the ‘Reference 
Population’?” – it was evidenced that different coverage rates would only induce a significant 
decrease of HPV 16 and 18 infections, which has been proposed [20] to reduce the management 
needed in a routine screening context. Nonetheless, it was shown that the ‘Study Population’ would 
evidence a small increase in the proportion of cervical lesions, when compared to the ‘Reference 
Population’, demonstrating the influence of routine screening in preventing cervical lesions  
associated to HPV infections. Cervical cancer screening programs, even in a co-approach including 
HPV vaccination, would induce a significant decrease to every disease state of the model 
[24,49,54,58,63-65], and more importantly, this impact was evidenced by the expected decrease in 
cervical cancer cases in the ‘Reference Population’, when compared to the ‘Study Population’.  
Finally, to address question 3 – “How would be HPV vaccination effective in a population 
not exposed to HPV infection?” – additional scenarios were estimated in an ‘Hypothetical 
Population’. This population consisted in 2149 women that were all included in the ‘HPV-ve’ disease 
state at the entry of the model, as assumed by the modeler, to enable further comparisons. All women 
were assumed to have 18 years (youngest age for entering the model in the ‘Study Population’). The 
different scenarios evidenced a significant prevention of HPV 16 and 18 infections that would 
represent a significant reduction of low- and high-grade cervical lesions. Also, less cervical cancer 
cases would be expected among the ‘Hypothetical Population’, when compared to the other 
populations. Therefore, as extrapolated in other studies [20,26,28,29,60], when HPV vaccination is 
administered to a female population not previously exposed to HPV, it is highly effective in reducing 
HPV-associated cervical lesions development. This outcome provided by various mathematical 
models [26,54,60,61] justified the recommendation of HPV vaccination for adolescent girls, 
considering that the age for sexual debut is reducing, shifting the peak of HPV infections to younger 
women than what was previously observed [34,43]. 
 
In conclusion, through the analysis and comparison of every estimate and scenario, in 
addition to epidemiological data from Chapters 3 to 8, it was possible to gain further understanding 
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and insight of the special characteristics of the ‘Study Population’. The decision underlying the 
mathematical model assumed in this study will favor a clinical approach, where HPV-infected 
women would be followed through HPV testing and cytology, and in some cases, colposcopy and/or 
molecular markers. Furthermore, recently published studies [32,66] assume that a significant 
decrease on cervical cancer incidence rates will only be observed many years from now, considering 
that the majority of women has been already exposed and (if sexually active) remains at risk of being 
infected by HPV. Therefore, and regarding cervical cancer prevention, HPV vaccination will have a 
long-term impact, regardless of its highly significant recommendation to adolescent girls [32,66]. As 
referred elsewhere, if one woman chooses to be vaccinated, it is unlikely to induce changes in 
cervical cancer incidence rates [66]. 
This study may be assumed as limitative in the conclusions, since the described health 
outcomes can only be applied to the studied populations. In the absence of accurate epidemiological 
parameters, as there are no studies involving Portuguese populations to determine natural transitions 
between stages of HPV infection, future application of dynamic mathematical models will surely 
contribute more extensively to inform health authorities on better strategies for reducing cervical 
cancer. Especially when considering the tendency regarding the positive input pressure that HPV 
vaccination may represent for Portuguese women, an estimated reduction of HPV 16 and 18 
infections was evidenced by the present study. 
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a 
GLOBAL ANALYSIS: 
TOWARDS CERVICAL CANCER PREVENTION STRATEGIES 
a 
 
 
 
 
So far, the research on human papillomavirus (HPV) has gained tremendous knowledge and 
insight about HPV infectious process and its associated diseases; has formulated prevention strategies 
for one of the most frequent sexually transmitted infections (STI) in the world; has developed 
significantly sensitive molecular diagnostic assays for early detection of the viral DNA; and has 
developed prophylactic vaccines evidencing encouraging efficacy results. In the course of 
progressing this far on behalf of cervical cancer prevention, as one of the cancers that affects more 
women at ages 15 to 44 years, HPV research encountered more challenges to overcome, especially 
social and economic, to bring new options on short term management of HPV-infected women, and 
on an aimed long-term viral elimination. Below, the major aspects presented in this PhD thesis are 
discussed, and future perspectives in HPV research are addressed, in view of incrementing cervical 
cancer prevention, in particular among Portuguese women. 
Cervical cancer is one of the major malignancies affecting women worldwide. In an era 
where vaccination has become a reality for the prevention of some genotypes, the paradigm of HPV 
infection is shifting. In the words of the Nobel Prize winner Harold zur Hausen, “instead of pursuing 
to avoid HPV infection, or cervical cancer development mechanisms, the path to follow is 
prevention” (TV interview, October 2013).  
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Main Findings 
 
In Portugal, cervical cancer incidence rate is high (12.2 per 100,000 women), highlighting the 
importance of continuously monitor HPV-infected women [7,13]. Epidemiologic data is always 
required, including in populations at increased risk, as the women evaluated through the present PhD 
thesis. High-risk HPV infection was detected frequently in normal cytology cases (22.6%), which can 
constitute a risk factor for cervical cancer development, despite the potential bias over HPV positivity 
rate considering that the study was based on an opportunistic screening-type population (Chapter 3). 
In fact, the characteristics of the Study Population may have increased and overstated HPV 
prevalence, consequently increasing its proportion among cervical disease. Moreover, women 
included in this study were referred to HPV testing due to the identification of cytological 
abnormalities, which boosts the probability of HPV-positive results. In addition, many women were 
undergoing HPV testing for the first time, increasing the possibility of identifying transient 
infections, especially in young women. This raises the question on how to manage HPV infection in 
younger women, as an elevated HPV positivity rate was determined in women below 30 years (peak 
registered in women aged 25 to 29 years). 
Regarding HPV RNA testing, the positivity rate in women with normal cytology was only 
6.0% in women below 30 years of age, which contrasted significantly with the elevated percentage of 
HPV DNA detected in younger women (28.6%). For women above 30 years, HPV RNA detection 
rate decreased to 4.9%, evidencing the fewer clinically active HPV infections due to viral persistency , 
and therefore, at higher risk for cervical lesion development [280]. 
The genotype-specific profile that was identified, demonstrated that HPV 16, 31, 53, 51, 18 
and 66 were the most frequent genotypes. The prevalence rates of these genotypes differed according 
to cytological diagnosis evidencing a significant association of HPV 16 and 18 to cervical cancer 
development. These two oncogenic genotypes were responsible for more than 65.0% of high-grade 
cervical lesions, meaning that HPV vaccines currently available in Portugal (which include these 
genotypes) may contribute to the decrease of HPV 16/18-associated cervical diseases in our country. 
It is important to continuously monitor HPV dissemination, especially in populations with high 
disease rate in order to discriminate the main circulating HPV genotypes and their specific 
contribution to high-grade cervical lesions, putatively enabling statistical validations with fewer 
women [228,229,235]. Moreover, the vast majority of Portuguese women have already been exposed 
to HPV infection prior to vaccination implementation, turning HPV genotype-specific distribution 
evaluation as particularly important to clarify future public health decisions [151,281,282]. 
 
 
Chapter 10 – Global Analysis 
 
163 
Chapters 4 to 6 evidenced the importance of HPV testing in cervical cancer screening 
strategies, as opposed to the routinely applied cytology. HPV testing has the advantage to increase 
sensitivity of viral detection, since this is one of cytology’s disadvantages. Routine cytology testing 
provides cervical disease detection demonstrating high specificity, while complementary HPV testing 
can improve early detection of viral infection due to higher sensitivity. However, in younger women, 
HPV testing will over-estimate the number of false positive results (v.g. high-risk HPV positivity 
without subsequent high-grade cervical lesions development). In opposition, for older women, HPV 
testing prior to cytology represents a better strategy due to its higher sensitivity which is most linked 
to persistent infections [228-230,238,282-287]. Moreover, the high proportion of oncogenic HPV 
genotypes circulating in Portugal is of some concern, due to their higher probability of inducing 
persistent infections and subsequent cervical disease development.  
The primary testing in cervical cancer screening is of some importance since the loss of 
specificity would promote unnecessary treatment procedures with associated costs. It has been shown 
that HPV RNA testing increases the specificity of cervical disease detection, without putting at risk 
the increased sensitivity of HPV DNA testing. Thus, HPV RNA testing could constitute an 
alternative for the management of HPV-infected women, while avoiding potentially unnecessary 
colposcopy referral [238,280,281]. 
HPV 16 and 18 have a well established significant association to cervical cancer development 
[13,151,160]. Considering this, in Chapters 7 and 8, it was exploited the prognostic significance of 
HPV 16 and 18 loads, of viral physical status, and the predictive value of these potential molecular 
markers. This fact raises the possibility of additional screening stages in order to better discriminate 
HPV infections that would develop more rapidly in cervical cancer cases. 
An inverse relation between the two molecular markers, within the same genotype, could be 
observed. A significant association between high HPV 16 viral load and high-grade cervical lesions 
development was evidenced; in opposition, HPV 16 DNA physical status was not associated with 
cervical lesion development, for the same sample. In fact, the HPV 16 viral load increased 
significantly with the severity of clinical diagnosis, while the DNA determined in the linear form 
(with integration potential) was not often detected, even in high-grade cervical lesions. This pattern 
suggests the need for closely monitor the quantitation of viral load in women infected by this 
genotype, while HPV 16 integration seems not to be essential for malignant transformation, since 
concomitant forms were the most frequently detected, independently of the clinical diagnosis 
[270,288,289].  
Regarding HPV 18-positive cases, viral load only evidenced a possible association with the 
persistency of HPV infection, while a significant association was evidenced between the presence of 
HPV 18 linear forms and cervical disease progression. The higher values of HPV 18 viral load in 
low-grade cervical lesions could favor an increased rate of HPV 18 integration, as linear forms 
identification increased with cervical disease diagnosis. Furthermore, when integrated HPV 18 was 
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detected, a decrease in the correspondent viral load was identified, which could be expected 
considering that after viral genome integration, viral replication stops. At this stage, viral replication 
depends of host cell mechanisms, since viral genome becomes part of host genome [290-292]. 
Consequently, during the final stages of cervical carcinogenesis, HPV 18 viral load would not 
influence progression to cervical cancer, but the determination of HPV 18 DNA physical status 
would be predictive of the risk of malignant transformation [276]. These molecular markers may be 
included in routine cervical cancer screening algorithms, and may act as effective triage tools for risk 
stratification of HPV 16 and 18-infected women, potentially reducing the need for colposcopy and 
biopsy referral, which are uncomfortable, expensive and time consuming invasive procedures 
[293,294]. Furthermore, HPV 18 has the predisposition to infect glandular cells, where 
adenocarcinomas are particularly difficult to detect cytologically; thus, viral load and physical status 
are of additional significance in women infected with HPV 18, when compared to HPV 16. 
Nevertheless, various measurements are required over time, to ascertain a persistent infection and an 
accurate risk assessment through these molecular markers. 
Chapter 2 addressed the scenario of cervical cancer screening measures in Portugal, where 
screening programs are regionally-based, implying disparities on health-care policies among regions. 
These measures may be further weakened if the screening programs are not monitored to evaluate its 
success. At present, there are a few gaps that affect the prevention provided by the implemented 
screening programs. These gaps are related to the effectiveness in recruiting eligible women for 
screening, and to differences on primary testing and age range of screened women. This fact raises 
the need to apply additional measures, which may adequate more properly the treatment options to 
those lesions that constitute a real increased risk for high-grade cervical lesions development. To 
assure an increased specificity in specific stages of the screening algorithm is a way to detect cervical 
disease more effectively [236,295-297], while to propose alternative algorithms may improve 
management of HPV-infected women (Fig.1). 
Additionally, in Chapter 9 it was described how mathematical models would help to better 
decide between clinical strategies by estimating different scenarios for HPV natural history. Here, it 
was chosen to develop a simple compartmental Markov model that would describe the evolution of 
the studied population, and it was further exploited the prevention induced by the introduction of 
HPV vaccines, measured in the proportion of reduced cases of HPV infection and cervical disease. It 
was estimated that high-risk HPV infection, namely HPV 16 and 18, would remain high within the 
first years, and then decreasing over time, thus representing a low proportion of high-grade cervical 
lesions. This means no expected increase of clinical resources would be necessary for the 
management and treatment of HPV-infected women. Moreover, the comparison between the ‘Study 
Population’ and a ‘Reference Population’ evidenced the importance of routine screening for cervical 
cancer prevention. Despite the aimed benefits in reducing HPV cervical disease as a result of the 
current vaccination programs, successful HPV management should not rely on primary prevention 
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only, but also on early detection and treatment of cervical lesions, in order to achieve more 
immediate effects. 
 
All the chapters contributed to some extend for a formulated strategy (Fig.1) that would 
provide a better management of HPV-infected women in Portugal: i) Chapter 3 have provided 
baseline information on HPV genotype-specific distribution and its associated cervical lesions; ii) 
Chapters 4 to 6 provided clinical relevance to the use of HPV DNA and HPV RNA testing; iii) 
Chapters 7 and 8 provided clinical significance on two important and emerging molecular markers; 
iv) Chapter 2 provided the actual scenario on screening strategies that would need improvement; and 
v) Chapter 9 provided future possible scenarios for the Study Population. 
 
 
 
Fig.1: Algorithm proposal for HPV/cervical cancer routine screening. 
Re-screening
(5 years)
LBC Screening Test (25-65 years)
NILM
Major
abnormalities
Excisional Treatment
HPV 16/18 Test (+)
ASC-US ≥ LSIL
Colposcopy
HPV 16/18 + HR Test (-)
Minor 
abnormalities
HPV HR Test (+)
Re-screening 
(1 year)
HPV 16/18 + HR Test
(12 months)
HPV 16/18 Test (+)
HPV 16 Viral load
Major
abnormalities
Excisional Treatment
E2/E6 Ratio < 0.520
HPV 18 Physical Status
Colposcopy
< 22,000 copies / 103 cells
Minor 
abnormalities
≥ 22,000 copies / 103 cells E2/E6 Ratio ≥ 0.520
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Final Remarks 
 
HPV infection is so prevalent that is almost unavoidable, affecting millions of women around 
the world, including Portugal. Thus, it is urgent to rationalize better health-care and a higher quality 
of life for women, and also diffuse the right message to the society, while taking an active part on 
preventing the dissemination of this STI, which begins by a safer behavioral attitude. 
 
Large HPV longitudinal studies, either prospective or retrospective, as well as HPV screening 
evaluations will provide data that will inform about prevention programs adequate to each specific 
setting (country, region, age, sexual habits, risk factors, etc). Women exposed to HPV and potentially 
harboring persistent infections, constitute cervical cancer candidates, and should beneficiate from 
accurate and up-to-date diagnostic tests and treatment options, being surgery the least desirable 
compared to early and regular screening.  
 
HPV infection is demanding in so many aspects, making prevention strategies even more 
challenging. To globally embrace a definitive reduction on cervical cancer incidence, it is important 
to highlight the special features intrinsic of each genotype’s natural history of carcinogenesis. In this 
context, basic research on HPV viral mechanisms responsible for the development of anogenital 
cancers remains essential. These studies should be conducted for each genotype, after establishment 
of its specific epidemiological contribution. This way, underlying viral mechanisms that resulted in 
successful adaptations to host cell environment should be further investigated. One example is the 
more aggressive behavior of HPV 18 in cervical cancer development. Why is HPV 18 more prone to 
infect glandular cells and induce the development of adenocarcinomas with worse prognosis? What 
nucleic acid mutations and variations are responsible for a more rapid progression to cervical cancer? 
What differences result in an increased oncogenic role for viral proteins? These questions have now 
the possibility to get answered through new-generation sequencing. This new technology will provide 
important information on viral genomic rearrangements and valuable insight on viral full-genome 
data that still remain unknown for most genotypes. High quality sequences obtained from full 
genome sequencing offer new possibilities and novel information to: 1) characterize genomic viral 
variants; 2) assess mechanisms of oncogenicity for these variants; 3) identify genomic recombination 
sequences from multiple HPV infections; 4) establish specific routes used from molecular variants 
within host cell environment; 5) identify novel sequences with malignant transformation potential; 
and 6) identify novel genotypes [298]. 
 
There are many other fields to pursue on HPV research with new-generation sequencing: 
What are the most common viral integration sites on host cell genome? What determines the viral 
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disruption site and the consequent integration site? What host cell mechanisms are affected by viral 
integration? What integration sites represent an advantage to a more aggressive behavior? And if so, 
how viral mechanisms act to achieve this advantage? Which viral proteins take a role in this process, 
and which nucleic acid variations are more successful? These questions would provide interesting 
data on HPV research and cervical cancer prevention. The progress in preventing HPV-related 
diseases becomes attainable if studies are conducted throughout all stages of infection and disease, 
improving measures and technology, and translating the obtained results into the clinical field 
[299,300]. 
 
On a screening context, as a result of substantial population growth in developed and 
developing areas, universal screening and effective early treatment are issues that have to be readily 
addressed. Additionally, it would be important to identify potential target DNA sequences of 
diagnostic interest using new-generation sequencing. These sequences could be further used for the 
improvement of current HPV tests, as well as for the development of new tests that would bring 
advances in HPV detection and risk assessment. In fact, a more effective prevention may be linked to 
specific strategies at a genotype level. For instance, it is still unknown if other high-risk genotypes 
will present a higher contribution to cervical cancer development, in particular after the expected 
decrease of HPV 16 and 18 prevalence through vaccination. One statement consists in the assumption 
that some degree of cross-protection conferred by HPV vaccination will prevent genotype 
replacement in cervical cancer incidence [301]. Nonetheless, it is likely to observe some increase of 
otehr high-risk HPV genotypes in association with precancerous cervical lesions, which might have 
to be included in future HPV vaccines [213,221,302-304]. 
 
Concerning the immunology related to HPV infection, it would be important to clarify which 
viral mutations may contribute to elude the host immune system, as a way to “silence” HPV 
persistent infection without recognition from host cells. Recently, the recurrence to adjuvants to boost 
T-cell mediate response from the host immune system has evidenced interesting results [305]. 
Moreover, the arising of mutations on HPV 16 and 18 variants may contribute to escape the 
immunity conferred by HPV vaccines and, in this case, it will be crucial to identify these mutations 
[298]. Ultimately, it will be fundamental to establish a match between viral features and host immune 
responses to better understand viral-host interactions, as recently published [306].  
 
HPV is a virus well adapted to infect human epithelial cells, and have co-evolved within the 
host, raising questions on how the virus manages to remain so widespread in the population, even 
increasing its incidence in some anogenital cancers. Such questions remain to be answered and 
require extended research. Furthermore, two of the most oncogenic viral proteins, E6 and E7, 
constitute potential targets for research namely to the understanding of how these oncoproteins 
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interact with cellular proteins p53 and pRb that was shown to conduct to the malignant 
transformation of host cells, or identifying particular features linked to their oncogenicity (at a 
genotype level) [296,298-300]. Additionally, specific mechanisms that are responsible for differences 
at a protein level remain unknown, and will most certainly influence the progression to cervical 
cancer. 
 
The work presented through the present PhD thesis exposes a comprehensive and extensive 
research on HPV that ultimately may result in prevention strategies more appropriate to Portuguese 
women. The identification of some gaps in the actual HPV screening programs implemented in 
Portugal enables further improvement of available technologies rationalizing the use of resources 
more adequate and applicable, while providing enhanced health-care to Portuguese women. 
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